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Abstract
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer.
Tumour recurrence is common and accounts for the poor 5-year survival rates of
GBM (<10%). The ability to re-grow the tumour after surgical removal of the
tumour bulk has been attributed to cells with stem cell-like phenotypes, termed
glioma stem cells (GSCs). Identification of molecular GSC vulnerabilities targetable
by therapeutic agents is urgently required. In this context, I examined the potential
anti-GSC effect of KHS101, an experimental compound that induces differentia-
tion in neural progenitor cells in vitro and in vivo. Interestingly, in patient-derived
GSCs, KHS101 selectively reduced viability. KHS101 cytotoxicity was associated
with a vacuolisation/autophagy phenotype, and loss of clonogenicity of GSCs. Con-
sistently, KHS101 significantly reduced xenograft tumour growth and invasion and
prolonged survival of mice bearing GSC-derived tumours. Analysis of the mech-
anism of action of KHS101 indicated the disruption of oxidative phosphorylation
leading to metabolic exhaustion of GSCs.
To go beyond the possibilities of single agent treatment, I explored the potential
of a combination therapy integrating oncolytic virotherapy with coxsackievirus A21
(CVA21). Targeting of tumour cells by CVA21 requires surface expression of In-
tercellular Adhesion Molecule-1 (ICAM-1), which is a limiting factor in GBM tu-
mours. Notably, genetic manipulation of GSCs showed that expression of ICAM-1
is sufficient to increase susceptibility to CVA21. To identify ICAM-1 inducing com-
pounds, I carried out a focused combination compound screen for the induction
of ICAM1 expression in GSCs. From a panel of 23 compounds, I identified com-
bined retinoic acid (RA) and KHS101 as an efficient ICAM1 mRNA up-regulation
treatment. RA/KHS101 also significantly increased surface expression of ICAM-
1 protein on GSCs. Notably, RA/KHS101-induced ICAM-1 expression rendered
GSCs vulnerable to CVA21-mediated oncolysis in vitro. Hence, a combination of
pharmacological treatment and oncolytic virotherapy could complement available
chemo-/radiotherapy by eliminating the GSC population and thus preventing tu-
mour recurrence.
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1 Introduction
1.1 Glioblastoma Multiforme (GBM)
1.1.1 Glioma classification
Gliomas are tumours of the central nervous system and are thought to originate from
cells of the glial lineage. Based on the morphological features the tumour shares
with certain types of glial cells, gliomas can be classified into different categories
including astrocytomas, ependymomas, oligodendrogliomas and oligoastrocytomas.
In addition to this classification based on predominant cell types, classification of
gliomas can also be done according to tumour grade. Based on pathological fea-
tures of the tumour, their growth rate and potential to spread into nearby tissue,
the World Health Organisation (WHO) grading system distinguishes four classes of
gliomas, grade I – IV. Whereas, grades I and II are defined as low-grade gliomas,
grades III and IV are rated as high-grade tumours [1] [2]. Classified as WHO grade
IV, glioblastoma multiforme (GBM) poses the most common and aggressive type of
primary brain tumour.
1.1.2 Incidence and prognosis of GBM
Each year approximately 2,100 new cases of GBM are diagnosed in England [3].
Incidence rates rise with increasing age peaking between 65 and 75 years of age [3].
Although they only account for ∼2% of all cancers [4], GBM tumours are among the
most devastating cancers as GBM leaves patients with a median survival time of ap-
proximately 15 months from the time of diagnosis. Despite multi-modal treatment
efforts, a 5-year survival rate of less than 10% has been reported [3] [5]. Moreover,
GBM is associated with ∼20 life years lost, more than any other cancer [6].
The poor prognosis for GBM is mainly caused by the highly infiltrative nature of
GBM concomitant with diffuse tumour edges that complicate complete surgical re-
section. Consequently, tumour recurrence commonly occurs near the site of the
primary lesion [7]. In addition to the invasive nature, GBM tumours are char-
1
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acterised by the presence of highly heterogeneous cell populations of molecularly
different phenotypes that cause individual sensitivities and resistances of these pop-
ulations to therapeutic approaches (see 1.3 ‘Inter- and intratumour heterogeneity
of GBM’). Notably, this heterogeneity has been described at the inter- and intra-
tumoural level, hence calling for a shift from a universal treatment regime to a
combination of standard chemo-/radiotherapy and novel therapies specifically tar-
geting distinct subpopulations of GBM tumours.
1.1.3 Treatment of GBM
The current standard of care for GBM patients includes maximal surgical resection of
the main tumour mass, followed by radiotherapy and concomitant chemotherapy. In
order to enhance maximal surgical resection, methods based on tumour-specific fluo-
rescent staining using 5-aminolevulinic acid (ALA) have been developed. ALA stain-
ing facilitates differentiation between tumour and non-tumour brain tissue during
surgery and therefore can help the surgeon to maximise the precision of tumour re-
section [8] [9]. The currently applied chemotherapeutic agent temozolomide (TMZ)
is an alkylating agent that triggers apoptosis through induction of DNA methyla-
tion damage [10]. Concurrent radiotherapy and TMZ treatment has been shown to
increase median survival by 2.5 months [11]. Despite multi-modal treatment efforts
GBM remains mostly incurable, as tumour recurrence is inevitable [12]. Therefore,
novel therapies are urgently needed. Intensive research has led to the development
of new promising classes of therapeutic agents directly targeting GBM cells or mod-
ulating the tumour microenvironment. These novel therapeutic approaches include
the use of monoclonal antibodies to disrupt specific ligand-receptor binding and
thus prevent activation of receptor signaling. In this context, bevacizumab was de-
veloped to prevent neovascularisation through blocking vascular endothelial growth
factor (VEGF) signaling. However, clinical trials have shown limited efficacy of be-
vacizumab in combination with standard treatment, as no significant improvement
in patient survival was observed compared to standard treatment alone [13]. Mon-
oclonal antibodies can also be used to direct a cytotoxic agent to the target cells.
AMG595, for example, combines an antibody specifically targeting EGFRvIII, an
epidermal growth factor receptor (EGFR) mutant frequently found in GBM, with
the cytotoxic agent mertansine to facilitate specific killing of mutation-carrying tu-
mour cells [14]. Other attempts to treat GBM are aimed at activating the patient’s
innate immune system to eliminate the tumour. This can be achieved through pre-
sentation of tumour lysate to the patient’s own dendritic cells, thereby activating an
2
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anti-tumour T cell response upon reintroduction of the tumour antigen-presenting
dendritic cells. One such system, DCVax-L, is already being tested in a phase III
clinical trial (ClinicalTrials.gov Identifier: NCT00045968; [15] [16]). Another ap-
proach relies on the ex vivo engineering of chimeric antigen receptor (CAR) T cells.
CARs consist of a an extracellular variable antibody region enabling recognition of
a tumour-specific antigen, and at least one T cell co-stimulatory domain facilitat-
ing T cell activation independent of major histocompatibility complex (MHC). The
GBM-specific mutated form of EGFR (EGFRvIII) is one example of a GBM anti-
gen that can be targeted by CAR T cells [17]. Notably, anti-EGFRvIII CAR T cell
platforms are currently being evaluated in clinical trials (ClinicalTrials.gov Identi-
fier: NCT02209376). Additionally, several studies in the field of GBM biotherapy
focus on the use of oncolytic viruses and are described in 1.7 ‘Oncolytic virotherapy
for cancer/GBM treatment’.
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1.2 GBM subtype classification
A better understanding of the individual genetic and molecular alterations that drive
malignant growth could be the basis for the development of personalised medicine
[18]. A large number of studies focusing on revealing the genomic abnormalities
and gene expression profiles associated with GBM tumourigenesis have been carried
out. Mutations have been identified, for example, in retinoblastoma 1 (RB1), tumour
protein p53 (TP53), phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1), neu-
rofibromatosis type 1 (NF1), Erb-B2 receptor tyrosine kinase (ERBB2); gene am-
plification of EGFR, gains of chromosome 7 and loss of chromosome 10 are frequent
alterations in GBM tumours [19]. In this context, work has focused on identifying
clinically relevant subclasses of GBM by genomic profiling (e.g., [20]) or gene expres-
sion profiling (e.g., [21] [22] [23] [24]). Building on these studies, Verhaak et al. es-
tablished a comprehensive GBM subtype classification scheme based on mutational,
DNA copy number and transcriptional signatures. Applying multi-dimensional ge-
nomic data analysis, four different GBM subtypes were identified: Proneural, neural,
classical and mesenchymal. The proneural subtype of GBM is mainly characterised
by alterations in platelet-derived growth factor receptor α (PDGFRA; highest lev-
els of PDGFRA amplifications/expression and sometimes PDGFRA mutations) or
isocytrate dehydrogenase 1 (IDH1), together with TP53 mutations and high expres-
sion of oligodendrocyte transcription factor 2 (OLIG2). Classification into the neural
subtype is based on transcriptional expression of neuron markers (i.e. neurofilament,
light polypeptide (NEFL), gamma-aminobutryc acid A receptor, α 1 (GABRA1),
synaptotagmin 1 (SYT1), solute carrier family 12 member 5 (SLC12A5)). GBM
tumours of the classical subtype are characterised by amplification of chromosome
7 and concurrent loss of chromosome 10, and amplification and mutations of EGFR
while being TP53 wild type. Transcriptional changes include high expression of, for
example, NES, NOTCH3, smoothened, frizzled class receptor (SMO) and GLI fam-
ily zink finger 2 (GLI2). Expression of mesenchymal markers such as CHI3L1 and
MET, together with low expression levels of NF1 and mutations in TP53 and phos-
phatase and tensin homolog (PTEN) define the mesenchymal subtype of GBM. The
characteristic genomic profiles are suggested to be correlated with patient survival,
for example a trend toward longer survival associated with the proneural subtype
was observed. Furthermore, GBM subtypes are thought to be predictive for distinct
responses to treatment and, therefore, are believed to have implications for future
therapeutic advancements [25].
4
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Subtype classification of other cancer types has proven advantageous for develop-
ment of effective therapies [26] [27], and in the case of GBM, application of a uni-
versal treatment strategy has failed to achieve long-term remission [28] [11]. Hence,
inter- and intratumoural GBM subtype classification has to be taken into account
when investigating new treatment options.
5
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1.3 Inter- and intratumour heterogeneity of GBM
An important feature of GBM tumours is their high level of heterogeneity. This
heterogeneity includes mutational and transcriptional variability between tumours
as well as distinct genetic, epigenetic, functional and phenotypic stages of subsets
of cells or even single cells within a tumour. Early studies described differences in
genetic and marker expression profiles of cells isolated from glioma specimens and
glioma cell lines [29] [30]. Since then, a number of mutational events and molecu-
lar markers have been identified that contribute to heterogeneity across and within
GBM tumours (e.g., [31] [32]). A well-known example of a gene heterogeneously
expressed is the O6-methylguanine-DNA methyltransferase (MGMT) gene, which
encodes a DNA repair enzyme. Epigenetic silencing of the MGMT gene has been
associated with a favourable response to TMZ. However, MGMT has not only been
found to exhibit heterogeneous expression between different GBM specimens, but
MGMT promoter methylation has been shown to vary between distinct tumour
areas [33] [34]. Similarly, inter- and intratumour heterogeneity has also been de-
scribed for expression of the EGFR mutant EGFRvIII, whose gene product is a
constitutively active version of EGFR that drives tumourigenicity [35] [36] [37]. In
a hallmark study, Sottoriva et al. investigated intratumoural heterogeneity using
tumour fragments taken from different regions of the same tumour. By integration
of genome-wide copy number variation and gene expression microarray profiling,
the authors demonstrated that most patient tumours contained molecularly diverse
subpopulations and revealed a high variability in the expression of GBM subtype
classifier genes. Strikingly, identification of the clonal composition of each tumour
revealed distinct patient-specific signatures of cancer evolution, thus adding a new
level to GBM heterogeneity [38]. More recently, Patel et al. employed functional
RNA sequencing to achieve characterisation of individual cells isolated from GBM
tumours. Consistent with Sottoriva et al., they describe extensive intratumoural
heterogeneity of GBM subtype classification and, in addition, in expression levels
of signaling molecules relevant for GBM biology, e.g., EGFR, PDGFRA, fibroblast
growth factor receptor 1 (FGFR1) and NOTCH2. This cell-to-cell variability high-
lights the complexity of GBM and the challenges for GBM treatment directed at
specific signaling pathways [39].
Notably, given the high degree of intratumoural mutational and transcriptional het-
erogeneity in important factors of signaling pathways driving tumour growth, ex-
clusive targeting of a specific pathway will not eliminate the entirety of the tumour
and will promote the expansion of resistant cells. Therefore, an effective anti-GBM
strategy should combine treatments aimed at different deregulated pathways, or be
6
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targeted at vulnerabilities common to all GBM cells independent of their genetic or
transcriptional background.
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1.4 Cellular plasticity in GBM
Heterogeneity as described for GBM has been discussed to be a consequence of a
hierarchical organisation driven by clonal evolution. In this context, the identifi-
cation of cancer stem cells (CSCs) that drive cancer progression and give rise to
the more differentiated cells with specific features, promoted advancement in un-
derstanding the origin of cellular heterogeneity of cancer. Similar to normal stem
cells, differentiation of CSCs is thought to result in heterogeneous cell populations
[40] [41]. Moreover, the influence of the tumour microenvironment on the biology
of tumour cells has increasingly been investigated. In GBM, a complex network
of normal brain cells, macrophages, endothelial cells and extracellular matrix pro-
vides a local environment or niches favourable for tumour growth, migration and
immune escape [42]. Microenvironmental cues have been shown to play crucial roles
in maintaining the glioma stem cell (GSC) pool and changes in niche factors may
influence cellular plasticity resulting in altered GSC/non-GSC ratios. Accordingly,
accumulating evidence indicates that tumour cell populations are dynamic with a
high degree of interconversion between GSCs and non-GSCs [41]. This capacity
of tumour cells to alter their phenotypic and functional state is governed by mi-
croenvironmental factors like hypoxia, transcription factors, microRNAs (miRNAs)
and therapeutic pressure [41]. For example, by comparing epigenetic profiles of
GSCs and their differentiated counterparts, and subsequent functional validation,
Suva` et al. identified a core set of transcription factors (i.e. POU class 3 home-
obox (POU3F2), SRY-box 2 (SOX2), spalt-like transcription factor 2 (SALL2) and
OLIG2) that control GBM propagation. Most importantly, induction of these four
neurodevelopmental transcription factors is sufficient to reprogram differentiated
GBM cells into tumour-propagating GSCs [43]. Additionally, important regulatory
roles in GSC biology have been attributed to miRNAs. Two examples of miRNAs
that have been implicated in GSC proliferation and their tumourigenic potential in
vivo are miRNA-34a and miR-18a* [44] [45]. Chemotherapeutic challenge of GBM
cells with TMZ has also been demonstrated to affect cellular phenotypes. Auffinger
et al. recently described TMZ-induced conversion of differentiated GBM cells into a
stem cell-like state characterised by expression of ‘stemness’ markers and enhanced
infiltrative behaviour in vivo [46]. Growing evidence highlights the importance of
the bidirectional cross-talk between GSCs and their microenvironment (reviewed
in [47]). In this context, hypoxia has been shown to influence the GSC pool by
suppressing differentiation and promoting expression of self-renewal genes in stem
and non-stem populations mainly through hypoxia inducible factor (HIF), Notch
and c-Myc signaling [48] [49] [50]. Within the perivascular niche, GSC ‘stemness’,
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metastasis and escape from therapy are promoted, for instance, by sonic hedgehog
(SHH), Notch ligands (i.e. Delta-like 4 (DLL4) and Jagged-1) and the chemokine
interleukin (IL)-8, secreted by endothelial cells within the niche [51] [52] [53]. Figure
1.1 depicts the signaling modes within the hypoxic and the perivascular niches that
regulate GSC maintenance and contribute to cellular plasticity within GBM tumours
[54]. Transition between different GSC states has recently been shown by Bhat et
al. who collected evidence that GSCs are able to transition from a proneural to a
more aggressive mesenchymal state via nuclear factor of κ light polypeptide gene
enhancer in B-cells (NF-κB) signaling. Notably, the authors suggest an involvement
of macrophages/microglia present in the tumour microenvironment [55].
Fig. 1.1: Signaling modes within the vascular and hypoxic niches that modulate GSC
maintenance (adapted from [54]).
In conclusion, adaptation of GBM cells to different microenvironmental settings
providing distinct GSC-promoting cues significantly contributes to the high degree
of genetic, epigenetic and functional heterogeneity observed in GBM. Moreover,
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identification of key effectors that critically influence non-GSC/GSC phenotypes and
trigger interconversion between different GBM cell types furthers our understanding
of cellular plasticity of GBM. Insight into the molecular basis of plasticity and
heterogeneity reveals potential new targets for GBM therapy. Certainly, the high
degree of cellular plasticity observed for GBM tumours, necessitates comprehensive
treatment strategies aiming at all cell types, including GSCs, non-GSC and their
intermediate states.
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1.5 Glioma Stem Cells (GSCs)
1.5.1 Characteristics of GSCs
Fig. 1.2: Functional characterisation of CSCs/GSCs. GSCs are functionally defined by
sustained self-renewal, proliferation and tumour initiation upon intracranial
transplantation. GSCs also share characteristics with neural stem cells includ-
ing their frequency within a tumour, expression of neural stem cell markers and
differentiation capacity along multiple lineages [56].
The critical role of GSCs in cellular plasticity and heterogeneity of GBM neces-
sitates a profound understanding of the nature of these cells. The main features
defining GSCs are summarised in figure 1.2. By definition, GSCs are undifferen-
tiated malignant cells that are characterised by their clonal growth ability based
on their capacity to self-renew and to give rise to more differentiated cell progeny
of neuronal, astroglial and oligodendroglial phenotypes. Therefore, they share sev-
eral characteristics with neural stem cells (NSCs) including the expression of NSC
markers (e.g., neuroectodermal stem cell marker (NESTIN), SOX2, OLIG2, CD133,
CD44). In vitro, GSC differentiation can be induced, particularly upon exposure
to bone morphogenic proteins (BMPs) or serum. Continuous propagation in the
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presence of serum alters the molecular and phenotypic characteristics of GSC to-
wards a differentiated state. Notably, the resulting GSC differentiation phenotype
is associated with significantly decreased tumourigenicity. However, a recent study
by Caren et al. revealed that BMP-induced astrocyte differentiation and cell cy-
cle arrest of GSCs is heterogeneous and reversible. In fact, even after prolonged
exposure (54 days) of GSCs to BMP, the cells retain the capacity for cell cycle re-
entry and de-differentiation, presumably due to incomplete differentiation-specific
reconfiguration of DNA methylation patterns. Consistent with the described lim-
ited differentiation in vitro, BMP-treated GSCs as readily form orthotopic xenograft
tumours as untreated GSCs [57]. The ability to initiate tumour formation upon or-
thotopic transplantation into immunocompetent mice is the most important method
to functionally characterise GSCs. This approach allows for the assessment of the
tumourigenic potential of GSCs [56] [58] [59] [60]. Strikingly, GSC-derived xenograft
tumours maintain the genotypic and phenotypic features of the original patient tu-
mour [61].
The observed interconversion between GSCs and non-GSCs (described in 1.4 ‘Cel-
lular plasticity in GBM’) requires an experimental therapeutic to be tested on both,
GSCs and GSC-derived more differentiated cells in order to ensure a broad efficacy
in a GBM tumour setting. Thus, the ability of patient-derived GSCs to give rise
to differentiated progeny of diverse lineages, together with GSC-derived xenografts
phenocopying the important features of the parental tumour, makes GSCs an ideal
model to test the anti-GBM effects of novel treatments in vitro and in vivo.
1.5.2 Isolation of GSCs
The concept of a tumour-initiating subpopulation of cells was first validated in
haematopoietic malignancies. In leukemia, surface expression levels of markers such
as CD33, CD34, CD44 or chemokine (C-C motif) ligand 1 (CCL-1) are used to iso-
late the malignant stem cells [62] [63] [64] [65] [66] [67]. However, heterogeneity in
leukemia stem cell marker signatures has been described, which complicates identifi-
cation of a conclusive and universally applicable marker [68]. Similarly, enrichment
of the stem cell population of brain tumours was initially based on the expression of
surface markers. In 2003, Singh et al. demonstrated that the CD133-positive pop-
ulation isolated from human brain tumours exhibits stem cell characteristics [69].
Only the CD133+ cell population was able to grow xenograft tumours displaying
histopathological resemblance with the original tumour [70]. However, other studies
have shown that the informational content of CD133 as a universal GSC marker is
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limited as, in some cases, CD133 negative cells can also have tumourigenic potential
[71] [72]. In addition to CD133, several other GSC markers have been proposed, e.g.
CD15, integrin α6 and CD44 [73] [74] [75]. Since cell surface markers are often in-
volved in the cross-talk of tumour cells with their microenvironment, isolation from
their tumour surroundings may lead to a reorganisation of the proteins on the cell
surface. Hence, the cells’ stemness marker signature is likely lost upon propagation
in vitro [56].
Other methods of isolating and culturing of the stem cell population of brain tu-
mours have been investigated. Enrichment of GSCs from GBM samples can also be
achieved using serum-free culture conditions that select for a GSC phenotype. GSCs
isolated by this method can then be grown as neurospheres or in adherent culture
[69] [76]. Most notably, these GSCs and the xenograft tumours they generate closely
mimic the genotype and phenotype of the parental tumour, including important fea-
tures such as the highly invasive nature of GBMs. GSC-derived xenograft tumours
also maintain cellular heterogeneity and populations of CD133 and CD44 express-
ing cells can be isolated by flow cytometry [61] [76]. The possibility of long-term
maintenance of GSCs as monolayers in serum-free medium facilitates investigation
into the mechanisms underlying the malignant nature of this disease and the identi-
fication of factors that can manipulate GSCs towards a less tumourigenic phenotype.
1.5.3 Differentiation therapy to target GSCs
GSCs are thought to be responsible for tumour initiation, progression and recur-
rence after therapeutic intervention [56]. Accordingly, resistance to radiation and
DNA damaging agents, conceivably due to enhanced DNA repair mechanisms and
ATP-binding cassette (ABC) transporter mediated resistance to chemotherapeutic
agents have been attributed to GSCs and complicates effective targeting of these
cells [77] [78] [79]. The challenge of specifically targeting GSCs has been linked
to the idea of driving these cells into differentiation to deprive them of their self-
renewal and tumour-initiating abilities. Upon differentiation, GSCs show a signifi-
cantly decreased tumourigenicity and display increased susceptibility to conventional
chemotherapy and radiotherapy [59]. Therefore, differentiation therapy could be a
highly effective strategy to target GSCs, in particular, in combination with currently
available DNA-damaging therapies.
Specific elimination of GSCs can be approached from different angles taking into
account the increasing knowledge about proteins and networks that drive ‘stemness’
and the malignant nature of GSCs. Various different growth factor and cytokine
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signalling pathways, such as the transforming growth factor β (TGF-β) and Notch
pathways, have been implicated in the regulation of NSCs and aberrant activation
of these pathways may promote tumourigenesis [80]. Several of these factors (e.g.,
BMP, TGF-β, Notch), and their respective downstream signaling pathways regulate
GSC maintenance [58] [81] [82] [83]. Moreover, accumulating evidence suggests a
role of different miRNAs, as well as genetic factors, for example the histone mod-
ifying proteins BMI1 and enhancer of zeste 2 polycomb repressive complex 2 sub-
unit (EZH2), c-Myc, IDH1 and the transformation/transcription domain-associated
protein (TRRAP) in GSC biology [84] [85] [86] [87] [88] [89] [90] [91]. Addition-
ally, various studies indicate a differentiation effect of small chemical compounds.
Among the compounds tested, retinoic acid (RA), resveratrol, curcumin, rapamycin
and 2-Hydroxyoleate gave promising results leading to a more differentiated state
of GSCs and/or inducing autophagy [92] [93] [94] [95]. A more detailed overview on
the current concepts of induced differentiation of GSCs is given in [96].
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1.6 Forward chemical genetics: Identification of small
molecules for anti-GBM treatment
Unlike other types of cancer in which detection of driver mutations has led to the
development of effective new drugs, the diversity of GBM genetics and the cellular
plasticity associated with GBM growth and recurrence limits success of a targeted
therapy against GBM [97] [98] [99]. Therefore, identification of acquired cellular
properties and molecular vulnerabilities of GBM is needed and can be facilitated by
investigation of patient-derived GSCs. In this context, the potential of small chem-
ical compounds to modulate cell fate has been investigated (e.g., [100] [101] [102]).
Efforts to identify small molecule disruptors of complex oncogenic mechanisms that
drive GBM growth have benefited from the development of high throughput screen-
ing approaches. Unlike reverse chemical genetics, which is based on screening small
molecules against a specific target, forward chemical genetics aims at identifying
small molecules that cause a specific phenotypic response in a cellular system. As
the choice of a molecular target is not limited in forward chemical genetics, it is a
well-suited approach to tackle the complexity of GBM and support the development
of therapeutic strategies that exploit GBM vulnerabilities [103] [104]. Notably, a
comprehensive understanding of the mechanism underlying a compound’s activity
is essential to be able to explain the observed effect. Therefore, mechanism-of-action
(MOA) studies are a critical addition to phenotypic screening. MOA studies mostly
focus on the identification of the target the compound binds to, or the biochemical
pathway the compound interferes with [105]. A commonly used method for target
identification is affinity chromatography. Herein, the compound labeled with an
affinity tag (e.g., biotin) is used to immobilise and separate the unknown target
protein [106]. Alternatively, a biotin-labeled compound analog with a phenyl azide
moiety can be used for photo-crosslinking the small molecule and the target pro-
tein. Identification of the drug target can then be achieved by SDS-PAGE or a (2D)
Western Blot detecting biotin followed by mass spectrometry [106] [105]. Another
frequently applied method to uncover a compound’s MOA is transcriptome analysis.
Here, comparing the gene expression profiles of compound-treated cells and control
cells (vehicle-treated or treated with an inactive analog of the compound) reveals
the gene alterations induced by the compound, thus giving an indication of the path-
ways affected. When investigating a toxic compound, identification of mutations in
resistant cells, for example, by whole-genome sequencing can be a powerful approach
to uncover the compound’s MOA [105].
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1.6.1 Small molecules in GBM
A growing number of studies focus on small molecule screens to discover compounds
that selectively affect GBM cell fate. Tan et al., for example, screened 10,000 natu-
ral product-like compounds for their ability to inhibit the HIF-1 pathway in glioma
cells. They discovered the small molecule 103D5R which strongly reduced HIF-1α
protein synthesis in vitro and prevented the hypoxia-induced activation of VEGF
and glucose transporter-1 (GLUT1), two factors critically involved in survival under
anaerobic conditions [107]. Screening for GBM growth inhibitors targeted at cells
carrying the EGFRvIII mutation, Trembath et al. identified the small compound
NSC-154829 by using an isogenic cell-based approach; NSC-154829 selectively in-
creases apoptosis in EGFRvIII expressing GBM cells [108]. Since stress response
regulated by Heat Shock Factor 1 (HSF1) has been implicated in cancer cell survival,
a phenotypic screen conducted by Santagata et al. focused on the identification of
compounds able to activate the heat shock response and disrupt protein home-
ostasis. One candidate compound, withaferin A, was further investigated for its
therapeutic potential in vivo and shown to increase median survival of mice bearing
glioma xenograft tumours [109]. Aiming at identifying small-molecule inhibitors of
the canonical Wnt signaling, the small molecule SEN461 was discovered. Notably,
in vivo administration of SEN461 resulted in reduced growth of GBM xenograft
tumour [110]. Furthermore, in order to discover novel radiosensitisers, Goglia et al.
conducted a cell-based small molecule screen for inhibitors of double-strand break
repair systems. Among the 20,000 compounds screened, the FDA-approved drug
mibefradil dihydrochloride was found to act as a radiosensitiser in vitro [111]. In an
attempt to identify an agent that could act synergistically with the tricyclic antide-
pressant, imipramine, in the induction of autophagy-associated cell death, Shchors
et al. screened a number of already clinically approved drugs. The anticoagulant
ticlopidine was found to improve efficacy of imipramine and combination treatment
exhibited cytotoxicity in GBM cell culture and prolonged survival in a glioma mouse
model [112]. Additionally, small molecule screening approaches have been applied to
specifically target GSCs. For example, Visnyei et al. combined a high-throughput
screen identifying compounds affecting proliferation/viability of GSCs with a sub-
sequent target-based approach further characterising the candidate compounds for
their effect on expression of mitotic genes negatively correlated with clinical outcome.
Notably, the four most potent compounds demonstrated an inhibitory activity on
GSC self-renewal in vitro and in vivo [113]. Similarly, in an effort to specifically
target GSC proliferation without compromising growth of normal NSCs, Danovi
et al. identified the compound J101 among a panel of 160 small molecule kinase
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inhibitors. Their data indicate that J101 exerts its GSC-specific anti-proliferative
activity through inhibition of polo-like kinase 1 [114]. More recently, a study con-
ducted by Kitambi et al. identified a quinine derivative that displayed selective
cytotoxicity in GSCs. Moreover, functional validation using an analog of the ‘hit’
compound, Vacquinol-1, uncovered a GSC vulnerability based on macropinocytic
vacuolisation and membrane ruﬄing. Further investigation into the in vivo activity
of Vacquinol-1 demonstrated attenuated tumour progression and prolonged survival
in a GBM mouse model [115].
Taken together, several studies have identified and validated small molecules with
anti-GBM activity through effects on cell proliferation, autophagy, cell death and
transcriptional pathways known to drive GBM cell survival and therapy resistance.
These studies highlight the great potential of small chemical compounds as promis-
ing new therapeutic options.
1.6.2 Candidate small molecules with potential anti-GBM
properties: KHS101 and retinoic acid (RA)
1.6.2.1 The small molecule KHS101
The small chemical compound KHS101 (figure 1.3), a neuropathiazol analog, was
initially identified in a phenotypic screen as a potent inducer of differentiation in the
adult central nervous system. Notably, KHS101 specifically induces neuronal differ-
entiation in neural progenitor cells (NPCs) of the adult rat hippocampus resulting
in functionally active maturing neurons. The compound overrides BMP-induced
astrocyte differentiation of NPCs. Additionally, microarray profiling and functional
assays revealed that proliferation of NPCs is decreased in the presence of KHS101.
Moreover, the differentiation and anti-proliferation effect of KHS101 on NPCs has
been shown both in vitro and in vivo. Most importantly, KHS101 is able to cross the
blood-brain barrier in murine models when injected intravenously or subcutaneously
[116].
The MOA of KHS101 is still being investigated; however, Wurdak et al. identified
the transforming acidic coiled coil containing protein 3 (TACC3) as a KHS101 target
through affinity-based pulldown assays. Importantly, upon knockdown of TACC3
NPCs displayed a similar neuronal differentiation phenotype as induced by KHS101
treatment further confirming an interaction of KHS101 with TACC3. In addition,
targeting TACC3 with KHS101 was shown to promote nuclear translocation of the
transcription factor aryl hydrocarbon receptor nuclear translocator 2 (ARNT2), a
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Fig. 1.3: Chemical structure of KHS101.
known interaction partner of TACC3 [116] [120]. Following up on this finding, dis-
ruption of TACC3/ARNT2 binding by KHS101 has been demonstrated to be a
consequence of KHS101-mediated proteasomal degradation of TACC3. Notably, an
indirect effect of KHS101 on HIF-1α protein levels under hypoxic conditions was
also identified in this study, indicating KHS101 as a modulator of HIF-1α signaling
[121].
As a member of the transforming acidic coiled-coil containing protein family, TACC3
is characterised by a highly conserved C-terminal coiled coil domain. The TACC3
protein co-localises with microtubules of the mitotic spindle (figure 1.4 A) and acts
as a centrosomal adaptor promoting its stabilisation, thus contributing to correct
chromosomal segregation [122] [118]. More precisely, phosphorylated TACC3 is
able to bind to microtubules, thus enabling TACC3 to interact with clathrins and
colonic and hepatic tumor overexpressed gene (ch-TOG) leading to the crosslink-
ing between microtubules (figure 1.4 B; [118]). Consistent with its function in the
assembly of the mitotic spindle, TACC3 is a proposed regulator of cellular growth
and mainly expressed in highly proliferative tissue, e.g. the gastrointestinal tract
or the spleen ([123]; TACC3 protein levels according to the Human Protein At-
las: www.proteinatlas.org; [124]). As a crucial factor for cell proliferation, TACC3
has been intensively investigated for its role in cancer progression. Indeed, elevated
TACC3 levels were found in numerous different human cancer types including breast
cancer, bladder cancer, sarcoma, lung cancer, gastric cancer, hepatocellular carci-
noma, lymphoma and GBM [125]. Notably, high expression of TACC3 has been
correlated with poor prognosis (figure 1.4 C; [126] [127]) and a role for TACC3 in
cancer invasion, through promoting epithelial-mesenchymal transition (EMT), has
been suggested [128]. Recently, an oncogenic fusion protein of FGFR3 and TACC3
has been reported in a small subset of GBM tumours. This FGFR3-TACC3 fusion
protein is localised to the mitotic spindle poles (figure 1.4 D) and causes defects in
chromosomal segregation leading to aneuploid cells. Strikingly, targeting FGFR3
kinase activity by a specific inhibitor results in prolonged survival of mice bearing
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Fig. 1.4: Function of TACC3 and its role in glioma. A) Immunofluorescence im-
ages of HeLa cells stained for the microtubule protein tubulin and TACC3
(adapted from [117]). B) Scheme of proposed TACC3/ch-TOG/clathrin-
mediated crosslinking of microtubules of the mitotic spindle (adapted from
[118]). C) Kaplan-Meier survival plots of glioma (left) and GBM (right) pa-
tients with high or low TACC3 expression levels (obtained from the REpository
for Molecular BRAin Neoplasia DaTa, www.betastasis.com/glioma/rembrandt).
D) Immunofluorescence images of cells stained for α-tubulin and FGFR3-
TACC3 [119].
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FGFR3-TACC3-driven glioma [119]. Similarly, FGFR3-TACC3 fusions were also
detected in bladder cancer, lung cancer and cervical cancer [129] [130] [131]. No-
tably, disruption of TACC3 by conditional knockout in a lymphoma mouse model
triggers tumour regression [132]. Moreover, targeting TACC3 protein degradation
by small molecules can induce selective cancer cell death in vitro [133].
In conclusion, a multitude of studies implicates TACC3 in cancer progression and
point to TACC3 as a potential molecular target for development of drugs against
various types of highly TACC3-expressing cancer, including GBM.
1.6.2.2 The small molecule RA
Fig. 1.5: Chemical structure of RA.
RA (figure 1.5) is a naturally occurring vitamin A metabolite that acts as an es-
sential physiological signaling molecule regulating developmental processes in the
embryo but also fulfilling crucial tasks in the adult body. Depending on the cell
type, RA can induce cell growth, differentiation but also apoptosis [134]. RA elicits
differentiation of NSCs, inducing an astrocytic cell fate [135]. Due to their natural
occurrence, and differentiation effects on NSCs and various other cell types, retinoids
have been extensively investigated for their anti-tumourigenic properties. Retinoid-
based differentiation therapy alone or as part of a combination therapy, consisting
of conventional chemotherapy and differentiation therapy, is particularly effective
in the treatment of acute promyelocytic leukemia (APL), juvenile chronic myeloge-
nous leukemia, Kaposi’s sarcoma, breast cancer, and neuroblastoma [134] [136]. The
anti-tumourigenic effect of RA has also been demonstrated in brain tumours and the
RA differentiation pathway appears to be deregulated in malignant glioma as several
RA signalling molecules (e.g. CRBP1, aldehyde dehydrogenase 1 family, member A1
(ALDH1A1), cytochrome P450, familiy 26, subfamily B, polypeptide 1 (CYP26B1),
fatty acid binding protein 5 (FABP5)) show an aberrant expression profile [137].
Even though a differentiation effect of RA has been reported for GSCs, RA fails to
bias the cells towards terminal differentiation [138]. This merely partial differenti-
ation effect could explain the limited efficacy of RA in the treatment of malignant
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glioma observed in clinical trials [139]. Nevertheless, these preclinical studies and
clinical trials demonstrated the safety of RA administration and confirmed its acces-
sibility to the brain [140]. These characteristics make RA an interesting candidate
for investigation into a new application of RA in glioma therapy.
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1.7 Oncolytic virotherapy for cancer/GBM treatment
The concept of using live non-pathogenic viruses that preferentially infect and de-
stroy cancer cells, while sparing non-cancerous cells, has been known many decades
[141]. These so called oncolytic viruses (OVs) have since been intensely investigated
and expanding knowledge in molecular biology and virology has further expedited
development of OV therapeutics. OVs can have a natural preference for cancer cells
or can be manipulated to target cancer cells that express tumour-specific surface
proteins or have altered signaling pathways that provide the cellular environment
favourable for OV replication (e.g., [142] and [143]). Several naturally oncolytic and
genetically engineered viruses have been investigated for their anti-GBM activity
and safety in preclinical models and clinical trials, including reovirus, different New-
castle disease virus (NDV), adenovirus, herpes simplex virus (HSV), measles virus
and vaccinia virus strains [144]. One promising naturally occurring oncolytic virus is
reovirus, which has been reported to have a strong cytotoxic activity against GBM
in vitro and in vivo [145]. However, genetic modifications can be introduced into
OVs to enhance their oncolytic activity, and hence safety, by optimisation of selec-
tive targeting and replication in cancer/GBM cells or by expression of cytotoxic gene
products in infected cancer cells. For example, increased tumour specificity of on-
colytically active viruses can be achieved by retargeting OVs through manipulation
of the glycoprotein composition to promote binding to tumour-associated receptors,
e.g. EGFR, or more specifically, to GSCs expressing CD133 [146] [147]. The vac-
cinia virus strain JX594, on the other hand, exhibits improved selective replication
in cancer cells through genetic deletion of thymidine kinase and has been shown to
be active against GBM [148]. To improve efficiency of OV therapy by increasing
the viruses’ oncotoxic activity, OVs such as HSV have been engineered to carry the
gene for tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
thereby prolonging survival of mice bearing intracranial tumours [149].
Notably, virus-induced lysis of tumour cells does not seem to be the sole reason for
the therapeutic activity of OVs. Instead, preclinical and clinical studies indicate a
role for OV-induced anti-tumour immune responses, including recruitment of natu-
ral killer (NK) cells and granulocytes. Release of cytokines and tumour-associated
antigens (TAAs) by lysing tumour cells also leads to maturation of dendritic cells
and presentation of TAAs on their cell surface. Consequently, cytotoxic T cells
are activated and have the potential to identify and target tumour cells at distant
sites (figure 1.6) [150] [151] [152] [153]. Hence, in addition to their direct oncolytic
effect, therapy with oncolytic viruses stimulates an ongoing adaptive anti-tumour
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immune response through activated cytotoxic T cells. Naturally occurring, unmod-
ified oncolytic viruses known to elicit anti-tumour immunity include reovirus, HSV,
coxsackievirus B3 [152] [154] [155], and in the GBM context, NDV [156].
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Fig. 1.6: Dual mode of action of oncolytic viruses. Upon infection of a tumour cell with an
oncolytic virus, the tumour cell is lysed thereby releasing more virus particles
that spread and infect more tumour cells. Also, lysis of tumour cells results
in release of tumour-associated antigens and other immunogenic signals such
as cytokines that trigger an anti-tumour immune response via maturation of
dendritic cells and activation of T cells.
Advances in genetic manipulations offer a wide range of possibilities to improve OV
selectivity, replication and lysis of cancer cells, and enhance the ability of OVs
to stimulate an anti-tumour immune response. For example, OVs armed with
granulocyte-macrophage colony-stimulating factor (GM-CSF), which recruits NK
cells and mediates antigen presenting cell (APC)-induced T cell activation, induce
anti-tumour immunity [157] [158] [159] [160] [161].
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1.8 Coxsackievirus A21 (CVA21) and Intercellular
Adhesion Molecule-1 (ICAM-1)
One clinical grade, naturally occurring oncolytic virus is the coxsackievirus A21
(CVA21), a human enterovirus with a positive-sense, single-stranded RNA genome
[162]. CVA21 preferentially eliminates malignant cells while sparing on non-tumour
cells [163]. Effective targeting and killing of tumour cells by CVA21 requires surface
co-expression of Intercellular Adhesion Molecule-1 (ICAM-1) and decay-accelerating
factor (DAF). While the role of DAF seems to be restricted to attachment and
concentration of the viral particles, ICAM-1 is thought to facilitate both binding
and internalisation of CVA21 [164]. The anti-tumour capacity of CVA21 has been
demonstrated in vitro, for example, in multiple myeloma and prostate cancer cell
lines that, in contrast to most non-malignant cells, co-express high endogenous levels
of ICAM-1 and DAF [165] [166]. Treatment of subcutaneously established tumours
of a prostate cancer xenograft model with CVA21 lead to tumour regression upon
systemic delivery of the virus, hence demonstrating in vivo efficacy of CVA21 vi-
rotherapy [166]. Notably, xenograft tumours derived from ICAM-1 positive GBM
cells treated with CVA21 have been shown to regress upon a single intracranial in-
jection followed by multiple intraperitoneal CVA21 injections [167]. Thus, a number
of studies demonstrate a proof-of-concept for efficient virotherapy with CVA21 in
various cancers including melanoma, prostate cancer and malignant glioma. Most
importantly, safety and efficiency of CVA21 therapy is already being evaluated in
clinical trials for the treatment of solid tumours such as melanoma, breast cancer,
lung cancer and prostate cancer (e.g., ClinicalTrials.gov identifier NCT01636882,
NCT00636558, NCT02043665). However, surface expression of ICAM-1 is a prereq-
uisite of efficient virotherapy with CVA21.
ICAM-1 (also known as CD54) is a glycosylated transmembrane protein with five
extracellular immunoglobulin-like domains, a transmembrane domain and short cy-
toplasmic domain at the carboxyl-terminus [168]. It is constitutively expressed on
the surface of various different cell types including epithelial and endothelial cells,
fibroblasts and leukocytes [169]. As a ligand for β2 integrin lymphocyte function-
associated antigen (LFA)-1, ICAM-1 functions as an adhesion molecule promoting
interactions between different immune cells and between immune cells and the vas-
cular endothelium. Thus, ICAM-1 is involved in cell recognition and homing of
immune cells [170] [171]. Furthermore, a role for LFA-1/ICAM-1 interaction has
been suggested in the activation of T cells by facilitating cross-talk between T cells
and APCs [172]. The expression of ICAM-1 is mediated by several different immune
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stimuli including inflammation and viral infection as well as by certain cytokines and
hormones. Inflammatory cytokines such as IL-1β, TNF-α and interferon γ (IFN-γ)
represent efficient activators of ICAM-1 expression on various cell types including
endothelial and epithelial cells as well as fibroblasts. In contrast, anti-inflammatory
cytokines, for example TGF-β or the hormone glucocorticoid hamper the induc-
tion of ICAM1 gene expression [173] [174]. Transcriptional activation of ICAM1
expression is complex and, depending on the kind of stimulus and the cell type,
is regulated by signaling through various different pathways such as the NF-κB,
the mitogen-activated protein (MAP) kinase, the signal transducers and activa-
tors of transcription (STAT) or the protein kinase C (PKC) signaling pathways
[174] [175]. The ICAM1 promoter region contains various different transcriptional
enhancer elements. These include a palindromic interferon-γ-responsive element
(pIγRE), CCAAT/Enhancer binding protein (C/EBP), activator protein 1 (AP-1)-
like, NF-κB, Ets and specificity protein 1 (SP1) elements, and more recently a CRE
binding domain has also been identified within the ICAM1 promoter [176] [177] [178]
[179] [180] [181] [182].
A role of the small molecule RA in ICAM-1 regulation has long been investigated
[183]. RA-induced gene expression is usually mediated through binding to retinoic
acid receptors (RARs) and subsequent interaction with RA responsive elements
(RAREs) within the promoter regions of target genes. Notably, the ICAM1 pro-
moter has been shown to contain a putative RARE which interacts with RARs
complemented with retinoid X receptors (RXRs) [184]. In human epithelial cells, a
synergistic effect of RA and TNF-α involving interplay between the RARXα and
NF-κB binding sites leading to highly increased ICAM1 promoter activity has been
demonstrated [185]. Also, ICAM-1 expression has been shown to be regulated by
RA in human tumour cell lines, including thyroid carcinoma cells, melanoma cells,
breast cancer cells [186] [187] [188] [189]. Moreover, ICAM-1 induction through
RA treatment increases susceptibility of tumour cells to immune cell-mediated lysis
[188].
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1.9 Aims and objectives
Despite intensive research efforts, prognosis for patients with GBM has not sig-
nificantly improved due to rapid tumour recurrence after therapeutic intervention.
Therefore, novel therapies to effectively target GSCs, the cell population suggested
to drive tumour recurrence, are urgently needed. To achieve this, I focused on in-
vestigation of the small molecule KHS101 and oncolytic virotherapy with CVA21 as
effective anti-GSC treatments and aimed to address several questions, e.g. whether
single compound treatment can affect GSC viability and growth of GSC-derived
tumours, whether molecularly diverse GSCs share features or vulnerabilities that
can be targeted by this small molecules, or whether virotherapy with CVA21 repre-
sents a feasible treatment option for elimination of GSCs. Therefore, in this study, I
sought to elucidate novel strategies to eliminate GSCs pursuing two different aims:
1) Determining the anti-tumourigenic potential of the neurogenic small molecule
KHS101, and 2) assessing the efficacy of a combination therapy of small molecule
treatment and oncolytic virotherapy.
1. The first aim involved the use of the small molecule KHS101 that has recently
been identified as a differentiation factor in NPCs. Furthermore, KHS101
has been found to affect proliferation of NPC through degradation of the
mitotic spindle protein TACC3 [116]. The functional similarities between nor-
mal NSCs and GSCs prompted investigation into KHS101 as an anti-GSC
compound. To address GBM heterogeneity, a clinically and molecularly di-
verse panel of patient-derived GSCs was used for assessment of the effect of
KHS101. For analysis of the KHS101-induced phenotype different methods
determining GSC self-renewal, differentiation, proliferation, cell viability, cell
death and autophagy were applied. Additionally, preliminary investigation
into the MOA of KHS101 was carried out including gene expression analysis
and metabolic profiling. Moreover, as KHS101 has previously been shown to
access the brain, its potential as an anti-tumourigenic agent was assessed in a
GSC-derived xenograft mouse model upon systemic administration.
2. For the second aim, I sought to assess the possibility of improving efficacy of
virotherapy with CVA21 for GBM treatment through small molecule induced
expression of ICAM-1. First, the consequences of high ICAM-1 expression
in GBM on immune cell populations were determined in a syngeneic mouse
model. Subsequently, a focused small molecule screen was conducted aiming at
identifying a compound with the potential to synergistically stimulate ICAM1
mRNA expression in GSCs together with the known ICAM-1 regulator RA.
26
1 Introduction
Chemically induced ICAM-1 expression was further analysed in vitro. Finally,
I investigated whether induced ICAM-1 expression is sufficient to increase
susceptibility of GSCs to CVA21-mediated cell lysis.
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potential of GSCs through induction of a
cellular self-destruction phenotype
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2.1 Results
2.1.1 KHS101 induces vacuolisation, autophagy and apoptotic
cell death in a panel of molecularly different GSCs
2.1.1.1 Characterisation of patient-derived GSCs
The small molecule KHS101 has been previously described as an agent with differ-
entiating effects on rat NPCs of the rat dentate gyrus [116]. Given the molecular
and phenotypic characteristics shared between NPCs and glioma stem cells (e.g.,
[59] [56]), I aimed to analyse the effect of KHS101 on GSCs. For investigation
of the potential anti-tumourigenic effects of KHS101, I used patient-derived GSC
models that were propagated under adherent and serum-free cell culture conditions.
These conditions have been shown to maintain stem cell-like characteristics includ-
ing self-renewal/clonal growth and BMP/serum-induced differentiation capabilities
[76]. Moreover, GSCs give raise to xenograft tumours that mirror the invasive nature
of GBM [61]. These qualities make patient-derived GSCs a well suited in vitro and
pre-clinical in vivo model for investigating the anti-tumourigenic activity of small
molecules.
I used six different GSC lines derived from primary GBM (GSC1, 4, 13), recurrent
GBM (GSC14, 20) and gliosarcoma (GSC11; table 2.1). In contrast to GSC1, 4, 11
and 13, GSC14 and GSC20 cells were derived from recurrent GBM with a treatment
history of radiation and chemotherapy (TMZ). Notably, glioma cells cultured under
GSC conditions have been shown to maintain their overall phenotype, genotype and
gene expression profile upon propagation in vitro for at least 11-13 passages [61].
Validation of these findings in my GSC models was beyond the scope of this thesis.
However, in order to ensure reproducibility of my results, I only used GSCs that
have been passaged for less than 12 passages.
All patient tumours and GSC lines were tested for methylation status of the MGMT
promoter. MGMT is an enzyme involved in DNA repair mechanisms, for example in
response to DNA damage caused by alkylating agents such as TMZ. Upon methy-
lation of the MGMT promoter, the MGMT gene is silenced and TMZ can more
efficiently exert its genotoxic effect [190]. Therefore, MGMT promoter methylation
has been described as predictive of a survival benefit for GBM patients treated
with TMZ. Among our set of GSCs, MGMT hypermethylation was only detected
in GSC lines GSC1, GSC11 and GSC14. The respective GSC1 and GSC11 patient
tumours were also tested positive for MGMT methylation. However, the GSC14 pa-
tient tumour only showed moderate levels of methylation at the MGMT locus. As
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Cell line
Patient
Type
Treatment
MGMT hyper-
methylation
Age Gender history Patient
GSC
line
GSC1 58 F Primary
GBM
None Yes 67%
GSC4 Unknown Unknown Primary
GBM
None Low 19%
GSC11 75 F Gliosarcoma None Yes 60%
GSC13 79 F Primary
GBM
None No 2%
GSC14 58 M
Recurrent
Giant Cell
GBM
Radiotherapy,
TMZ Moderate
91%
GSC20 50 M Recurrent
GBM
Radiotherapy,
TMZ,
IMA950
No 2%
GBMX 50 F Giant Cell
GBM
None No N/A
Cell line Karyotype Cytogenetics GSC Subtype
Patient GSC line GSC line
GSC1 Unknown Ch7 Amp
Classical,
Proneural
GSC4 Unknown Ch7 Amp
Mesenchymal,
Classical,
Proneural
GSC11 45,XX,+7.-10.der (11:13)
(q10:q10) [4]/46, idem, +8 [2]
Ch7 Amp, Ch10 Amp Mesenchymal
GSC13 Unknown
Ch7 Amp (& centromere
imbalance)
Proneural
GSC14 45.X.-Y[20]/46,XY [10] Ch7 Amp
Proneural,
Mesenchymal
GSC20 Unknown
Ch7 Amp, Ch10
monosomy
Proneural,
Mesenchymal
GBMX Unknown N/A N/A
Table 2.1: Clinical information, cytogenetic data and molecular subtype classification of
the patient-derived cell lines (TMZ: temozolomide; MGMT: O6-methylguanine-
DNA methyltransferase). The predominant GBM subtypes are shown in bold.
mentioned in 1.3 ‘Inter- and intratumour heterogeneity of GBM’, MGMT promoter
methylation can be heterogeneous within a tumour [34]; therefore, in the GSC14
model, selection of the GSC subpopulation or the cell culture conditions might have
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led to an enrichment of cells with a hypermethylated MGMT locus, as observed in
the GSC14 cell line.
Additional cytogenetic analysis was carried out to identify chromosomal aberra-
tions in the different GSC lines revealing gains of chromosome 7 in all GSC lines.
Chromosome 7 polysomy with or without amplification of EGFR is a frequently
observed alteration in GBM tumours [191]. In GSC20, a chromosome 10 mono-
somy was detected. Loss of heterozygosity on chromosome 10 includes the deletion
of the tumour suppressor gene PTEN and is associated with decreased survival of
patients [191]. Moreover, mutational analysis for the presence of a FGFR3-TACC3
fusion and immunoblot assays showed that none of our GSC lines are harbouring
the fusion mutation/protein, but all have elevated TACC3 protein levels compared
to non-malignant neural progenitor cells (E. Polson, unpublished data).
In 2010 Verhaak et al. postulated a molecular subtype classification for GBM by
multi-dimensional genomic data analysis. Based on mutational, gene expression and
DNA copy number data, they established four different subtype signatures classify-
ing GBM tumours into proneural, neural, classical and mesenchymal subtypes [25].
Notably, application of this GBM classification at the single cell level revealed a
high level of intratumour heterogeneity of GBM subtypes [39]. Thus, to determine
the molecular subtypes of our GSC models and concomitantly address heterogene-
ity, we performed single cell qRT-PCR quantifying the expression of 88 selected
stemness, proliferation and ‘Verhaak et al.’ GBM classifier genes. This methodol-
ogy provides the opportunity to determine the relevant gene expression signatures
in individual cells of a cell population and, thus, indicates subtype heterogeneity
within and across the GSC models. In order to integrate the Verhaak data and
our single cell data, the expression values of both data sets were discretised using a
3-level data discretisation approach (Edith Ross, personal communication). Finally,
after cell cycle normalisation, the discretised Verhaak data set provided the basis
for subtype prediction of individual GSCs. This analysis revealed that GSC models
contain cell populations of up to two different subtypes. GSC11 and GSC13 showed
predominantly mesenchymal, and proneural signatures, respectively. GSC1, GSC14
and GSC20 contained two subpopulations of cells with different subtype features
(GSC1: Classical and proneural; GSC14/GSC20: Proneural and mesenchymal).
Our GSC4 model harboured three different subtype compartments: the predomi-
nant subtype in GSC4 cells was mesenchymal that mixed with smaller proneural
and classical subtype compartments (table 2.1).
Taken together, the clinical, cytogenetic and GBM subtype classification data of
our patient-derived GSC lines indicate that our panel of GSC models cover a con-
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siderable spectrum of clinical and molecular GBM subtypes. We reasoned that
the various GBM types (primary, recurrent GBM, gliosarcoma), the genetic differ-
ences and the GBM transcriptional and subtype heterogeneity across and within the
GSC lines provide the molecular variety needed for comprehensively investigating
KHS101-induced anti-GBM responses.
2.1.1.2 KHS101 reduces proliferation of GSCs
KHS101 has been shown to bind TACC3 protein leading to its proteasome degra-
dation [116] [121], TACC3 is critically involved in the stabilisation of the mitotic
spindle during cell division [122] [118]. Work in our lab has shown that TACC3
protein levels are significantly reduced in GSCs upon treatment with KHS101 (E.
Polson, unpublished data). As KHS101 targets a protein crucial for cell division, my
hypothesis was that KHS101 treatment affects the proliferative capacity of GSCs.
To this end, I examined cell proliferation using immunofluorescence staining for
the nuclear protein KI67, which is only expressed in cycling cells, and therefore
a commonly used marker for proliferation [192]. To address the effect of KHS101
on proliferation in different GBM subtype contexts, I used the proneural/classical
GSC1, the mesenchymal/proneural/classical GSC4, the mesenchymal GSC11, and
the proneural/mesenchymal GSC20 models. Additionally, the normal adult NPC
line NP1, which has been derived from tissue samples taken from patients during
epilepsy surgery [89], was used as a non-cancerous control cell line. As an inactive
derivative of KHS101, such as KHS92, was not available at the time of this study and
previous studies indicated that KHS92 and the vehicle, dimethyl sulfoxide (DMSO),
gave similar results regarding gene expression changes in rat NPCs [116], DMSO was
used as the control treatment. Images of KI67 stainings of GSC1, GSC4, GSC11,
GSC20 and NP1 cells treated with vehicle reveal a highly proliferative phenotype
with the majority of nuclei (DAPI-stained) being KI67-positive. Upon treatment
with 1 µM or 7.5 µM KHS101 the number of DAPI/KI67 co-stained nuclei decreased
(expectedly) in both GSCs and NP1 cells (figure 2.1A).
The lowest KHS101 concentration tested (1 µM) reduced the percentage of pro-
liferative GSCs from ∼60% to 18-25% (∼3-fold; GSC1 and GSC4), from 75% to
40% (1.9-fold; GSC11) or from ∼70% to 10% (7-fold; GSC20). Treatment with 7.5
µM KHS101 further diminished these percentages to ∼15% (4-fold; GSC1), ∼8%
(7.5-fold; GSC4), ∼25% (3-fold; GSC11) or ∼1% (70-fold; GSC20). Interestingly, a
similar trend was visible for NP1 cells with 7.5 µM KHS101 leading to a decrease
from ∼50% to ∼12% (4-fold) in proliferative cells compared to the vehicle-treated
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cells. However, while a KHS101 concentration of 2.5 µM was sufficient to induce a
significant reduction in KI67 positive GSCs (p<0.05), statistical significance in NP1
cells was only achieved by the higher concentration of 7.5 µM KHS101 (figure 2.1B).
2.1.1.3 KHS101 induces a lethal vacuolisation phenotype in GSCs
Expression of the proliferation marker KI67 in CSCs has been associated with main-
tenance of the cells’ stem cell properties [193]. Accordingly, studies suggest that GSC
differentiation is associated with a reduction in GSC proliferation [58]. Furthermore,
forced differentiation of GSCs is accompanied by marked morphological changes [58].
Thus, to be able to study GSC behaviour including possible alterations in cell mor-
phology I used live cell imaging monitoring GSCs upon treatment with vehicle (0.1%
DMSO) or KHS101 (7.5 µM). Surprisingly, time lapse movies of GSC1 cells treated
with KHS101 over 72 hours revealed a different GSC fate. Compared to the vehicle
control (0.1% DMSO) treated GSC1 cells, KHS101 (7.5 µM) treated cells displayed
a distinct phenotype characterised by reduced cell growth and the emergence of
large vacuoles. This phenotype was followed by cell fragmentation associated with
cell rounding and death. In contrast, NP1 cells did not exhibit vacuolisation or cell
fragmentation upon KHS101 (7.5 µM) treatment (figure 2.2A).
The observed macro-vacuolisation phenotype has not been previously attributed to
KHS101, and we therefore sought to investigate this finding further. First, we tested
whether the KHS101-related vacuolisation phenotype can be exclusively observed in
GSC1 cells or also in different patient-derived GSC lines. Phase contrast images of
GSC11 and GSC20 cells taken after 12 hours of KHS101 (7.5 µM) treatment showed
the presence of vacuoles (as observed in KHS101-treated GSC1 cells). Interestingly,
KHS101 treatment did not induce vacuolisation in NP1 cells and no obvious mor-
phological changes were observed in KHS101-treated NP1 cells when compared to
vehicle (0.1% DMSO)-treated NP1 cells (figure 2.2B).
In order to quantify the KHS101-induced vacuolisation phenotype, randomly se-
lected phase contrast images of GSC1, GSC11, GSC20 and NP1 cells treated with
vehicle (0.1% DMSO) or KHS101 (1, 2.5 and 7.5 µM) for 12 hours were analysed
using ImageJ software. To this end, the vacuolated cellular area was highlighted by
colour thresholding (see image panels in figure 2.2C) and quantified as percentage
of the total cellular area. The bar graph in figure 2.2C depicts the dose-dependent
increase in the percentage of vacuolated area in the tested GSC lines upon treat-
ment with 1, 2.5 and 7.5 µM KHS101. The lowest tested concentration of KHS101
(1 µM) significantly increased vacuolisation in GSCs by ∼4- to 8-fold compared
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Fig. 2.1: KHS101 reduces proliferation of GSCs. A) Example images of KI67 immunoflu-
orescence staining in GSC1, GSC4, GSC11, GSC20 and NP1 cells treated with
vehicle or KHS101 (1 µM or 7.5 µM) for 48 hours. Nuclei were stained with
DAPI. B) Quantification of the concentration-dependent reduction in the per-
centage of proliferative (KI67 positive) cells 48 hours after KHS101 treatment
of GSC1, GSC4, GSC11, GSC20 and NP1 cells (data shown as mean ± SD;
n=3; *, P<0.05; **, P<0.01; Student t test).
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to their vehicle-treated counterparts. Treatment with 7.5 µM KHS101 increased
the percentage of vacuolated cellular area by ∼16-fold (GSC1), ∼33-fold (GSC20)
and ∼40-fold (GSC11) compared to the vehicle-treated control cells. In contrast,
quantification of vacuolisation in NP cells demonstrated that there is no significant
change in the percentage of vacuolated area in NP1 cells upon KHS101 treatment.
Notably, comparing KHS101-induced vacuolisation in GSC and NP1 cells revealed
a statistically significant difference in vacuolated GSC cellular area (P<0.01), hence
confirming the initial observation of a selectively induced vacuolisation phenotype
in GSCs (figure 2.2C).
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Fig. 2.2: KHS101 induces a lethal vacuolisation phenotype in GSC models. A) Repre-
sentative still images of live cell imaging of GSC1 and NP1 cells treated with
vehicle (0.1% DMSO) or 7.5 µM KHS101 indicating vacuolisation and cell death
only in GSC1. B) Example phase contrast images of GSC1, GSC11, GSC20 and
the normal NPC line NP1 treated with vehicle or 7.5 µM KHS101 for 12 hours.
Magnified images in top right corner highlight macro-vacuolisation in KHS101-
treated GSCs compared with NP cells. C) Left: phase contrast images of GSC1
cells treated with 7.5 µM KHS101 for 12 hours. Red outlines mark the vacuo-
lated cytoplasmic area. Right: quantification of the concentration-dependent
KHS101-induced vacuolisation in GSC1, GSC11, GSC20 and NP1 cells after 12
hours of KHS101 treatment. Statistical significance was either determined for
KHS101 treatment versus vehicle treatment (middle graph) or KHS101-treated
GSCs versus KHS101-treated NP1 cells (right graph; data shown as mean ±
SD; n=3; *, P<0.05; **, P<0.01; Student t test).
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2.1.1.4 KHS101 affects autophagic activity in GSCs
Recently, a vacuolisation phenotype has been described in GSCs in response to the
small molecule Vacquinol-1 [115]. Kitambi et al. conclude that the observed catas-
trophic vacuolisation induced by Vacquinol-1 is not associated with accumulation
of autophagic vacuoles but appears as a result of membrane ruﬄing and macro-
pinocytosis. Given the similarity of the Vacquinol-1 and KHS101-induced pheno-
types, I tested whether pinocytosis is the underlying mechanism of vacuolisation
and self-destruction in KHS101-treated GSCs. To this end, I treated GSC11 cells
with KHS101 in the presence of the extracellular-phase fluid tracer Lucifer Yellow
(LY), whose endocytic uptake into the cells is indicative of the pinocytotic process.
However, KHS101 treatment did not increase intercellular incorporation of LY and,
therefore, does not seem to affect GSC pinocytosis (figure 2.3A).
In addition to pinocytosis, cellular vacuolisation has been linked to cell starvation
and autophagy [194]. To test this possibility, I used the CytoID® assay, which al-
lows for selective staining of autophagic compartments in live cells and quantification
of CytoID®-positive/autophagic cells based on fluorescence images, as a first line
investigation method. Indeed, CytoID® positive staining was obtained for all tested
GSC lines (GSC1, GSC4, GSC11, GSC20) upon treatment with KHS101 (7.5 µM;
figure 2.3B). For assessment of a KHS101 dose dependent autophagy induction, the
different GSCs were treated with increasing concentrations of KHS101 for 48 hours.
The graph in figure 2.3C depicts the obtained dose response data for GSC1, GSC4,
GSC11 and GSC20 cells. Significant (P<0.01) induction of autophagy was triggered
by KHS101 (2.5 µM and 7.5 µM concentrations were tested) in all cell lines resulting
in 75-98% of autophagic cells. In contrast, only 1-7% autophagic cells were detected
in vehicle-treated cells. Observation of GSCs over time revealed a steady increase
of CytoID® positive cells over a 12-hour KHS101 treatment peaking at 48 hours
with ∼90% of CytoID® positive cells (figure 2.3D). Importantly, CytoID® posi-
tive staining was significantly elevated after treatment with KHS101 for 48 hours
in the four different GSC models (GSC1, GSC4, GSC11, GSC20) as compared with
vehicle (DMSO 0.1%) treated cells. The strongest effect was observed in the gliosar-
coma model GSC11 and co-staining of the autophagosomal CytoID® dye with the
lysosomal LysoID® dye revealed their partial co-localisation (figure 2.3E). This
suggested fusion of autophagosomes with lysosomes upon KHS101 treatment. How-
ever, autophagy is a complex process, thus requiring a more detailed insight into
the nature of KHS101-induced autophagy. To test this, I additionally carried out
immunofluorescence staining for microtubule-associated protein 1 light chain 3 β
(LC3B), a protein that is ubiquitously distributed in the cytoplasm and is recruited
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to form autophagosomes, e.g. during starvation [195] [196] [197]. High resolution
confocal LC3B immunofluorescence images of vehicle- and KHS101-treated GSC11
cells at the 12-hour time point showed a clear difference in staining patterns. In
contrast to the diffuse signal in the control cells, the KHS101-treated cells displayed
a punctate LC3B staining pattern as characteristic for LC3B protein associated with
autophagosomes (figure 2.4A; [195]).
As expected, the other tested GSC lines (GSC1 and 20) also presented altered LC3B
staining upon KHS101 treatment as shown by phase contrast/LC3B overlay images
in figure 2.4B. Based on those images, we determined the LC3B positive area as a
percentage of the total cellular area using the ImageJ software. The images in figure
2.4C show the selection of the LC3B positive area by the software and the graph
depicts the results of the LC3B measurements for GSC1, 11, 20 and NP1 cells. In
all tested GSC lines, a significant increase in LC3B positive area, ranging between
9-fold (in GSC1) and 23-fold (in GSC11) was obtained by treatment with 7.5 µM
KHS101. The apparent discrepancy between CytoID® data and LC3B stainings
at lower (1 µM, 2.5 µM) KHS101 concentrations can be explained by the different
time points and different read-outs chosen for the analysis. While the quantification
of the LC3B staining, based on the determination of the percentage of LC3B posi-
tive area, represents the autophagic stage after 12 hours of KHS101 treatment, the
CytoID® stainings, analysed by determination of the percentage of positive cells,
were done at the 48-hour time point. Therefore, at an earlier time point (12 hours),
only a KHS101 concentration of 7.5 µM leads to a significant increase in autophagic
vesicles in all tested GSC models. However, upon a prolonged exposure (48 hours),
a KHS101 concentration of 2.5 µM significantly induces the number of autophagic
Fig. 2.3 (preceding page): KHS101 induces a CytoID positive phenotype in GSC mod-
els. A) Example images of LY uptake into GSC11 cells treated with vehicle
(0.1% DMSO) or 7.5 µM KHS101 for 16 hours indicating that KHS101-induced
vacuolisation is not a result of increased endocytotic activity (white arrows
highlight vacuoles not containing LY). B) Example images of CytoID/LysoID
co-staining in GSC11 cells treated with vehicle or 7.5 µM KHS101 for 48 hours.
Nuclei were stained with Hoechst 33342. White arrows highlight examples of
CytoID/LysoID staining overlap. C) Example images of CytoID staining in
GSC1, GSC4, GSC11, GSC20 and NP1 cells treated with vehicle or 7.5 µM
KHS101 for 48 hours. Nuclei were counterstained with Hoechst 33342. D)
Graph showing the increase in the percentage of autophagic (CytoID-positive)
GSC11 cells over time peaking at 12 hours of KHS101 (7.5 µM) treatment. E)
Graph summarising the percentage of autophagic (CytoID positive) cells after
treatment with vehicle or increasing concentrations of KHS101 in GSC1, GSC4,
GSC11, GSC20 and NP1 cells at the 48 hour time point (data shown as mean
± SD; n=3; *, P<0.05; **, P<0.01; Student t test).
39
2 KHS101 abrogates the tumourigenic potential of GSCs
DAPI LC3B
DMSO KHS101
200 µm
DAPI LC3B
A
D
M
S
O
K
H
S
1
0
1
GSC1 GSC11 GSC20 NP1
100 µm
DAPI LC3B  PhC
B
50 µm
C
0
1
2
3
4
5
6
7
8
9
7.5 µM
**
**
*
KHS101
0
1
2
3
4
5
6
7
8
9
DMSO 1.0 2.5 7.5
%
 L
C
3
B
+
 A
re
a
GSC1
GSC11
GSC20
NP1
KHS101 [µM]
*
*
*
*
*
*
*
Fig. 2.4: KHS101 induces LC3B-positive early autophagosome formation in GSCs. A)
Example images of LC3B immunofluorescence staining in GSC11 cells treated
with vehicle (0.1% DMSO) or 5 µM KHS101 for 12 hours. Nuclei were coun-
terstained with DAPI. B) Representative images of LC3B immunofluorescence
staining in GSC1, GSC11, GSC20 and NP1 cells treated with vehicle or 7.5 µM
KHS101 for 12 hours. Nuclei were counterstained with DAPI. C) Left: LC3B
immunofluorescence images of GSC1 cells treated with 7.5 µM KHS101 for 12
hours. Yellow outlines mark the LC3B positive area. Right: Quantification of
the concentration-dependent KHS101-induced LC3B-positive staining in GSC1,
GSC11, GSC20 and NP1 cells. Statistical significance was either determined for
KHS101 treatment versus vehicle treatment (middle graph) or KHS101-treated
GSCs versus KHS101-treated NP1 cells (right graph; data shown as mean ±
SD; n=3; *, P<0.05; **, P<0.01; Student t test).
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cells. Notably, in contrast to GSCs, NP1 cells did not exhibit a significant change
in LC3B staining upon KHS101 (7.5 µM; 12 hours) treatment.
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Fig. 2.5: Representative EM images of GSC1, GSC11 and NP1 cells treated with vehicle
(0.1% DMSO) or 7.5 µM KHS101 for 12 hours. Scale bar: 5 µm. Magnified
images on the right show electron-dense vacuoles in KHS101-treated GSC1 and
GSC11 cells. Scale bar: 500 nm. N: nucleus; black arrow highlights vacuole with
double membrane; black arrowheads highlight vacuoles with single membrane;
red arrows highlight fusing vacuoles.
In addition to CytoID® and LC3B detection methods, a third line investigation
of KHS101-induced autophagy was based on electron microscopy (EM). We con-
ducted EM analysis of two representative GSC models (GSC1, GSC11) and NP1
cells treated with 7.5 µM KHS101 for 12 hours. The EM images of KHS101-treated
GSC1 and GSC11 cells shown in figure 2.5 display the presence of macro-vacuoles
(>1 µm in diameter). Higher magnification of the vacuoles in KHS101-treated GSCs
revealed double-membraned vacuoles filled with electron-dense material (indicative
of autophagosomes) and single-membraned vacuoles (indicative of lysosomes). Par-
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tial fusion of these vacuoles could also be seen in the high magnification images
(figure 2.5). In contrast to GSC1 and GSC11 cells, no vacuoles were formed in
KHS101-treated NP1 cells. This was consistent with live cell imaging of NP1 cells
and the observation that KHS101 treatment did not alter the vacuolated and LC3B-
positive cellular area measured in NP1 cells in contrast to vehicle-treated cells, thus
further supporting the notion of a selective and combined KHS101-induced vacuoli-
sation and autophagic phenotype in molecularly different GSC lines.
Together, these observations indicate the recycling of various cytoplasmic compo-
nents through an autophagic route, suggesting a self-degradation process triggered
by KHS101. However, autophagy is a dynamic process and an increase in autophagic
and lysosomal vesicles, as observed in KHS101-treated GSCs, could also be indica-
tive of a block in autophagic flux. Hence, further investigation into the effect of
KHS101 on autophagic flux would be a future task and could be achieved by assessing
LC3 turnover by immunoblot analysis or by detection of autophagosomal/lysosomal
degradation of labeled proteins (see also 2.2 ‘Discussion’).
2.1.1.5 KHS101 reduces viability of molecularly different GSCs and induces
apoptosis in GSCs but not NPs
As a cellular degradation process, autophagy has been associated with cell death
programs, e.g., apoptosis and necroptosis [198]. Notably, recent studies link in-
creased cellular autophagy with reduced cell viability and apoptosis of glioma cell
lines [112] [199] [200]. Therefore, I sought to assess whether KHS101-induced au-
tophagy is associated with reduced GSC viability and onset of apoptosis. To test
the effect of KHS101 on cell viability, we conducted luminescence-based cell viability
assays (CellTiter-Glo®, Promega) using our panel of six molecularly diverse GSCs
(GSC1, GSC4, GSC11, GSC13, GSC14 and GSC20), thus enabling us to ascertain
whether diverse GSC lines show differential responses to KHS101. Additionally, two
different NPC lines (NP1 and NP2) were tested serving as non-cancerous controls.
Figure 2.6 shows the cell viability dose response curves and respective IC50 val-
ues for GSCs and NPs treated with KHS101 (0-20 µM) for 2 days and for 5 days.
Consistent with previous observations from live cell imaging, KHS101 did not sig-
nificantly affect cell viability of NP cells. Even after 5 days of treatment with up
to 20 µM KHS101, both tested NP cell lines, NP1 and NP2, displayed only a small
reduction in cell viability (IC50 > 18 µM). In contrast, GSC lines exhibited a sig-
nificant concentration-dependent decrease in viability after 2 and 5 days of KHS101
treatment. For example, treatment of GSC1 with 5 µM KHS101 for 2 days reduced
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Fig. 2.6: KHS101 exhibits differential cytotoxicity in GSCs and adult neural progenitor
cells. A and B) Differential cell viability dose response curves of the patient-
derived GSC lines GSC1, GSC4, GSC11, GSC13, GSC14 and GSC20 (A), and
the patient-derived normal NPC lines NP1 and NP2 (B) are shown (data shown
as mean ± SD; n=3).
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the percentage of cell viability by ∼56%. Treatment with 20 µM KHS101 for 2 days
decreased cell viability by >90%. Longer exposure (5 days) of GSC1 cells to KHS101
led to a decrease in cell viability by 78% (5 µM) and 100% (20 µM; figure 2.6A). In
summary, irrespective of their subtype classification, clinical background or cytoge-
netic profile, all tested GSCs were susceptible to KHS101-induced cytotoxicity with
5-day-IC50 values ranging between ∼1 µM in GSC4 and ∼5 µM in GSC11 (table
2.2).
Cell line
IC50
2 days 5 days
GSC1 3.62 (3.10;4.23) 2.23 (2.02;2.47)
GSC4 2.37 (1.73;3.25) 0.97 (0.90; 1.04)
GSC11 > 18 5.05 (4.51;5.64)
GSC13 4.25 (3.65;4.95) 3.28 (2.77;3.89)
GSC14 3.46 (2.98;4.02) 1.98 (1.67;2.33)
GSC20 3.39 (2.63;4.36) 1.87 (1.58;2.21)
NP1 > 18 > 18
NP2 > 18 > 18
Table 2.2: IC50 values [µM] for GSCs and NPs treated with KHS101 for 2 days or 5 days
(data shown with 95% confidence interval).
To investigate whether KHS101-induced autophagy in GSCs, and the observed re-
duction in GSC viability, is associated with cell death via the apoptotic pathway, I
assessed the activity of executioner caspases of the apoptosis pathway in KHS101-
treated GSCs. To this end, caspase 3/7 activity was measured using a luminescence
assay (Caspase-Glo® 3/7 Assay). First, I analysed the induction of apoptosis over
time to determine the optimal time point for further analysis of caspase 3/7 ac-
tivity. To this end, the combined activity of caspase-3 and -7 was determined in
GSC1 cells at t0 and after 6, 12, 24 and 48 hours of treatment with 7.5 µM KHS101.
Caspase 3/7 activity steadily increased upon KHS101 treatment from 2-fold at 12
hours over 4.5-fold at 24 hours to 7-fold at 48 hours (compared to t0). In com-
parison to vehicle-treated cells, a significant 3.5-fold higher fold change value was
obtained for KHS101-treated GSC1 cells at the 48 hour time point (figure 2.7A).
Next, I tested whether caspase 3/7 activity was also induced by KHS101 in other
GSC lines. Due to the KHS101-induced caspase 3/7 activation peak at 48 hours, I
measured apoptosis activation in KHS101-treated GSC1, GSC11 and GSC20 cells at
this time point. Treatment with KHS101 (7.5 µM) significantly induced activation of
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caspase-3 and -7 resulting in a 4-fold (GSC11), 8-fold (GSC1) and 15-fold (GSC20)
increase compared to the vehicle controls (figure 2.7B). The presence of the caspase
inhibitor Z-VAD-FMK efficiently abolished KHS101-induced caspase activity in all
tested cell lines reducing the signal to baseline levels measured in vehicle-treated
cells. Notably, KHS101 treatment induced caspase3/7 activity comparable to treat-
ment with 1 µM of the known apoptosis inducer staurosporine [201], which was used
as a positive control. Staurosporine also activated the apoptotic pathway in NP1
cells (>5-fold); however, treatment of NP1 cells with KHS101 did not significantly
alter caspase-3/7 activity. Statistical comparison of the obtained data for GSCs and
NP1 cells showed a significant difference in apoptosis activation by KHS101 between
the GSC models and the non-tumour NP cells.
Taken together, the data presented in section 2.1.1 indicate that in a glioma stem
cell-like context, KHS101 dose-dependently induces a distinct phenotype charac-
terised by reduced cell proliferation, the formation of large vacuoles, and the onset
of autophagy. Notably, this KHS101-induced vacuolisation/autophagy GSC pheno-
type is associated with reduced cell viability and onset of caspase-dependent apop-
tosis in molecularly different GSC models. This lethal phenotype is selectively in-
duced in GSCs, but not NP cells indicating differential cellular responses to KHS101
in malignant glioma versus non-cancerous cells. Interestingly, TACC3 knockdown
studies indicate a TACC3-independent MOA of KHS101-induced cytotoxic vacuoli-
sation/autophagy in GSCs (E. Polson, unpublished data).
2.1.2 KHS101 attenuates the GSC phenotype
Assessment of the effect of KHS101 on cell viability (figure 2.6) revealed that the
cytotoxic effect of KHS101 is dose dependent leaving 44-84% and up to 38% vi-
able cells after 5 days of KHS101 treatment with 1 µM and 7.5 µM, respectively.
Therefore, I was interested in determining the cell fate of these ‘surviving’ cells. Lit-
erature evidence indicates that autophagy plays a critical role in development and
differentiation [202] and increased autophagy has been shown to be correlated with
reduced ‘stemness’ properties of GSCs [93]. Thus, I sought to analyse the ‘stemness’
characteristics of KHS101-treated GSCs. To this end I assessed the expression of
GSC ‘stemness’ markers NESTIN and SOX2 [203] [204] [205] and determined the
clonal growth capacity of GSCs.
NESTIN and SOX2 immunofluorescence stainings of GSC1 and GSC20 cells treated
with a low (1 µM) and a high (7.5 µM) concentration of KHS101 for 5 days sug-
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Fig. 2.7: KHS101 selectively induces apoptotic cell death in GSCs. A) Time course of
KHS101-induced caspase 3/7 activation in GSC1 cells indicating an increase over
time. Data normalised to t0 (data shown as mean ± SD; n=3). B) Fold changes
of caspase 3/7 activation in GSC1, GSC11, GSC20 and NP1 cells induced by
7.5 µM KHS101 (K) or 7.5 µM KHS101 + 2 µM Z-VAD-FMK (Z; caspase
inhibitor) for 2 days, or 1 µM staurosporine (S; apoptosis inducer) for 6 hours.
Data normalised to vehicle control (0.1% DMSO). Statistical significance was
either determined for compound treatment versus vehicle treatment (left graph)
or KHS101-treated GSCs versus KHS101-treated NP1 cells (right graph; data
shown as mean ± SD; n=3; *, P<0.05; **, PP<0.01; Student t test).
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gested a reduced expression of both ‘stemness’ markers compared to vehicle (0.1%
DMSO)-treated cells (figure 2.8A). Quantification of NESTIN stainings was done by
allocating stained cells into three different groups based on the intensity of the im-
munofluorescence signal. The three groups were defined by measuring the mean flu-
orescence intensity (MFI) of single cells using ImageJ software. The cells were then
classified as NESTINhigh (MFI > 25), NESTINlow (MFI = 5-25) or non-expressing
(MFI < 5) cells. The resulting percentages of NESTINhigh, NESTINlow or NESTIN-
negative GSC1 and GSC20 cells are depicted in figure 2.8B. In GSC1 cells, KHS101
treatment decreased the percentage of NESTINhigh cells from ∼50% to ∼28% (1
µM) and ∼10% (7.5 µM). Similarly, the percentage of NESTINhigh GSC20 cells was
reduced upon KHS101 treatment from 21.6% to 16.4% (1µM) and 0.8% (7.5 µM).
Quantification of SOX2 stainings by allocating cells into SOX2high, SOX2low and
SOX2-negative cells revealed a similar trend as observed for NESTIN. In GSC1, the
percentage of SOX2high cells was decreased from 56% to 32% (1 µM) and 11% (7.5
µM). A comparable pattern was obtained for GSC20 cells with KHS101 causing a
decrease in the percentage of SOX2high cells from 49% to 38% (1 µM) and 2.5% (7.5
µM; figure 2.8B). Notably, the observed reduction in the expression of ‘stemness’
markers was not accompanied by a concurrent increase in the expression of proteins
associated with a more differentiated phenotype, i.e. glial fibrillary acidic protein
(GFAP; [206]), an astroglial lineage marker, and neuron-specific class III β-tubulin
(TUJ1; [207]), a neuronal lineage marker (data not shown).
In order to assess the effect of KHS101 on the clonal growth ability of GSCs, the cells
were seeded at clonal density, treated with KHS101 and the single cells were counted
the following day. As soon as colonies consisted of a minimum of six cells (after 7-10
days), the number of colonies was determined and the percentage of colony forming
cells was calculated (see left part of scheme in figure 2.9A). All five tested GSC
lines (GSC1, GSC4, GSC11, GSC13, GSC20) completely lost their ability to form
colonies upon treatment with KHS101 (1 µM and 7.5 µM; figure 2.9B).
In the light of reports indicating that differentiated GSCs are able to regain GSC
features after removal of the differentiation stimulus, e.g. BMP [57], I tested whether
cells recover from KHS101-induced impairment of GSCs’ clonal growth capacity af-
ter removal of the compound. To address this, a second approach for assessment of
the colony formation efficiency was adopted. GSCs were treated with KHS101 (1
µM; 7.5 µM) for 2 days, the compound removed and the colony formation efficiency
was determined 7-10 days later (pre-treatment; see right part of scheme in figure
2.9A). Notably, 1 µM KHS101 did not have a significant effect on the colony for-
mation capability of GSC1 and GSC20 cells. However, compared to vehicle (0.1%
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Fig. 2.8: KHS101 reduces expression of the stem cell markers NESTIN and SOX2. A) Ex-
ample images of NESTIN and SOX2 immunofluorescence staining in GSC1 and
GSC20 cells treated with vehicle (0.1% DMSO) or KHS101 (1 µM or 7.5 µM) for
5 days. Nuclei were stained with DAPI. B) Quantification of the concentration-
dependent reduction in highly NESTIN- or SOX2-expressing GSC1 and GSC20
cells after 5 days of KHS101 treatment. NESTIN/SOX2negative: MFI<5;
NESTIN/SOX2low: MFI 5-25; NESTIN/SOX2high: MFI>25 (MFI: Mean Flu-
orescence Intensity; data shown as mean ± SD; n=3).
48
2 KHS101 abrogates the tumourigenic potential of GSCs
DMSO) treatment, pre-treatment with 7.5 µM KHS101 reduced the colony forma-
tion efficiency of all three tested GSCs by 5.7-fold (GSC1), 8-fold (GSC11) and
∼3-fold (GSC20; figure 2.9C). Hence, even after removal of KHS101, GSCs exhibit
a diminished ability to form colonies from single cells.
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Fig. 2.9: KHS101 reduces/abrogates the clonal growth capability of GSCs. A) Scheme
depicting the experimental protocol for assessment of the clonal growth capa-
bility of GSCs upon direct treatment with KHS101 (green) or after 48 hours of
treatment with KHS101 (blue). B) KHS101 treatment leads to complete abro-
gation of clonal growth capacity of GSC1, GSC4, GSC11, GSC13 and GSC20
(as determined according to the workflow depicted in green in A). C) Reduction
of clonal growth capability of KHS101 pre-treated GSC1, GSC11 and GSC20
cells compared to vehicle-treated cells (as determined according to the workflow
depicted in blue in A). Data shown as mean ± SD; n=3; *, P<0.05; **, P<0.01;
Student t test.
In conclusion, parallel investigation into the fate of KHS101-treated GSCs was con-
ducted addressing their ‘stemness’ characteristics by applying marker as well as
functional assays. Strikingly, the GSC population that survives 5 days of KHS101
treatment displayed reduced levels of ‘stemness’ markers NESTIN and SOX2. More-
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over, a significant reduction in the clonal growth capacity was observed in KHS101-
treated GSCs. In summary, KHS101 targets GSCs by mitigating essential stem cell
characteristics.
2.1.3 KHS101 elicits anti-tumourigenic effects in vivo
2.1.3.1 Systemic administration of KHS101 leads to reduced proliferation of
GSCs in established xenograft tumours
To investigate the effect of KHS101 in vivo, I used a pre-clinical mouse model based
on intracranial injection of GSC1 cells into immunocompromised mice [89]. After
xenograft tumours had established (six weeks), KHS101 was systemically adminis-
tered according to a dosing regimen adapted from published work [116]. In their
study, Wurdak et al. describe quick brain distribution of KHS101 upon intravenous
injection of 3 mg/kg reaching >30 µM and significant neurogenic effects of KHS101
after 14 days when injected subcutaneously (s.c.) at 6 mg/kg. However, the pharma-
cokinetic profile of KHS101 was obtained for rats and in the context of a neurogenesis
readout. Also, the half-life of KHS101 in the brain was demonstrated to be <1 hour.
Together with my finding that KHS101 function (e.g., on cell viability and clonal
growth capability) is stronger upon prolonged exposure, the short in vivo half life
of KHS101 prompted adaptation of the dosing regimen applied by Wurdak et al. to
ensure extended exposure of tumours to KHS101. Therefore, a 10-week treatment
strategy of two daily s.c. injections of KHS101 (6 mg/kg) was applied. However, to
reduce skin irritation caused by continuous s.c. injections, dosing was limited to 5
and 3 treatment days per week with bi-weekly alteration.
To confirm in vitro data on the effect of KHS101 on proliferation, immunological
analysis for the expression of the proliferation marker KI67 in the xenograft tumours
was performed. The immunofluorescence images shown in figure 2.10A demonstrate
a strong nuclear KI67 staining in the control tumours and a reduced positivity for
KI67 in KHS101-treated tumours. Identification of the nuclear KI67 immunopos-
itive area in vehicle- and KHS101-treated tumours revealed a significant decrease
in the percentage of KI67-positive tumour area upon KHS101 treatment by 2-fold
(12% to 6%; graph in figure 2.10A).
Furthermore, histological analysis of KHS101-treated tumours revealed morpholog-
ical features associated with necrosis including small nuclear fragments and overall
decreased nuclear density (figure 2.10B).
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Fig. 2.10: KHS101 reduces proliferation of GSCs in xenograft tumours and leads to
changes in tumour morphology. A) Left: Representative images of HK2-stained
GSC1-derived tumour sections (examples of two different specimen per group
are shown). Right: Quantification of the HK2-positve tumour area indicating
an increased HK2 expression in KHS101- versus vehicle-treated tumours (n=5;
**, P<0.01; Mann Whitney U-test). B) Example images of H&E stained sec-
tions of GSC1-derived xenograft tumours treated with vehicle of KHS101 show-
ing changes in tumour morphology upon KHS101 treatment including highly
necrotic areas (marked with white arrows). Scale bar: 200 µm.
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2.1.3.2 KHS101 reduces GSC invasion and tumour burden
The highly invasive nature of GBM tumours complicates treatment and targeting
this feature of GBM tumours constitutes a much needed addition to current therapies
to control GBM tumours [208]. Since a defining feature of GSCs is their highly
infiltrative growth behaviour in vivo, GSC-derived xenograft model, which have
been shown to be characterised by infiltrative behaviour [61], are well suited for
investigating the effect of KHS101 on tumour cell invasion. After engraftment of
GSC1 cells into the striatum (2.5 mm from the midline, 2.5 mm anterior from the
bregma), GSC1 xenograft tumours expand caudally, but cells also migrate along
the corpus callosum (CC) into the brain hemisphere contralateral to the injection
site. Notably, infiltration of tumour cells into the hemisphere contralateral to the
original tumour site is a pathological measure to define advanced GBM tumours in
patients (personal correspondence with neurosurgeon R. Mathew; [209]). Therefore,
to analyse the effect of KHS101 on GSC invasion, I measured both, caudal tumour
expansion and GSC migration into the other brain hemisphere.
To assess caudal tumour expansion, I determined the tumour area in different parts
of the mouse brains based on hematoxilin and eosin (H&E) stainings. To this end,
four distinct brain areas (rostral to caudal) were defined. The mouse brain sketch
and H&E-stained sections in figure 2.11A illustrate the location and histological fea-
tures of the selected brain areas 1-4. Area 1 covers the most rostral brain part and
includes the GSC injection site, thus representing the original tumour site. Area
4, on the other hand, is defined by the emergence of the ventricles and constitutes
the most caudal brain part used for this analysis. Figure 2.11B depicts images of
H&E sections of vehicle- or KHS101-treated brains with example sections shown
for the four analysed areas. Based on the H&E-stained sections, the tumour area
was calculated as a percentage of the total area of the brain section and results are
shown in figure 2.11C. As expected tumour burden was most pronounced in proxim-
ity to the injection site (area 1; ∼19% tumour area in control group) and gradually
attenuates reaching the lowest level in area 4 (∼8% tumour area in control group).
Compared to treatment with vehicle, treatment with KHS101 significantly reduced
tumour mass in areas 2-4 indicating a reduction in caudal tumour expansion.
Further assessment of invasiveness was achieved by determining cell migration across
the CC into the contralateral hemisphere. To this end, I stained the brain sections
obtained from the GSC xenograft model for human VIMENTIN (VIM) to visualise
VIM-positive GSC cells engrafted in the brain. CC-infiltration by GSCs was quan-
tified by fluorescence threshold-based measurement of VIM-positive area in the CC
of the hemisphere contralateral to the injection site. Notably, only 8% of CC area
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Fig. 2.11: KHS101 reduces tumour burden and invastion in GSC1 xenograft models after
10 weeks of systemic administration. A) Left: Sketch of mouse brain illustrat-
ing the approximate location of the four brain areas chosen for analysis. Right:
H&E stained sections of a mouse brain showing the morphological features of ar-
eas 1, 2, 3 and 4. Scale bar: 2 mm. B) Example images of H&E stained sections
of GBM1-derived xenograft tumours treated with vehicle or KHS101. Scale bar:
2 mm. C) Quantification of GSC1 tumour size in different areas of the brain
indicating reduced caudal tumour expansion in KHS101 (K) versus vehicle (V)
treated animals (n=5 (V) or 6 (K); *, P<0.05 ; **, P<0.01; Mann Whitney
U-test). D) Left: Representative images of VIMENTIN-stained GSC1-derived
tumour sections with the area of the corpus callosum (CC) highlighted (exam-
ples of two different specimen per group are shown). Right: Quantification of
VIMENTIN-positive area in the corpus callosum of the hemisphere contralat-
eral to the injection site indicating reduced GSC invasion in KHS101- versus
vehicle-treated brains (n=4; **, P<0.01; Mann Whitney U-test).
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of KHS101-treated brains contained VIM-positive cells (GSCs) compared to 24% in
vehicle-treated brains suggesting an inhibitory effect of KHS101 on GSC invasion
across the CC (figure 2.11D).
The observation of reduced tumour burden associated with reduced GSC prolifera-
tion and invasiveness upon treatment with KHS101 further supports the notion that
KHS101 significantly suppresses the tumourigenic potential of GSCs.
2.1.3.3 KHS101 prolongs survival in the GBMX xenograft model
Encouraged by the promising results obtained for GSC1-based xenografts (reduced
tumour burden and tumour cell invasion), I further investigated whether KHS101
treatment also affects survival of mice bearing intracranial GBM xenograft tumours.
To this end, I used a different patient-derived GBM xenograft model based on the
exclusively in vivo propagated GBMX cells. The predictable time frame of mor-
bidity in the GBMX model (11-13 weeks) facilitates survival analysis upon KHS101
treatment. Determination of the experimental endpoint for the survival readout was
based on early removal criteria (e.g., significant weight loss or neurological signs).
For a first survival analysis, established GBMX tumours (6 weeks after intracra-
nial injection) were treated with systemically administered KHS101 (according to
the dosing regimen described above) until the experimental endpoint. The brains
harvested at the end of the experiment were subjected to histological analysis. The
obtained H&E-stained brain sections of two different specimens per group are shown
in figure 2.12A and were used to calculate the percentage of tumour area per section.
In line with the results of the tumour burden assessment in the GSC1 model, the
analysis of tumour burden in the GBMX survival model indicated a significantly
reduced tumour mass in the KHS101-treated group compared to the vehicle-treated
group (>2-fold; figure 2.12B). Consistent with a reduced tumour burden in the treat-
ment group, KHS101 treatment significantly prolonged survival of GBMX-bearing
animals compared to the control group (P=0.0062; left graph in figure 2.12C).
To test whether the effect of KHS101 on survival is sustained after termination of
KHS101 administration, I performed a second survival analysis. To this end, treat-
ment with KHS101 started two weeks after intracranial injection of GBMX cells
and was maintained for 70 days following the treatment regime described above.
Whereas the survival endpoint of the vehicle control group was reached shortly
after the end of treatment with a median survival time of 90 days, KHS101 treat-
ment significantly prolonged survival resulting in a median survival time of 130 days
(P=0.0279; right graph in figure 2.12C).
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Fig. 2.12: KHS101 reduces tumour burden and prolongs survival in GBMX xenograft
models after 10 weeks of systemic administration. A) Images of H&E stained
sections of GBMX-derived xenograft tumours treated with vehicle or KHS101.
Brains were harvested at the experimental endpoint as defined by survival. Scale
bar: 3 mm. B) Quantification of GBMX tumour size indicating decreased tu-
mour burden in KHS101- versus vehicle-treated mice (n=4; **, P<0.01; Mann
Whitney U-test). C) Kaplan-Meier survival curves of GBMX tumour-carrying
animals showing prolonged survival in the KHS101 versus vehicle treatment
group with dosing start after 6 weeks of tumour establishment and continued
treatment (left; n=4; P=0.0062; log-rank test) or after 2 weeks of tumour es-
tablishment and 10 week of treatment (right; n=5; P=0.0279; log-rank test).
In summary, in vivo findings indicate KHS101 as an anti-GSC compound that sig-
nificantly reduces tumour cell proliferation and tumour burden, and also hinders
GSC invasion into caudal brain regions and the brain hemisphere opposite the ini-
tial engraftment site. Accordingly, KHS101 has a beneficial effect on the survival of
GBMX-bearing mice upon continued systemic administration, and this effect per-
sists even after treatment termination. Importantly, the KHS101 treatment regimen
applied in this study did not cause any obvious side effects or signs of intolerance
in the two different mouse models tested. Also, H&E-stained liver sections of mice
treated with vehicle or KHS101 for 10 weeks did not show any noticeable differences
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in the morphological features of the livers (figure 2.13, suggesting that KHS101 ad-
ministration for 10 weeks does not have any acute toxic effects in the tested mouse
models.
2 mm
Vehicle
2 mm
KHS101
400 µm
Vehicle
400 µm
KHS101
Fig. 2.13: Liver sections show intact tissue morphology after 10 weeks of treatment with
KHS101. Representative images of H&E stained liver sections of GSC1 tumour
bearing animals treated with KHS101 for 10 weeks show no indication of toxicity
compared with the vehicle-treated controls.
2.1.4 Gene expression and metabolic flux analysis suggest an
energy metabolism-obstructing mechanism of action of
KHS101
2.1.4.1 KHS101 alters expression of ‘stemness’, metabolism and glioma
proliferation genes
The mitotic spindle protein TACC3 has been identified as a KHS101 target in rat
NPCs and HEK293T cells [116] [121] and TACC3 immunoplot analysis shows a
reduction in TACC3 levels in GSCs upon treatment with KHS101 (E. Polson, un-
published data). Notably, lentivirally-induced knockdown of TACC3 results in re-
duced proliferation, as measured by KI67 immunofluorescence stainings, comparable
to KHS101 treatment. However, knockdown of TACC3 in GSCs does not induce
the vacuolisation/autophagy phenotype characteristic for KHS101-treated GSCs (E.
Polson, unpublished data), pointing to other mechanisms that play a role in the phe-
notype induced by KHS101. Therefore, unknown KHS101 targets must be responsi-
ble for the observed phenotype, hence requiring further MOA studies. A commonly
applied method of MOA investigation is transcriptome analysis, which allows for
the identification of direct or indirect consequences of compound treatment on gene
expression. By following a comprehensive gene expression analysis approach, I an-
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ticipated to better understand the molecular basis of KHS101-induced phenotypic
changes characterised by vacuolisation, autophagy and cell death, and to identify
potential pathways affected by KHS101. To achieve this, we performed a gene ex-
pression analysis using the Illumina HumanHT-12 v4 beadchip (Cambridge genomic
services). For this analysis, total mRNA isolated from GSC1 cells after 24 hours of
treatment with vehicle or KHS101 (7.5 µM) was used.
Differentially expressed genes were defined by fold changes (FC) ≤ -2 or ≥ 2, a
P-value ≤ 0.001 and a false discovery rate (FDR) ≤ 0.075, yielding a total of 828
significantly altered genes. Gene set enrichment analysis (GSEA) of vehicle (0.1%
DMSO) versus KHS101-treated GSC1 cells indicated a number of pathways affected
by KHS101. Consistent with known effects of KHS101 in rat NPCs, several cell cycle
pathways were identified to be altered in KHS101-treated cells. Notably, GSEA also
revealed changes in metabolic pathways such as oxidative phorphorylation and the
tricarboxylic acid (TCA) cycle (figure 2.14A). A number of factors critically involved
in oxidative phosphorylation (e.g., heme oxygenase (HMOX2) and thioredoxin re-
ductase 1 (TXNRD1); [210] [211]) and glycolysis (e.g. hekokinase 2 (HK2), SLC2A3
and phosphoglycerate kinase 1 (PGK1); [212] [213]) were upregulated upon KHS101
treatment. Additionally, genes implicated in ‘stemness’ (e.g., nitric oxide synthase
2 (NOS2) and S-phase kinase-associated protein 2 (SKP2); [214] [215]) and tumour
growth (e.g., v-akt murine thymoma viral oncogene homolog 1 (AKT1); [216]) were
downregulated, whereas tumour suppressors (e.g., tribbles pseudokinase (TRIB3)
and n-myc downstream regulated 1 (NDRG1); [217] [218]) and autophagy/apoptosis
activators (e.g., harakiri (HRK), gamma-aminobutyric acid A receptor-associated
protein-like 1 (GABARAPL1) and BCL2/adenovirus E1B 19 kDa interacting protein
(BNIP3); [219] [220] [221]) were upregulated. Based on their cellular function, we
allocated 25 of those factors to five different groups: ‘tumour suppression/growth’,
‘glycolysis’, ‘mitochondrial stress’, ‘autophagy/death’ and ‘stemness’. Displaying
the gene expression alterations of those 25 genes in a radar chart layout yielded a
distinctive pattern of gene expression changes caused by KHS101 (see red line in
figure 2.14B), which were confirmed by qRT-PCR (see blue line in figure 2.14B).
Since GSEA pointed to KHS101-induced metabolic changes in vitro, I sought to
test this finding in vivo by determining expression of HK2, a key factor in glucose
metabolism whose expression was found to be significantly altered upon KHS101
treatment. Consistent with up-regulation of HK2 mRNA in cultured GSCs, HK2
immunostainings of GSC1-derived xenograft tumours showed elevated levels of HK2
upon treatment with KHS101 compared to vehicle-treated tumours (immunofluo-
rescence images in figure 2.14C). Quantification of the HK2-positive area by colour
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Fig. 2.14: KHS101 affects expression of ‘stemness‘, metabolism and glioma proliferation
genes. A) Results of gene set enrichment analysis. B) Radar charts depicting
gene expression changes from microarray gene expression analysis (red line)
and targeted qRT-PCR (blue line) in GSC1 24 hours after with 7.5 µM KHS101
showing comparable results. C) Left: Representative images of HK2-stained
GSC1-derived tumour sections (examples of two different specimen per group
are shown). Right: Quantification of the HK2-positve tumour area indicating
an increased HK2 expression in KHS101- versus vehicle-treated tumours (n=5;
**, P<0.01; Mann Whitney U-test). D) Concentration dependent reduction of
mRNA expression of glioma ‘stemness’ markers NOS2 (left) and SKP2 (right) in
KHS101-treated GSC1, GSC11 and GSC20 cells after 24 hours (data normalised
to vehicle control and shown as mean of fold changes ± SD; n=2/3; *, P<0.05;
**, P<0.01; Student t test).
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thresholding confirmed the qualitative observation by revealing a significant increase
of approximately 2-fold (comparing the data means) in the percentage of HK2-
positive area in KHS101-treated tumours compared to control tumours (graph in
figure 2.14C).
Two of the ‘stemness’ factors whose expression were decreased in KHS101-treated
GSC1 cells, SKP2 and NOS2, have previously been demonstrated to promote GSC
features and tumour growth [214] [215]. To further corroborate the finding of the
gene expression analysis, I assessed the effect of KHS101 on NOS2 and SKP2 gene
expression in three different GSC models. To this end, GSC1, GSC11 and GSC20
cells were treated with vehicle or 1 µM, 2.5 µM and 7.5 µM KHS101 for 24 hours and
the relative NOS2 and SKP2 expression was determined by qRT-PCR. As expected,
KHS101 treatment of GSCs reduced expression of NOS2 mRNA in a concentration-
dependent manner reaching a reduction of up to ∼86% (GSC1), 92% (GSC11) and
97% (GSC20) after treatment with 7.5 µM KHS101 for 24 hours (left graph in figure
2.14D). Similarly, KHS101 decreased SKP2 expression in all three GSC lines result-
ing in up to 66% (GSC1), 81% (GSC11) and 83% (GSC20) (right graph in figure
2.14D).
2.1.4.2 KHS101 induces metabolic exhaustion in GSCs
Gene expression analysis and GSEA indicated KHS101-induced transcriptional al-
terations in components of metabolic pathways (i.e. glycolysis and oxidative phos-
phorylation). Therefore, we investigated the effect of KHS101 on the metabolic
phenotype of GSCs. We used an extracellular flux analyser to determine the extra-
cellular acidification rate (ECAR), a measure of the glycolytic activity of the cells,
and the oxygen consumption rate (OCR) to assess mitochondrial respiration in live
cells [222].
The direct consequence of KHS101 on the mitochondrial function was determined
measuring the OCR levels of GSCs and NPs upon addition of vehicle (0.1% DMSO)
or 7.5 µM KHS101. OCR measurements were taken every 10 minutes for the du-
ration of 140 minutes. Three measurements after addition of KHS101, compounds
that specifically target different components of the electron transport chain were
injected to allow for the identification of the effect of KHS101 on key parameters
of mitochondrial respiration. First, the adenosine triphosphate (ATP) synthase
inhibitor oligomycin was injected which obstructs ATP production in the mito-
chondria leading to a decrease in OCR below basal respiration levels. Addition
of carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) then uncouples
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oxygen consumption from ATP generation leading to disruption of the proton gra-
dient across the mitochondrial membrane which results in maximum oxygen con-
sumption. Consequently, OCR levels were elevated to maximal respiration. Lastly,
the complex I inhibitor rotenone and the complex III inhibitor antimycin A were
simultaneously injected to fully disable mitochondrial respiration and reduce OCR
levels to non-mitochondrial respiration levels. Control GSC1 cells (vehicle-treated)
showed reduced OCR levels upon oligomycin injection, followed by an increase
above basal levels upon addition of FCCP, and a drop in OCR to a minimum
after rotenone/antimycin A injection. In contrast, KHS101 treatment of GSC1
cells immediately decreased OCR from ∼124 pmol/min (basal respiration) to ∼80
pmol/min indicating an immediate effect of KHS101 on respiration. Addition of
oligomycin did not reduce OCR any further and the KHS101-treated cells were not
able to reach their maximum respiration capacity upon FCCP injection. Similarly,
injection of KHS101 limited oxygen consumption of NP1 cells depriving the cells of
their capacity to generate ATP by mitochondrial respiration. However, the basal
respiration levels of NP1 cells were approximately 2.5-fold lower compared to GSC1
cells, indicating a lower energy demand and, thus, reduced dependency on con-
stantly high rates of mitochondrial respiration. In conclusion, KHS101 immediately
affected mitochondrial respiration in GSC and NP cells by obstructing oxidative
phosphorylation (figure 2.15A).
The direct consequence of KHS101 on glycolysis was assessed by measuring the
ECAR levels. First, the baseline acidification caused by non-glycolytic proton ex-
trusion was determined by ECAR measurements in glucose-starved cells. Then,
vehicle (0.1% DMSO) or 7.5 µM KHS101 was added. After three more ECAR mea-
surements, glucose was added to activate the glycolytic pathway. Catabolism of
glucose by the cells leads to production of ATP and an accumulation of protons in
the media which results in an increase in ECAR. This proton accumulation allows
for the assessment of the basal glycolytic activity of the cells [222]. Addition of
the ATP synthase inhibitor oligomycin then disables ATP production by the mito-
chondria, thus further promoting the glycolytic pathway as the alternative route of
energy production. The resulting increase of ECAR revealed the cells’ maximum
glycolytic capacity. Finally, glycolysis was inhibited by addition of the glucose ana-
log 2-Deoxyglucose (2-DG) causing a drop in ECAR to baseline level. The resulting
‘glycolytic stress test’ profiles for GSC1 and NP1 cells are shown in figure 2.15B.
Compared to vehicle-treated cells, GSC1 cells treated with KHS101 (7.5 µM; acute
injection) elevated glycolytic energy production in the presence of glucose but lost
their ability to reach their glycolytic maximum since injection of oligomycin had no
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additional effect on ECAR levels. The immediate effect of KHS101 on glycolysis
in NP1 cells was similar to GSC1 cells. However, NP1 cells treated with KHS101
still had the capacity to attain their maximum glycolytic potential and had a sig-
nificantly lower ECAR rate consistent with the lower energy demand of non-tumour
cells compared to the highly energetic malignant cells.
The diagram in figure 2.15C summarises the findings of the metabolic profiling
of GSC1 and NP1 cells as a direct consequence of KHS101 treatment. The non-
malignant NP1 cells only showed a minimal immediate response to KHS101 treat-
ment. Upon exposure to KHS101, NP1 cells switched from a low aerobic/very low
glycolytic state to a very low aerobic/low glycolytic phenotype; however, remaining
in an overall low energy state. In contrast, GSC1 cells exhibited a more drastic
direct response to KHS101 and switched from a high aerobic/medium glycolytic to
a low aerobic/high glycolytic metabolism.
Critical gene expression changes in components of glycolytic and oxidative phospho-
rylation pathways were identified after 24 hours of KHS101 treatment. Therefore,
we sought to assess the metabolic state of KHS101-treated GSC1 and NP1 cells at
the 24 hour time point. In contrast to vehicle-treated cells, GSC1 cells treated with
7.5 µM KHS101 for 24 hours exhibited an oxygen consumption rate at the level
of non-mitochondrial respiration indicating a ‘shutdown’ of oxidative phosphoryla-
tion (figure 2.15D). In contrast to the direct effect of KHS101 on glycolysis, GSC1
cells treated with KHS101 for 24 hours displayed both, a reduced glycolytic activity
and a reduced maximal glycolytic capacity compared to vehicle-treated control cells
(figure 2.15E). The graphs in figure 2.15F outline the findings of KHS101-induced
changes in mitochondrial respiration and glycolysis in GSC1 and NP1 cells after 24
hours of treatment. GSC1 cells displayed almost 95% reduction in O2 consumption
compared to vehicle-treated cells (top graph in figure 2.15F) with a concomitant re-
duction in glycolysis by 25% and in glycolytic capacity by >50% (bottom graph in
figure 2.15F). In NP1 cells, treatment with KHS101 had the same effect on O2 con-
sumption leading to a decrease in ATP coupled respiration by 90% and, in maximum
capacity of mitochondrial respiration, by almost 80% (top graph in figure 2.15F).
However, in contrast to GSC1 cells, NP1 cells responded to KHS101 treatment with
up-regulation of the glycolytic pathway. After 24 hours of treatment with KSH101,
the extracellular acidification upon glucose addition was raised by almost 50% and
the cells’ maximum glycolytic capacity was 20% higher compared to vehicle-treated
NP1 cells (bottom graph in figure 2.15F).
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In conclusion GSEA of transcriptome data indicated a thus far unobserved effect
of KHS101 on metabolism pathways (i.e. glycolysis and oxidative phosphoryla-
tion). Accordingly, preliminary data investigating mitochondrial respiration and
glycolysis by extracellular flux analysis revealed that KHS101-treated GSCs de-
crease mitochondrial respiration and show a reduced glycolytic capacity compared
to vehicle-treated control cells. This KHS101-induced obstruction of the cells energy
metabolism ultimately leads to metabolic exhaustion in GSCs, but not NPs.
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2.2 Discussion
GBM is among the most devastating cancers and despite intensive research, treat-
ment options are limited and patient prognosis remains grim [3] [5]. Therefore, new
treatment approaches aiming at exploiting GBM vulnerabilities are urgently needed.
Identification of a tumour-driving stem-cell like subpopulation in GBM has fueled
research into GSCs and targeting this cancer cell population is thought to constitute
a promising therapeutic approach in order to prevent brain tumour recurrence [56].
Recently, a number of studies have demonstrated the anti-GBM potential of small
molecules, for example, through disruption of mitotic pathways [114], cell death
programs [108], pinocytotic activity [115] or autophagy regulation [112]. The small
molecule KHS101 has previously been identified as an anti-proliferation, neuronal
differentiation compound in NPCs that acts through targeting the mitotic spindle
protein TACC3. Moreover, KHS101 is able to cross the blood brain barrier [116].
Based on these properties, I sought to investigate the potential anti-GSC activity of
KHS101 by identifying molecular vulnerabilities intrinsic to GSCs.
One major challenge for GBM therapy is the molecularly and phenotypically het-
erogeneous nature of GBM tumours [223]. In order to address this diversity, I used a
panel of patient-derived GSC lines from various clinical backgrounds including pri-
mary and recurrent GBM, the latter with treatment history of radiation and TMZ,
and different MGMT methylation status. Moreover, single cell qRT-PCR analysis
revealed highly diverse transcriptional profiles among and within the different GSC
lines. Further computational analysis applying a recently published GBM subtype
classification scheme [25] indicated the presence of classical, proneural and mes-
enchymal subtype compartments in the GSC lines. Thus, our patient-derived GSC
lines constitute a considerable set of clinically and molecularly heterogeneous cell
populations representative of various GBM phenotypes, hence, providing an ade-
quate basis for investigation into the possible anti-GBM activity of KHS101 (table
2.1).
Consistent with previous findings on KHS101 as an anti-proliferative agent in NPCs
[116], KHS101 treatment also significantly decreased the proliferative potential of
GSCs (figure 2.1). This KHS101 effect on GSCs can be attributed to its known tar-
get TACC3, a protein essentially involved in mitotic spindle assembly, and thus cell
proliferation. In accordance to TACC3’s role in mitotic spindle architecture, deple-
tion of TACC3 has been linked to chromosomal instability and cell death. However,
these effects have only been reported for prolonged depletion of TACC3 (e.g., [224]).
In the case of KHS101, it is unlikely that genomic instability caused by KHS101-
induced reduction in TACC3 protein levels will have significant consequences as
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KHS101 exhibits strong cytotoxic effects through TACC3-independent mechanisms
(see below).
As a link between reduced proliferation and GSC differentiation has been described
(e.g., [225] [85]), I proceeded by monitoring KHS101-treated GSCs for morpholog-
ical changes indicative of a differentiation phenotype. However, live cell imaging
of GSCs revealed massive cellular vacuolisation resulting in cell death (figure 2.2).
A similar catastrophic vacuolisation phenotype has recently been described for the
small molecule Vacquinol-1 by Kitambi et al. and found to be a consequence of ex-
cessive pinocytotic activity. In vitro and preclinical validation of this phenotype con-
firmed selective targeting of GSCs through compound-induced vacuolisation [115].
To test whether KHS101 exerts its effects exclusively through hyper-vacuolization, I
initially assessed both the cells’ endocytotic activity (using a low permeability endo-
cytosis marker; [115] [226]), and autophagy. In contrast to the excessive pinocytosis
described for Vaquinol-1, treatment with KHS101 did not alter the level of extracel-
lular fluid uptake by GSCs. However, using different autophagy detection methods,
I gathered convincing evidence (increased dye-based staining and LC3B immunos-
taining of autophagosomal vacuoles as well as EM imaging showing the presence of
electron-dense autophagic/lysosomal vacuoles) that indicates a markedly increased
number of autophagosomes and lysosomes in KHS101-treated GSCs (figures 2.3,
2.4 and 2.5). Increased numbers of autophagic vacuoles can be indicative of a
hyperactive autophagic flux or can be the mere accumulation of autophagosomes
due to an interrupted flux, for example caused by impaired fusion with lysosomes
[227]. Staining of KHS101-treated GSCs with an autophagosomal and lysosomal
dye showed a partial co-localisation of the two dyes indicating an active autophagic
flux (figure 2.3). Consistently, examination of the EM images revealed the pres-
ence of both, double and single membraned electron-dense vacuoles, representing
autophagosomes and lysosomes, respectively. Moreover, membrane fusion of pre-
sumptive autophagosomes and lysosomes was observed, further corroborating the
notion of a KHS101-induced autophagic activity rather than a KHS101-induced
perturbation of the cells’ baseline autophagic flux (figure 2.5). This notion could
be further strengthened by applying methodologies specifically detecting autophagic
flux, such as measuring LC3 protein turnover by Western Blot in the presence or ab-
sence of late-phase autophagy inhibitors (e.g. bafilomycin A1, chloroquine) and the
determination of the difference in the amount of the lipidated form of LC3 (LC3-II).
Additional methods to assess autophagic flux are based on using mRFP-GFP-LC3
constructs and monitoring their cellular location and the colour change occurring
upon lysosomal degradation, or measuring isotopes released by degradation of long-
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lived isotope-labeled proteins [228].
As a ‘recycling’ process for degradation of cellular components, autophagy has been
described to be activated in response to damaged organelles or as an energy source
upon starvation. Hereby, autophagy serves as a survival mechanism of the cell, for
example to altered environmental stimuli or chemical compounds [229] [230]. How-
ever, formation of autophagic vesicles has also been found to be indicative of a cell
death program distinct from apoptotic cell death. In this autophagic cell death, the
autophagic activity is thought to be the cause of death rather than an attempt to
prevent it [231]. Shchors et al., for example, identified chemical compounds that
exhibit GBM cell cytotoxicity through induction of this so called autophagy asso-
ciated cell death, a cell death program that is independent of apoptosis [112]. My
data on caspase 3/7 activity, however, suggest apoptosis as the cell death mechanism
induced by KHS101 (figure 2.7). Future experiments focusing on using autophagy
inhibitors (e.g., wortmannin, 3-methyladenine) or silencing critical components of
the autophagic machinery (e.g., Beclin 1, autophagy related 5 (ATG5), unc-51 like
autophagy activating kinase 1 (ULK1)) by shRNA knockdown could give further
insight into the role of autophagy in KHS101 cytotoxicity and its link to KHS101-
induced vacuolisation.
Strikingly, by conducting comprehensive cell viability studies using a diverse set of
GSC models, I demonstrated that the cytotoxic effect of KHS101 is independent of
GBM subtype, parental tumour origin, treatment history and MGMT methylation
status (figure 2.6 and table 2.2). Thus, KHS101 may target a common vulnerability
of GSCs irrespective of their clinical and molecular background. Notably, GSC11,
derived from a gliosarcoma, exhibited a slightly delayed response to KHS101 com-
pared to the other five GSC lines tested. Interestingly, GSC11 also displayed the
most pronounced vacuolisation/autophagy phenotype in the phase contrast and EM
images. Hence, a more efficient recycling of cellular components through autophagy
could be one explanation of the longer survival of GSC11 cells upon KHS101 treat-
ment. However, other resistance or coping mechanism could play a part in a delayed
response to KHS101. Most importantly, assessment of cell viability upon KHS101
treatment demonstrated a marked differential cytotoxicity of KHS101 in GSCs and
NPs. With 5-day-IC50 values of >18 µM, KHS101 exhibits only minimal cyto-
toxic effects on NP cells suggesting a selective cytotoxic activity of KHS101. This is
consistent with the observed selective induction of the vacuolisation/autophagy phe-
notype in GSCs but not in NPs. Overall, these results indicate that KHS101 targets
a molecular vulnerability intrinsic to the malignant GSCs without affecting viability
of normal NP cells. The role of the KHS101 target TACC3 in KHS101 cytotoxicity
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has still to be elucidated. In this context, it would also be interesting to investigate
whether glioma cells with a FGFR3-TACC3 fusion protein, as it has been identified
in several different cancer types including glioma [119][129] [130] [131], display an
increased susceptibility to KHS101 compared to our TACC3 wild-type GSC mod-
els. Notably, targeting the FGFR3-TACC3 fusion protein by inhibiting the FGFR3
kinase activity in a glioma mouse model has been shown to have a beneficial effect
on survival [119]. However, FGFR3-TACC3 fusions are only detected in a small
subset of GBM specimen [232], hence limiting the possibility to obtain a GSC line
harbouring this mutation. An alternative approach could be the establishment of
FGFR3-TACC3 expressing NP cells by lentiviral transduction. Comparing the cy-
totoxic effect of KHS101 on TACC3 wild-type GSCs, FGFR3-TACC3 NP cells and
wild-type NP cells could then give an indication of the efficacy of KHS101 treatment
in the FGFR3-TACC3 context.
Viability assays also showed a residual viable cell population upon treatment with
lower concentrations of KHS101, which prompted the question whether GSCs that
survive KHS101 treatment still exhibit stem cell properties. This could have im-
plications for the in vivo/pharmacological use of KHS101 (e.g., upon systemic ad-
ministration in mice), when cells are not continuously and equally exposed to lethal
KHS101 concentrations. Notably, surviving GSCs are characterised by markedly
reduced levels of stemness markers (NESTIN and SOX2) and an attenuated clonal
growth capacity (figures 2.8 and 2.9). Thus, GSC populations that are exposed to
sublethal concentrations of KHS101 (<2 µM) exhibit a reduction in GSC features
(i.e. undifferentiated state, self-renewal) potentially making them less tumouri-
genic (e.g., [58] [59]). However, consistent with the incomplete terminal differentia-
tion and reversible cell cycle exit reported for BMP-treated GSCs and GSC-derived
oligodendrocyte-like cells [57], KHS101 only abrogates the colony formation capabil-
ity of GSCs upon prolonged exposure (figure 2.9B). When KHS101 is removed, some
cells are able to re-enter the cell cycle and grow colonies (figure 2.9C), indicating
that a 2-day-KHS101 treatment is not sufficient to induce a sustained differentiated
state in GSCs. Therefore, further investigation into the effect of long-term KHS101
treatment on GSC features and proliferation are required.
Consistent with the herein described anti-proliferative, anti-stemness, and cytotoxic
effects of KHS101 in GSC cultures, GSC-derived mouse xenograft models displayed
decreased KI67 immunostaining, increased necrotic areas and a significant reduction
in tumour burden (figures 2.10 and 2.11). Notably, the difference in tumour bur-
den is most pronounced in areas distant from the initial tumour site indicating that
KHS101 inhibits caudal expansion of established GSC-derived xenograft tumours.
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Moreover, KHS101 also inhibited contralateral tumour cell invasion as shown by VIM
staining (figure 2.11). This experimental readout has clinical relevance, as GBM tu-
mour spread into the other hemisphere constitutes a pathological sign for advanced
GBM in patients (R. Mathew, personal correspondence; [209]). Finally, consistent
with in vivo tumour growth inhibiting properties in GSC-derived xenograft, KHS101
also significantly prolonged survival of mice bearing GBM xenograft tumours (figure
2.12). Notably this survival effect was shown for a xenograft model based on in vivo-
propagated patient-derived GBM cells indicating an anti-tumourigenic function of
KHS101 beyond cell culture-propagated GSCs. Importantly, after 10 weeks of sys-
temic administration of KHS101, H&E-stained liver sections showed intact tissue
architecture and no obvious side effects of KHS101 were observed in treated animals
(figure 2.13). This is consistent with previously reported safety of KHS101 admin-
istration in rats [116]. Together, my in vivo data indicate a potential therapeutic
window of KHS101 treatment. Moreover, upon systemic administration KHS101
significantly reduces tumour burden, GSC invasion and prolongs survival of mice
bearing GBM xenograft tumours. Future in vivo work may include validation of
these findings using additional GSC-derived xenograft models as well as genetic
and/or syngeneic mouse models of GBM.
A commonly applied first line investigation method for small molecule MOA stud-
ies is gene expression analysis which allows for the identification of critical gene
expression alterations induced by a compound [105]. Furthermore, transcriptome
data can be used to reveal functional connections between compounds of unknown
MOA and compounds with known targets through identification of common gene
expression alterations [233]. Hence, in order to establish a possible explanation
of the mechanism that underlies KHS101-induced cytotoxicity, we performed tran-
scriptome analysis followed by GSEA. Consistent with previously identified KHS101
effects in rat NPCs [116], cell cycle and ‘stemness’ genes (e.g., NOS2, SKP2) were
significantly affected in GSCs. In addition to already known KHS101 effects, GSEA
of the gene expression data revealed altered expression levels of genes involved in di-
verse metabolic pathways including oxidative phosphorylation and glycolysis (figure
2.14). Notably, an altered energy metabolism has been recognized as a hallmark and
potential molecular vulnerability of cancer cells [234]. Cancer cells have adjusted
their energy metabolism in order to be able to meet their high energy demands and
fuel their rapid growth. It has long been known, that cancer cells can reprogram
their glucose metabolism to produce energy through glycolysis even in the presence
of oxygen [234]. This metabolic switch highlights the functional difference in energy
production of cancer and normal cells and makes the metabolic state of malignant
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cells a cancer-specific, ‘targetable’ feature. To uncover the metabolic state of our
GSC lines, we performed extracellular flux measurements. This analysis revealed
that GSCs have a massively increased bioenergetic demand (with both high oxida-
tive phosphorylation and high glycolysis rates) compared with the non-malignant
NP cells. KHS101 treatment alters the highly energetic metabolic phenotype of
GSCs by disrupting mitochondrial respiration and thereby inducing compensatory
glycolytic flux (figure 2.15). Consistent with the observed induction of glycolysis
by KHS101 determined by ECAR measurements, lactate accumulates in the media
of KHS101-treated GSCs (E. Polson and S. Allison, unpublished data). Lactate is
produced by glycolytic cells through lactic acid fermentation, thereby re-oxidising
NADH to NAD+, in order to provide the NAD+ needed for the glycolytic pathway.
Therefore, raised levels of lactate released by the cells is an additional indication
of an increased glycolytic activity. Other standard ways of identifying changes in
glycolytic activity include the measurement of glucose uptake by the cells, tracing
of 13C-labeled glucose and activity assays of rate-limiting glycolytic enzymes [235],
and could be part of future experiments on the effect of KHS101 on the glycolytic
pathway. In addition to evidence of elevated glycolysis derived from extracellular
flux measurements, increased expression of HK2, which catalyses the first step in the
glycolytic pathway and therefore critically defines the rate of glucose metabolism,
is detected in vitro and in vivo (figure 2.14). In its role as a critical rate-limiting
glycolytic enzyme, HK2 acts together with glucose transporters (e.g., SLC2A1 and
SLC2A3) to allow cancer cells to metabolise glucose at an elevated rate to fuel cell
proliferation [236]. This induction of HK2 and glucose transporters is consistent with
the observation that KHS101 treatment markedly increased HIF1α in the nucleus of
GSCs (E. Polson & C. Abbosh, unpublished data). HIF1α-dependent transcriptional
changes include the upregulation of various glycolytic enzymes and glucose trans-
porters [237]. Therefore, HIF1α signaling might play a role in up-regulation of gly-
colytic enzymes upon KHS101 treatment. However, although GSCs initially manage
to compensate ‘shutdown’ of mitochondrial respiration by elevating their glycolytic
rate, they exhaust their energy resources. An explanation for progressive glycolytic
exhaustion could be the functional dependence of HK2 on ATP provided by active
mitochondria [238]. In contrast to GSCs, the less energy dependent NP cells are
able to adjust their metabolic phenotype upon KHS101-induced obstruction of ox-
idative phosphorylation. These results indicate that selectivity of KHS101-induced
cell death could be due to distinct bioenergetic demands of malignant and non-
malignant cells. Together, this data suggest an energy metabolism-obstructing MOA
of KHS101. Various studies have demonstrated the interrelationship of metabolism
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and autophagy (e.g., reviewed in [239]). This includes systems to detect changes
in metabolic states and availability of nutrients that regulate autophagic pathways.
The herein observed KHS101-induced changes in GSC metabolism together with
increase in autophagic components are consistent with interactions described in the
literature. Especially, a decrease in cellular ATP levels, as detected by CellTiter-
Glo® assays (figure 2.6), accompanied by a massive rise in AMP levels, as re-
vealed by metabolomics analysis (data not shown), is known to stimulate autophagy
through activation of AMP-activated protein kinase (AMPK) [240]. Consistently,
immunoblot analysis revealed the presence of phosphorylated (activated) AMPK in
KHS101-treated GSCs (data not shown). Upon phosphorylation, AMPK activates
the tuberous sclerosis complex2 (TSC2), a suppressor of mammalian target of ra-
pamycin complex 1 (mTORC1), thereby stimulating autophagy [241]. Additionally,
inhibition of mTORC1 can be mediated through HK2 [242]. Notably, KHS101 treat-
ment also induced HK2 gene expression in GSCs (figure 2.14), further strengthening
the link between KHS101-induced metabolic changes and the observed increased
autophagic activity. As mentioned above, an accumulation of nuclear HIF1α is also
detected in KHS101-treated GSCs (data not shown), as well as transcriptional acti-
vation of HIF1α target genes, including BNIP3 (figure 2.14). Notably, BNIP3 is an
autophagy regulator that stimulates the clearance of dysfunctional mitochondria, a
selective form of autophagy termed mitophagy [243]. Taken together, the accumula-
tion of autophagic vesicles observed in GSCs upon KHS101 treatment can be linked
to our proposed metabolism-targeting MOA of KHS101. Strikingly, TACC3 knock-
down studies showed that this MOA is independent of the KHS101 target TACC3
(E. Polson, unpublished data) and points to additional target proteins involved in
cellular energy production. Subsequent identification of the direct binding partners
of KHS101 required the use of a benzophenone-KHS101 (BP-KHS101) probe, which
I had demonstrated to exhibit similar cytotoxic activity as unconjugated KHS101
(data not shown). Upon exposure to UV light BP-KHS101 forms a covalent bond
with its target, thus facilitating isolation of the target proteins. In order to identify
additional KHS101 targets affinity-based pull-down studies followed by mass spec-
trometry analysis have been carried out and results are currently being validated.
In summary, this study suggests an anti-tumourigenic activity of the small molecule
KHS101 through selective induction of a lethal vacuolisation phenotype. Most im-
portantly, this destructive GSC cell state was triggered in a clinically and molecu-
larly heterogeneous panel of GSCs. Notably, selective KHS101 cytotoxicity in GSCs
was associated with decreased proliferation, activation of autophagy and reduction
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of ‘stemness’ features. Moreover, preliminary data indicate the perturbation of
metabolic processes by KHS101 resulting in glycolytic exhaustion of GSCs. Pre-
clinical validation corroborated the notion of KHS101 as an anti-GBM agent, since
systemic administration of KHS101 significantly reduced tumour burden and pro-
longed survival of mice bearing GBM tumours.
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3.1 Results
A number of OVs has been investigated for their oncolytic activity in GBM and been
demonstrated to have significant therapeutic effects in vitro, in preclinical models
and clinical trials [144]. One OV that has been shown to exhibit selective toxicity
in ICAM-1 positive GBM models, leading to tumour regression upon intracranial
injection, is CVA21 [167]. CVA21 is also an effective anti-cancer agent for the treat-
ment of other ICAM-1 positive tumours (e.g., multiple myeloma, prostate cancer;
[165] [166]) and is currently being evaluated for its safety and efficacy in clinical tri-
als (e.g., ClinicalTrials.gov identifier NCT01636882, NCT00636558, NCT02043665).
Together, these promising results prompted me to further investigate the potential
of CVA21 as an anti-GBM therapy.
3.1.1 ICAM-1 expression in GBM is highly variable
Given the dependence of efficient infection with CVA21 on ICAM-1, establishment
of a virotherapy with CVA21 for treatment of GBM requires ICAM-1 to be present
at the cell surface. Therefore, we sought to assess the presence of ICAM-1 in patient-
derived high-grade glioma specimens. To this end, we analysed immunohistochem-
istry (IHC) images from the Human Protein Atlas database [124] for ICAM-1 im-
munopositivity using the ImageJ software. The percentage of ICAM-1 positive area
was determined by colour thresholding for ICAM-1 positive staining (see example
images in figure 3.1A). A total of 69 or 61 images from 12 or 11 patients were
analysed for two different ICAM-specific antibodies (HPA002126 or HPA004877),
respectively. The graph in figure 3.1B depicts the results of this analysis. Notably,
a high variability was observed between specimens with values ranging from 0-35%
for HPA002126 and from 0-24% for HPA004877. This is consistent with previously
reported minimal to moderate ICAM-1 expression in GBM cells with variable levels
between different tumours and cell lines [244] [245]. Consistently, a high degree of
variability in the percentage of ICAM-1 positive cells is found in our panel of GSC
lines, as determined by FACS analysis (figure 3.1C). Here, values range between
∼3% (GSC20) to ∼80% (GSC11) of ICAM-1 positive cells. The high variability
in ICAM-1 levels of GBM tumours and GSCs potentially limits efficacy of CVA21
virotherapy. Therefore, the objective was to identify a method that upregulates
ICAM-1 expression in tumour cells, and thus increase CVA21 efficacy in GBM.
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Fig. 3.1: ICAM-1 expression is highly variable in malignant glioma and GSCs. A) Rep-
resentative images of human glioma specimens stained for ICAM-1 using two
different antibodies (source: www.proteinatlas.org). Using colour thresholding
ICAM-1 positive areas are highlighted in red. B) Quantification of the ICAM-1
positve tumour area in human glioma specimen (n=11/12). C) ICAM-1 sur-
face expression in GSC1, GSC4, GSC11 and GSC20 cells. The percentage of
ICAM-1 positive cells as determined by flow cytometry is shown (data shown
as mean ± SD; n=3).
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3.1.2 Mouse ICAM-1 expression in a syngeneic mouse model
affects macrophage polarisation but not tumour growth
Increased ICAM-1 expression in tumours is expected to facilitate CVA21 entry and
efficiency. However, ICAM-1 expression in solid tumours has been implicated in
malignancy through cross-talk between cancer cells and immune cells including
ICAM-1-mediated macrophage adhesion, and promoting migration of cancer cells
(e.g., [246] [247] [248]). Hence, the potential pro-tumourigenic effect of ICAM-1
expression in tumours has to be taken into account. Therefore, I sought to assess
the consequences of ICAM-1 expression on possible pro- or anti-tumour immune
responses in an immunocompetent (syngeneic) mouse model based on CT2A mouse
glioma cells. The CT2A cell line was initially established by Seyfried et al. through
chemical induction with a highly carcinogenic polycyclic aromatic hydrocarbon and
forms poorly differentiated highly malignant anaplastic astrocytomas [249]. More-
over, the CT2A model has been found to represent important GBM features includ-
ing intra-tumoural heterogeneity and migration [250]. These characteristics make it
a suitable model for studying GBM biology in an immunocompetent environment.
The CT2A cells were lentivirally transduced with a mouse (m)ICAM-1 overexpres-
sion vector or the respective empty vector. Additionally, control and mICAM1-
transduced CT2A (mICAM1↑) cells were lentivirally transduced to stably express
firefly luciferase (F-luc) in order to enable in vivo monitoring of tumour growth by
non-invasive bioluminescence (IVIS) imaging. To test the efficiency of mICAM-1
overexpression in the transduced CT2A cells, I carried out fluorescence-activated
cell sorting (FACS) analysis detecting mICAM-1 on the cell surface. Approximately
90% of mICAM1↑ CT2A cells were ICAM-1 positive compared to only ∼4% of con-
trol CT2A cells transduced with the empty vector (figure 3.2A). After intracranial
implantation of control and mICAM1↑ CT2A cells into immunocompetent C57BL/6
mice, tumour size was determined weekly until a bioluminescence signal of 1x108-
1x109 photons/second was reached (an empirically determined maximum tolerable
signal intensity indicating an imminent onset of neurological signs). The graph in
figure 3.2B displays the growth curves obtained for control and mICAM1↑ CT2A
tumours. Notably, the mICAM-1 positive CT2A cells expanded in vivo at a rate
that was similar to mICAM-1 negative control cells. Hence, mICAM-1 overexpres-
sion in CT2A did not accelerate tumour growth in this syngeneic GBM mouse model
experiment.
Immune cell infiltration was investigated at the experimental endpoint (23 days).
To this end, the presence of different populations of immune cells (i.e. macrophages,
T cells, NK cells, granulocytic myeloid-derived suppressor cells [MDSC], monocytic
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MDSCs) in the CT2A tumours was determined by FACS analysis detecting the
respective immune cell markers. Cells of the myeloid lineage were identified by
their expression of the surface marker CD11b. Among those CD11b positive cells,
macrophages were distinguished by concomitant expression of F4/80 and high ex-
pression of CD45, while lacking expression of myeloid differentiation antigen GR1.
GR1 positivity, however, marks MDSCs, and expression of lymphocyte antigen 6
complex (Ly6)G and Ly6C allows differentiation between granulocytic and mono-
cytic MDSCs, respectively. Within the CD11b negative population, those cells that
were double positive for CD45 and CD3 were classified as T cells. Lastly, NK cells
were defined as CD45 positive, CD3e negative and natural killer cell p46-related pro-
tein (NKp46) positive. Notably, infiltration of CT2A tumours by any of the tested
immune cell types was not significantly altered upon overexpression of mICAM-1
compared to control tumours and the number of immune cells present within the
tumour were generally low: macrophages constituted 1.4-1.9%, T cells ∼0.1%, NK
cells 0.2-0.4%, granulocytic MDSCs ∼0.05% and monocytic MDSCs 6.1-12.3% of all
detected cells (figure 3.2C).
In addition to immune cell infiltration, we tested the polarisation status of the in-
filtrating macrophages and MDSCs, a measure that has been used to indicate their
tumour-promoting or anti-tumourigenic potential. Whereas macrophages/MDSCs
with a predominantly M2 phenotype have been described as immunosuppressive,
tumour growth- and invasion-promoting, M1-polarised macrophages/MDSCs have
been proposed to activate an anti-cancer immune response [251] [252]. The hall-
marks that are applied to define the M1 subset of macrophages/MDSCs in murine
models are expression of nitric oxide synthase 2 (iNOS) and MHC class II molecule,
whose presence is critical to trigger an immune response [253] [254]. Markers for the
M2 subset are arginase-1 (Arg1) and mannose receptor C type 1 (Mrc1 or CD206;
[253]). Therefore, we assessed the expression of Arg1, iNOS, CD206 and MHCII
on macrophage/MDSC populations present within mICAM1↑ and control CT2A
tumours. Within the MDSC (GR1 positive) population, expression of Arg1 and
CD206 was significantly decreased in mICAM1↑ CT2A tumours compared to con-
trol tumours. This is overall an indication of a shift of MDSCs away from a M2
tumour-promoting phenotype state. Expression of iNOS was significantly reduced
and expression of MHCII, remained unchanged in MDSCs from mICAM1↑ CT2A
tumours. Similar to MDSC phenotype within the macrophage (GR1 negative) pop-
ulation, Arg1 and CD206 protein levels were significantly lower upon expression
of mICAM-1 compared to control tumours. Notably, ICAM-1 positivity did not
alter expression of iNOS in this subset of cells and MHCII was undetectable in
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both, macrophages isolated from control and from mICAM1↑ tumours (figure 3.2D).
Taken together, overexpression of mICAM-1 in CT2A intracranial tumours in im-
munocompetent mice did not significantly alter the rate of tumour growth and had
no significant effect on immune cell infiltration into the tumour. The activation state
of tumour-infiltrating MDSCs and macrophages, however, was altered by ICAM-1
positivity leading to a switch away from a pro-tumourigenic phenotype.
3.1.3 Increased ICAM-1 expression renders GSCs susceptible to
CVA21-mediated cell death
ICAM-1 on the surface of human cancer cells is thought to be a prerequisite to suc-
cessful CVA21 virotherapy through rendering cells susceptible to CVA21-mediated
cell death [164]. To investigate whether ICAM-1 positivity increases susceptibility
of GSCs to CVA21 virotherapy, I generated human ICAM-1 overexpressing (hICAM-
1↑) GSCs by lentiviral transduction and tested their vulnerability to CVA21-mediated
oncolysis. The proneural/classical GSC1 and the mesenchymal GSC4 line were used
to assess susceptibility of GSCs of different subtypes. FACS analysis confirmed the
presence of ICAM-1 on hICAM-1↑ GSC1 and GSC4 cells. Consistent with the ob-
servation of ICAM-1 expression on mesenchymal stem cells [255], ∼35% of control
vector-harbouring GSC4 cells were ICAM-1 positive. Lentivirally induced ICAM-
1 overexpression resulted in a GSC4 population with 90% ICAM-1 positive cells.
Similarly, 96% of GSC1 cells were ICAM-1 positive upon transduction with the
ICAM-1 overexpression vector, wich equals a >10-fold increase compared to GSC1
cells transduced with the empty control vector (figure 3.3A).
Next, to test the susceptibility of GSC1 and GSC4 control and hICAM-1↑ cells
to CVA21-mediated cell death, the cells were infected with CVA21 at increasing
multiplicities of infection (MOI) of 0, 0.01, 0.1 and 1, and the percentage of dead
cells was determined 7 days post infection with CVA21 by FACS analysis using
the LIVE/DEAD® Fixable Red Dead Cell Stain (Invitrogen). Consistent with
their ICAM-1 expression levels, control GSC1 and GSC4 cells showed a cell death
rate of 20-50% upon CVA21 infection. However, lentivirally-induced ICAM-1 over-
expression doubled those numbers reaching up to 95% cell death upon treatment
with CVA21, thereby strengthening the notion of an ICAM-1 dependence of efficient
killing by CVA21. Interestingly, addition of CVA21 at a MOI of 0.1 was sufficient
to induce cell death in 90% of hICAM-1↑ GSC1 cells, and 86% of hICAM-1↑ GSC4
cells (figure 3.3B).
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Fig. 3.2: Mouse ICAM-1 (mICAM-1) expression in a syngeneic glioma model affects
macrophage polarisation but not tumour growth. A) ICAM-1 surface expression
is increased in mICAM-1 overexpressing mouse glioma cells (CT2A). The per-
centage of ICAM-1 positive cells as determined by flow cytometry is shown. B)
Monitoring CT2A (firelfy luciferase labelled) tumour growth by bioluminescence
imaging reveals a comparable rate of tumour growth over time in CT2A cells
transduced with an mICAM-1 overexpression vector (mICAM-1↑) and CT2A
cells transduced with an empty vector (data shown as mean ± SD; n=5). C)
FACS analysis showing no significant difference in infiltration of immune cells
(macrophages, T-cells, NK cells, granulocytic MDSCs, monocytic MDSCs) into
CT2A tumours four weeks after intracranial injection of CT2A mICAM-1 over-
expressing cells (mICAM-1↑) or CT2A control cells (empty vector; data shown
as mean ± SD; n=5). D) Flow cytometric analysis detecting macrophage po-
larisation markers in mICAM-1 overexpressing CT2A tumours compared with
control tumours (data shown as mean ± SD; n=5; *, P<0.05; **, P<0.01; Mann
Whitney U-test).
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In order to assess an alternative to lentiviral transduction-mediated overexpression, I
sought to determine whether induction of ICAM1 gene expression could be achieved
by treatment with known modulators of ICAM-1 expression. A potent inducer of
ICAM1 mRNA expression is the cytokine TNF-α, an immune cell regulator involved
in inflammation [173]. Thus, I tested TNF-α-induced ICAM1 mRNA expression in
GSCs by qRT-PCR. Treatment of GSC4 cells with TNF-α for 6 hours led to a marked
increase of ICAM1 mRNA levels compared to vehicle-treated cells (left graph in fig-
ure 3.4). This induction of ICAM1 at the gene expression level was followed by an
increase in ICAM-1 on the cell surface after 24 hours of treatment with TNF-α as
shown by FACS analysis (right graph in figure 3.4). Similar to lentivirally induced
ICAM-1 expression in GSC4 cells, TNF-α treatment of GSC4 cells led to a 3-fold
increase (from 32% in control cells to 91% in TNF-α-treated cells) in the percentage
of ICAM-1 positive cells.
In conclusion, ICAM-1 expression can be induced in GSC cells through genetic
manipulation or by treatment with TNF-α. Notably, overexpression of ICAM-1
markedly increases susceptibility of GSCs to CVA21-mediated cell death suggesting
a potential applicability of CVA21 treatment for effective elimination of ICAM-1
positive GSCs. However, TNF-α, which is currently only used as a locally delivered
anti-cancer treatment of sarcomas and melanomas [256], cannot be administered
systemically due to its severe side effects when given in therapeutically-active doses
[257]. In contrast, small molecules can offer a better balance between therapeutic
activity and adverse effects. Therefore, I sought to identify small molecules that
could selectively induce ICAM-1 in GSCs.
3.1.4 Combination of RA and KHS101 induces ICAM-1
expression in GSCs
3.1.4.1 A focused qRT-PCR screen identifies the combination of RA and
KHS101 as inducers of ICAM1 expression in GSCs
One small molecule that is known for its role as an inducer of ICAM-1 expression
in various different cell types is RA [183] [186] [187] [188] [189]. RA acts through
signalling via RAR and RXR [184]. Furthermore, RA has been shown to exhibit
differentiation-inducing activity in a cancer stem cell background and has been in-
vestigated in a preclinical and clinical setting as an anti-tumourigenic agent [134]
[139]. Most importantly, in vivo studies have demonstrated brain accessibility of RA
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[140], a feature that makes RA a promising candidate for modulating GSC biology.
Notably, assessment of the effect of the compound in our GSC models revealed no
obvious differentiation, anti-proliferative vacuolisation and cytotoxic activity of RA
as shown by immunostainings for the astroglial differentiation marker GFAP, the
GSC ‘stemness’ markers NESTIN and SOX2, the proliferation marker KI67, and by
cell viability assays (figure 3.5). Moreover, treatment of GSCs with RA only mod-
erately increased ICAM1 mRNA levels compared to TNF-α, which is 24-fold more
potent than RA in inducing ICAM1 gene expression (figures 3.4 and 3.6). There-
fore, my aim was to identify a compound that could either induce ICAM1 expression
greater than RA, or potentiate the effect of RA on ICAM1 expression in GSCs. To
this end, I conducted a focused qRT-PCR screen testing 23 small molecules for their
potential to induce ICAM1 expression as single agents or in combination with RA.
Two groups of compounds were tested: 1) Compounds that are known to be involved
in modulation of ICAM1 transcriptional regulations (ICAM-1 relevant compounds),
and 2) brain-penetrable compounds without reported connection(s) to the regulation
of ICAM1 expression. The full list of chemical compounds is shown in table 3.1 and
includes the PKC signaling modulators phorbol-12-myristat-13-acetat (PMA) and
(-)-indolactam-V, the RAR agonist AM580, the RXR agonists Bexarotene and 9-cis-
RA, the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059, the p38
inhibitor SB202190, the Wnt antagonist sulindac, the TGF inhibitor Losartan, the
SRC-family kinase inhibitor CGP76030, the omega-6 fatty acid linoleic acid, the rho-
associated protein kinase (ROCK) inhibitor Y27632, the HAT inhibitor curcumin
and the peroxisome proliferator-activated receptor (PPAR) α/γ ligand troglitazone,
as well as the anti-GBM chemotherapeutic TMZ and KHS101.
For the ICAM-1 screen, GSC1 cells were treated with RA or the test compound
alone, or with a combination of RA and the given compound. The relative gene ex-
pression levels of ICAM1 were determined by qRT-PCR after 24 hours of treatment.
In contrast to single treatment with RA, none of the compounds tested had an effect
on ICAM1 mRNA levels upon single treatment. Also, most of the double treatments
only induced ICAM1 expression to the same extent as RA alone, hence indicating no
additive effect of the combination treatment. However, two of the ‘ICAM-1 relevant’
compounds, i.e. CGP76030 and (-)-indolactam-V, enhanced the effect of RA single
treatment on ICAM1 mRNA levels by >4-fold and 2.5-fold, respectively. Strik-
ingly, the two top hits of the screen were the compounds KHS101 and Vacquinol-1,
which share the common feature of causing (lethal) hyper-vacuolisation selectively
in glioma cells (see also section 2.1.1 ‘KHS101 induces vacuolisation, autophagy
and apoptotic cell death in a panel of molecularly different GSCs’; [115]). Com-
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pared to treatment with RA alone, a highly significant >7-fold increase in relative
ICAM1 mRNA expression was obtained upon treatment with RA in combination
with KHS101. Combining RA with Vacquinol-1 had a comparable effect on ICAM1
expression (figure 3.6).
Since I comprehensively investigated the effect of the small molecule KHS101 on
GSCs in the first part of this thesis, I here focused on further investigating RA/KHS101-
induced ICAM-1 upregulation in GSCs with a focus on the question as to whether
chemical upregulation of ICAM-1 can be exploited for CVA21 virotherapy in GSCs.
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Fig. 3.5: The small molecule RA has only minimal effect on GSC differentiation, pro-
liferation and cell viability of GSCs. A) Example images of GFAP, NESTIN
and SOX2 immunofluorescence staining in GSC1 and GSC11 cells treated with
vehicle (0.1% DMSO) or RA (2 µM) for 5 days. Nuclei were stained with DAPI.
B) Example images of KI67 immunofluorescence staining in GSC1 cells treated
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DAPI. C) Cell viability curves of GSC1, GSC4, GSC11 and GSC20 treated with
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Compound Function Conc. References
PD98059 MEK inhibitor 30 µM [258] [259]
SB202190 p38 inhibitor 5 µM [260]
Sulindac Wnt antagonist 50 µM [261] [262]
PMA PKC inhibitor 1 µM [263] [264]
Losartan TGF inhibitor 5 µM [265] [266] [267]
CGP76030 SRC-family kinase inhibitor 10 µM [268] [269]
Linoleic acid Omega-6 fatty acid 10 µM [270] [271]
9-cis retinoic acid RXR Agonist 1 µM [185]
Y27632 ROCK inhibitor 20 µM [270] [272]
(-)-indolactam-V PKC activator 10 µM [273] [274]
Curcumin HAT inhibitor 2 µM [95]
Troglitazone PPAR alpha and gamma ligand 20 µM [275]
AM580 RAR agonist 50 nM [276]
Bexarotene RXR agonist 1 µM [277]
SU5416 VEGF inhibitor 20 µM [278]
Alsterpaullone Inhibitor of GSK-3β and CDK5/p25;
potent inhibitor of CDK1/cyclin B
1 µM [279] [280]
Mianserin Serotonin receptor antagonist 1 µM [281] [282]
Lapatinib RTK inhibitor of HER2 / EGFR 2 µM [283] [284]
Niacin Vitamin B3 10 µM [285] [286]
Yohimbine A2 antagonist adrenergic 10 µM [287] [288]
Temozolomide Alkylating agent for treatment of GBM 200 µM [289]
KHS101 Inducer of neural differentiation in rat
neural progenitor cells
7.5 µM [116]
Vacquinol-1 Inducer of catastrophic vacuolisation in
GBM cells
2.5 µM [115]
Table 3.1: List of the 14 ICAM-1 relevant compounds (top) and 9 blood brain barrier
penetrable compounds (bottom) selected for the ICAM1 qRT-PCR screen.
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3.1.4.2 Double treatment with RA and KHS101 affects viability, proliferation
and clonal growth of GSCs
Results on KHS101 as a single agent (see chapter 2 ‘KHS101 abrogates the tumouri-
genic potential of GSCs through induction of a cellular self-destruction phenotype’)
have demonstrated that the compound has anti-GSC activity. Therefore, I sought
to assess whether combining KHS101 with RA changes KHS101 effects in GSCs. To
this end, I determined the effect of RA/KHS101 compared to KHS101 alone on key
features that define KHS101 activity in GSCs, i.e. vacuolisation, cell viability, pro-
liferation and clonal growth capacity. Notably, addition of RA does not significantly
affect the KHS101-induced vacuolisation phenotype (data not shown). For cell via-
bility assays, GSCs were treated with vehicle (0.1% DMSO) or RA (2 µM; non-toxic
dose, see figure 3.5) and increasing concentrations of KHS101 (up to 20 µM), and
the percentage of viable cells was measured after 2 and 5 days of treatment. All
tested GSC lines showed a marked decrease in cell viability upon treatment with
RA/KHS101. However, compared to cell viability dose response curves obtained
for KHS101 single treatment (figure 2.6A), the 2-day-IC50 values of RA/KHS101
were elevated (2.7-fold for GSC1, 2.6-fold for GSC4, 4.7-fold for GSC20). In GSC11,
2-day-IC50 values for RA/KHS101 and KHS101 were both >18 µM indicating mini-
mal effects on cell viability. Notably, prolonged treatment diminished the differences
between RA/KHS101 and KHS101 treatment in GSC model responses (figures 3.7A
and 2.6A). Five-day-IC50 values of RA/KHS101 were only slightly elevated (1.5-fold
for GSC1, 2.3-fold for GSC4, 1.3-fold for GSC11, 1.4-fold for GSC20) compared with
the 5-day-IC50 values of KHS101 (figure 3.7A and table 3.2).
In order to ascertain the effect of RA/KHS101 on GSC proliferation, GSCs were
stained for the proliferation marker KI67 after 48 hours of treatment and the per-
centage of KI67-positive cells was determined. Consistent with the results from the
dose-dependent effect of KHS101 single treatment on GSC proliferation (figure 2.1),
treatment with RA/KHS101 markedly reduced the percentage of KI67-positive cells
by 5-fold (GSC1), 8.3-fold (GSC4), 8.5-fold (GSC11), and 14.8-fold (GSC20). No-
tably, this abrogation of GSC proliferation could mainly be attributed to KHS101,
as comparable values were obtained for treatment with KHS101 alone (figure 3.7B).
Additionally, I tested whether RA/KHS101 affects the colony formation efficiency
of GSCs compared to KHS101 single treatments. To this end, GSC colony for-
mation efficiency was determined following the pre-treatment protocol depicted in
figure 2.9A. As expected, the colony formation efficiency of GSCs was reduced upon
treatment with RA/KHS101 leading to a reduction of ≤6-fold (GSC1), ≤4.2-fold
(GSC11) and ≤3.9-fold (GSC20) compared to control cells. Similar values were ob-
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Fig. 3.7: RA/KHS101 double treatment affects viability, proliferation and clonal growth
capability of GSCs. A) Differential cell viability dose response curves of the
patient-derived GSC lines GSC1, GSC4, GSC11 and GSC20 after 2 days and
after 5 days of treatment with RA (2 µM) and KHS101 (1 – 20 µM) are shown
(data normalised to vehicle control and shown as mean ± SD; n=3 [2 days]
or n=1 [5 days]). B) Quantification of the percentage of proliferative (KI67
positive) cells 48 hours after treatment or GSC1, GSC4, GSC11 and GSC20
cells with vehicle (0.1% DMSO), KHS101 (7.5 µM), RA (2 µM) or RA (2 µM)
and KHS101 (1 or 7.5 µM; data shown as mean ± SD; n=2 [GSC1, GSC4] or n=1
[GSC11, GSC20] ; *, P<0.05; **, P<0.01; Student t test). C) Quantification
of the clonal growth capability of GSC1, GSC11 and GSC20 cells pre-treated
with vehicle (0.1% DMSO), KHS101 (7.5 µM), RA (2 µM) or RA (2 µM) and
KHS101 (1 or 7.5 µM; data shown as mean ± SD; n=2; **, P<0.01; Student t
test.
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tained for KHS101 single treatment, indicating minimal influence of RA in the effect
of RA/KHS101 on GSC clonal growth capacity (figure 3.7C).
In summary, the combination of KHS101 and RA treatment does not have an ad-
ditive effect on cell viability, proliferation and clonal growth of GSCs as compared
to KHS101 single treatment. However, neither does addition of RA significantly
hamper the anti-GSC activity of KHS101.
Cell line
2 days 5 days
KHS101 RA/KHS101 KHS101 RA/KHS101
GSC1 3.62 (3.10;4.23) 9.65 (6.48;14.36) 2.23 (2.02;2.47) 3.40 (2.17;5.22)
GSC4 2.37 (1.73;3.25) 6.21 (4.27;9.04) 0.97 (0.90; 1.04) 2.19 (1.66;2.88)
GSC11 > 18 > 18 5.05 (4.51;5.64) 6.46 (4.12;10.11)
GSC20 3.39 (2.63;4.36) 15.9 (4.20;60.42) 1.87 (1.58;2.21) 2.61 (0.95;7.19)
Table 3.2: IC50 values [µM] for GSCs treated with KHS101 or RA/KHS101 for 2 days or
5 days (data shown with 95% confidence interval).
3.1.4.3 Combination of RA and KHS101 induces ICAM-1 mRNA and protein
expression in different GSC models
RA/KHS101 treatment induced ICAM1 mRNA levels in GSC1 cells at the 24-hour-
time point (figure 3.6). To assess whether the RA/KHS101-induced ICAM1 mRNA
expression was transient, I determined ICAM1 mRNA levels by qRT-PCR in GSC1
cells treated with vehicle (0.1% DMSO) or RA (2 µM) and KHS101 (7.5 µM) at
different time points (0, 6, 24, 48 hours, 3 and 7 days). Activation of ICAM1 gene
expression reached a maximum after 24 hours of treatment with RA/KHS101 and
levels dropped thereafter reaching nearly baseline levels after 7 days (figure 3.8A).
Next, I tested whether shorter exposure of GSCs to RA/KHS101 followed by a ‘wash
out’ of compounds causes an increase of ICAM1 mRNA at the 24-hour-time point.
I treated GSC1 cells with RA (2 µM) and KHS101 (7.5 µM). The compounds were
removed (through media replacement) after 1, 2, 3, 4 or 7 hours of exposure and
ICAM1 mRNA levels were determined after 24 hours. All tested shorter treatment
times only reached up to ∼25% of ICAM1 mRNA levels compared to those induced
by 24 hours of treatment (figure 3.8B).
Based on these findings, the dose-dependence of ICAM1 mRNA expression in GSC
lines of proneural (GSC1), mesenchymal (GSC4, GSC11) and proneural/mesenchymal
(GSC20) subtypes was determined at the 24-hour-time point. GSC1, GSC4, GSC11
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and GSC20 cells were treated with vehicle (0.1% DMSO), KHS101 (7.5 µM), RA
(2 µM) or RA (2 µM) and KHS101 (1, 2.5, 7.5 µM) and ICAM1 mRNA levels
were assessed by qRT-PCR. In all tested GSC lines, ICAM1 expression was signif-
icantly up-regulated upon RA (>35-fold in GSC1, >20-fold in GSC4, >6-fold in
GSC11, >14-fold in GSC20) and RA/KHS101 (7.5 µM; >130-fold in GSC1, >22-
fold in GSC4, >25-fold in GSC11, >78-fold in GSC20) treatments. Notably, with
the exception of GSC4, RA/KHS101 treatment markedly potentiated the effect of
RA treatment by >3.5-fold (GSC1), >4-fold (GSC11) and >5.5-fold (GSC20; figure
3.8C).
Since ICAM-1 can only serve as an entry site for CVA21 when present at the cell
surface, I investigated whether the RA/KHS101-induced ICAM1 mRNA expression
leads to ICAM-1 protein incorporated into the cell membrane of GSCs. To this end,
I performed immunofluorescence staining for ICAM-1 on GSC1 cells treated with
vehicle (0.1% DMSO) or RA (2 µM) and KHS101 (7.5 µM) for 48 hours. Vehicle-
treated control cells showed a predominantly negative ICAM-1 immunostaining.
Upon treatment with RA/KHS101, a large population of GSC1 cells became pos-
itive for ICAM-1 showing a ICAM-1 immunofluorescence signal at the cell edges
indicative of a cell membrane location of ICAM-1 protein (see middle image and
right image in figure 3.9A).
To further confirm the presence of ICAM-1 on the cell surface and to determine the
number of ICAM-1 positive cells, FACS analysis was performed. GSC1 cells were
treated with vehicle (0.1% DMSO), KHS101 (7.5 µM), RA (2 µM) or RA (2 µM)
and KHS101 (1, 2.5, 7.5 µM) for 48 hours, stained for ICAM-1 and the percentage
of ICAM-1 positive cells was determined. Figure 3.9B shows example histograms
obtained for GSC1 cells and highlights the gating strategy used to define ICAM-1
positive cell populations based on the background fluorescence signal of the isotype
control. The isotpye signal was unchanged irrespective of treatment. Compared to
control cells, RA/KHS101 treatment significantly increased the number of ICAM-1
positive GSC1 and GSC4 cells reaching >80% (GSC1) and >90% (GSC4). Inter-
estingly, single treatment with RA also led to a significantly increased number of
ICAM-1 positive cells (>65% for GSC1, ∼95% for GSC4), indicating that at the
protein level, KHS101 does not have an additive effect over RA. In contrast to GSC1
and GSC4 cells, RA or RA/KHS101 treatment did not significantly alter the num-
ber of ICAM-1 positive GSC11 and GSC20 cells compared to control cells. Notably,
>80% of vehicle-treated GSC11 cells were ICAM-1 positive and RA/KHS101 only
slightly increased this number to ∼94%. Vehicle-treated GSC20 cells, however, were
mostly ICAM-1 negative and RA/KHS101 treatment only led to ∼30% of ICAM-1
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Fig. 3.8: RA/KHS101 double treatment induces ICAM1 mRNA expression in different
GSC models. A) Time course of ICAM1 mRNA induction in GSC1 cells treated
with 2 µM RA and 7.5 µM KHS101 for 0, 6, 24, 48 h, 3 and 7 days showing that
ICAM1 mRNA levels are highest after 24 hours of treatment (data normalised to
vehicle control and shown as mean of fold changes ± SD of technical triplicates;
n=1). B) ICAM1 mRNA expression in GSC1 cells treated with 2 µM RA and
7.5 µM KHS101. Compounds were ‘washed out‘ after 1, 2, 3, 4, 7, 24 hours and
cells harvested after 24 hours (data normalised to vehicle control and shown as
mean of fold changes ± SD of technical triplicates; n=1). C) Dose dependent
ICAM1 mRNA up-regulation in GSC1, GSC4, GSC11 and GSC20 cells treated
with 2 µM RA in combination with increasing concentrations of KHS101 or with
2 µM RA or 7.5 µM KHS101 alone for 24 hours (data normalised to vehicle
control and shown as mean of fold changes ± SD; n=3; *, P<0.05; **, P<0.01;
Student t test.
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positive cells (figure 3.9C and D).
In conclusion, RA/KHS101 double treatment more potently increases ICAM1 mRNA
levels in GSCs compared to RA single treatment. Only GSC4 cells show a com-
parable ICAM1 mRNA expression upon RA and RA/KHS101 treatment. The evi-
dence from ICAM-1 immunofluorescence staining and ICAM-1 FACS analysis jointly
demonstrates that RA/KHS101, but also RA alone leads to elevated ICAM-1 pro-
tein levels and significantly increased numbers of ICAM-1 positive GSC1 and GSC4
cells. Therefore, RA single treatment could be sufficient to induce ICAM-1 surface
protein required for CVA21 entry. Compared to GSC1 and GSC4 cells, GSC11 and
GSC20 cells showed a differential response to RA/KHS101 treatment. Although
ICAM1 mRNA expression was significantly increased upon RA/KHS101 treatment
in GSC11 and GSC20 cells, RA/KHS101 treatment did not significantly alter the
numbers of GSC11 and GSC20 cells positive for ICAM-1 on the cell surface. Based
on my initial focus to investigate the feasibility of compound-induced ICAM-1 ex-
pression to increase susceptibility of GSCs to CVA21 virotherapy, the subsequent
validation of a combination therapy consisting of compound treatment and CVA21
infection was carried out using the two responsive cell lines GSC1 and GSC4 cells.
3.1.5 Chemically-induced ICAM-1 expression increases
susceptibility of GSCs to CVA21-mediated oncolysis
Induced overexpression of ICAM-1 has been demonstrated to increase efficiency
of CVA21-mediated cell killing (figure 3.3B). Therefore, I sought to assess whether
RA/KHS101 treatment could also lead to increased infection and cell death of GSCs
upon CVA21 treatment. To determine whether compound-induced ICAM-1 expres-
sion facilitates infection with CVA21 and to determine virus load in the cells, I
used single cell qRT-PCR detecting CVA21 mRNA. This technology allows for as-
sessment of gene expression in individual cells. This single cell resolution enables
detection of a possible heterogeneous infection pattern and identification of diverse
responders to compound treatment. I treated GSC1 cells with vehicle (0.1% DMSO)
or RA (2 µM) and KHS101 (1 µM) for 48 hours followed by infection with CVA21
(MOI 1). The presence of CVA21 in the cells was determined 48 hours post infec-
tion in individual cells using primers specific for the 5’ untranslated region (UTR)
of the CVA21 mRNA. CVA21 expression was calculated for each cell with relative
expression values ranging between 0 (no expression) and 30 (maximum expression).
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Fig. 3.9: RA/KHS101 double treatment induces ICAM-1 protein expression in different
GSC models. A) Example images of ICAM-1 immunofluorescence staining in
GSC1 cells treated with vehicle (0.1% DMSO) or RA (2 µM) and KHS101 (7.5
µM) for 48 hours showing ICAM-1 positivity in the RA and KHS101 treated
cells. The high-resolution image on the right highlights the localisation of
ICAM-1 to the cell membrane. B) Representative FACS histograms of isotype
control or ICAM-1 stained GSC1 cells after 48 hours of treatment with vehicle
(0.1% DMSO), KHS101 (7.5 µM), RA (2 µM), or RA (2 µM) and KHS101 (1,
2.5, 7.5 µM). A gating strategy based on forward and side scatter was applied to
exlude debris and dead cells from the analysis. C and D) Compound-induced
ICAM-1 surface expression as determined by FACS. The percentage of ICAM-1
positive cells is depicted for GSC1 cells treated with vehicle (0.1 % DMSO), RA
(2 µM), KHS101 (7.5 µM) or RA (2 µM) and KHS101 (1, 2.5, 7.5 µM; C) and
for GSC4, GSC11 and GSC20 treated with vehicle (0.1% DMSO), KHS101 (7.5
µM), RA (2 µM) or RA (2µM) and KHS101 (1 µM; D) for 48 hours (data shown
as mean ± SD; n=3; *, P<0.05; **, P<0.01; Student t test).
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The data is shown as bean plots in figure 3.10A. Due to the sequence similarity
of the 5’ UTR of CVA21 and other enteroviruses, the primers used here possibly
detect not only CVA21 but other enterovirus species as well. Furthermore, since it
is highly unlikely that the person our GSC1 cells are derived from was never ex-
posed to any enteroviruses, it is expected that the primers will detect virus mRNA
even in CVA21-uninfected cells. Accordingly, a low to moderate relative virus ex-
pression was measured in vehicle-treated and RA/KHS101-treated GSC1 cells that
were not infected with CVA21. Upon infection with CVA21, the virus mRNA was
detected at levels that were markedly higher than the background signal in both,
vehicle- and RA/KHS101-treated GSC1 cells. Notably, the expression pattern ob-
tained for vehicle-treated cells infected with CVA21 indicates the presence of a single
population of medium/high expressers (relative expression values: 17-20). In con-
trast, RA/KHS101-treated cells displayed a bimodal expression pattern of elevated
CVA21 expression (relative expression values: 19-27) suggesting increased efficiency
of CVA21 infection of RA/KHS101-treated GSCs (figure 3.10A).
As CVA21 is an oncolytic virus that lyses and kills cancer cells upon infection, I
next investigated the effect of RA/KHS101 treatment on susceptibility of GSCs to
CVA21-mediated cell death. In order to be able to determine cell death caused
by the oncolytic activity of CVA21, the cytotoxic effect of KHS101 was to be kept
minimal. Therefore, a KHS101 concentration of 1 µM, which was shown to leave
>75% of viable GSC1 and ∼45% of viable GSC4 cells after 5 days of treatment (fig-
ure 2.6A), was used. Most importantly, FACS analysis showed that RA/KHS101
treatment with 1 µM KHS101 leads to comparable percentages of ICAM-1 positive
GSC1 cells as RA/KHS101 treatment with 7.5 µM KHS101 (figure 3.9C). Thus,
GSC1 and GSC4 cells were treated with vehicle (0.1% DMSO), KHS101 (1 µM),
RA (2 µM) or RA (2 µM) and KHS101 (1 µM) for 48 hours. Then the cells were
infected with CVA21 at increasing MOIs (0, 0.01, 0.1, 1) and the percentage of dead
cells was determined by FACS after 7 days. Notably, KHS101 and RA/KHS101
treatment (no CVA21) only caused low levels of cell death (<10%) similar to ve-
hicle treatment indicating that the observed cell death in CVA21-treated cells is
a consequence of the virus’ oncolytic function rather than KHS101-induced cyto-
toxicity. In the presence of CVA21, however, cell death was significantly elevated
in RA/KHS101-treated GSCs reaching ∼69% in GSC1 and even ∼96% in GSC4
cells, which equals a >5-fold increase compared to their respective CVA21-treated
control cells. Similar to RA/KHS101 double treatment, single treatment with RA
significantly increased CVA21-mediated cell death in GSC1 and GSC4 cells leading
to 74.3% and 93.9% of dead cells, respectively (figure 3.10B).
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In summary, RA/KHS101 double treatment as well as single treatment with RA
rendered GSC1 and GSC4 cells vulnerable to CVA21-mediated cell death. More-
over, a positive correlation between the number of ICAM-1 positive cells as detected
by FACS analysis and susceptibility of GSCs to CVA21-mediated oncolysis could be
observed.
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Fig. 3.10: RA/KHS101-induced expression of ICAM-1 increases susceptibility of GSCs to
CVA21-mediated cell death. A) Bean plots of single cell gene expression analysis
detecting CVA21 mRNA in GSC1 cells treated with vehicle (0.1% DMSO) or
RA (2 µM) and KHS101 (1 µM) for 48 hours followed by infection with CVA21
(MOI 1) for 48 hours. B) Increased cell death of GSC1 (left) and GSC4 (right)
cells treated with vehicle (0.1% DMSO), RA (2 µM), KHS101 (1 µM) or RA
(2 µM) and KHS101 (7.5 µM) for 48 hours followed by infection with CVA21
at MOI of 0, 0.01, 0.1 and 1. The percentage of dead cells was determined by
FACS using a LIVE/DEAD® fixable dead cell stain 7 days post infection (data
shown as mean ± SD; n=3; *, P<0.05; **, P<0.01; Student t test).
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3.2 Discussion
Oncolytic virotherapy is a promising field in GBM therapy. Numerous studies have
investigated the potential of different oncolytically active viruses including reovirus,
vaccinia virus, NDV, HSV and CVA21 [145] [144] [167]. The oncolytic activity of
several OVs has been demonstrated in human glioma cell culture and preclinical
models, and some strains have already been evaluated for their safety in phase I
and II clinical trials [144].The naturally occurring CVA21 is currently being tested
in the clinic for treatment of different solid tumours (e.g., ClinicalTrials.gov identi-
fier NCT01636882, NCT00636558, NCT02043665) and its efficacy has been demon-
strated in intracranial xenograft models of malignant glioma [167]. In their study,
Chan et al. show tumour regression of xenograft tumours derived from ICAM-1
positive GBM cells corroborating the requirement of ICAM-1 protein on the surface
of tumour cells for CVA21 infection and oncolysis. However, ICAM-1 expression in
GBM is heterogeneous and generally low (figure 3.1; [244] [245]), hence hindering
effective CVA21 virotherapy. Consistently, analysis of ICAM-1 expression on two
different patient-derived GSC lines, GSC1 and GSC4, that exhibit distinct molecular
features (hyper- and hypomethylation of MGMT gene, classical/proneural and mes-
enchymal subtype, respectively) also revealed minimal to moderate ICAM-1 levels,
and accordingly, these cells showed limited vulnerability to CVA21. When ICAM-1
overexpression was induced through genetic manipulation by lentiviral transduction
or through treatment with TNF-α, a significant increase in ICAM-1 positive GSCs
was detected by FACS and CVA21-mediated cell death of GSCs significantly ele-
vated supporting an ICAM-1 dependent susceptibility to CVA21 in the GSC context
(figure 3.3).
The role of ICAM-1 in cancer has been controversially discussed (e.g., [290] [291]
[189] [292] [293] [294] [247] [248]). Studies focusing on ovarian, breast and gastric
cancer have linked upregulated ICAM-1 mRNA and protein expression to reduced
tumour growth and metastasis [290] [189] [292]. However, a correlation between
high ICAM-1 expression and cancer cell migration as well as poor patient progno-
sis has been suggested for breast cancer, hepatocellular carcinoma and esophageal
squamous cell carcinoma [248] [294] [295] [247]. In this context, ICAM-1 has been
implicated in modulating immune responses through facilitating macrophage in-
filtration [246]. These observations raised the question whether ICAM-1 overex-
pression in GBM would affect the composition and functional profile of infiltrating
immune cells. To this end, the tumour-infiltrating immune cell population and the
macrophage/MDSC polarisation state was analysed using a syngeneic mouse model
based on intracranial transplantation of ICAM-1 overexpressing mouse glioma cells.
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Non-invasive bioluminescence imaging revealed comparable growth rates of ICAM-1
overexpressing and empty vector-expressing tumours. Furthermore, no increase in
the number of infiltrating immune cells was observed. The role of tumour-infiltrating
macrophages/MDSCs has been found to depend on their functional state. While
a M2 polarisation state of tumour macrophages has been found to be favoured
in an immunosuppressed microenvironment and further supports an immunosup-
pressive network and tumour growth, M1-polarised macrophages correlate with an
anti-tumourigenic activity. Notably, in GBM tumours, macrophages are mostly of
the M2-polarised, tumour supportive subtype [296]. In our ICAM-1 overexpressing
syngeneic mouse model, the number of infiltrating macrophages was not significantly
changed compared to control tumours. However, macrophage profiles were altered
with reduced expression of M2 defining markers (Arg-1, CD206) in ICAM-1 posi-
tive tumours. As the markers for M1-polarised macrophages do not simultaneously
increase, the macrophages might be in an intermediate activation state with the
potential to transition to M1-polarised macrophages. Still, this data indicates a
shift away from the pro-tumourigenic M2 polarisation state (figure 3.2). This find-
ing is consistent with a recently published role for ICAM-1 in suppressing M2 po-
larisation of macrophages leading to reduced metastatic tumour progression [297].
Hence, induction of ICAM-1 expression in GBM could potentially trigger a shift
from a tumour-promoting to an anti-tumourigenic immune response in infiltrating
macrophages. However, since M1/M2 polarised macrophages represent functionally
diverse groups that are strongly influenced by various different extracellular stimuli,
including chemokines and cytokines secreted by the tumour, macrophage polarisa-
tion phenotypes are not as well defined in vivo as they are in vitro [253]. Therefore,
additional studies are required to further clarify macrophage polarisation states in
ICAM-1 expressing tumours, for example, by combining detection of M1/M2 mark-
ers, pro-inflammatory cytokines and transcription factors that regulate macrophage
polarisation [298] [253].
In my study, the aim was to identify compounds with the ability to selectively
induce ICAM-1 expression in GSCs and thus increasing homogeneity of ICAM-1 ex-
pression in GBM in order to enhance efficiency of CVA21-mediated oncolysis. One
known modulator of ICAM-1 expression acting through signaling via RAR/RXR is
RA [184]. As a differentiation-inducing agent, RA has been investigated in CSCs
and its anti-tumourigenic activity has been demonstrated in vivo and in the clinic
for treatment of APL [134]. Consistent with previous reports demonstrating that
RA fails to induce terminal differentiation of GSCs [138], no marked effect of RA
on GSC ‘stemness’ and differentiation was observed (figure 3.5). Although tran-
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scriptional expression of ICAM1 was induced upon RA treatment, this increase was
minimal compared to TNF-α, a potent ICAM-1-inducing cytokine (figures 3.4 and
3.6). Therefore, to identify compounds that strongly induce ICAM-1 or potentiate
ICAM-1 induction by RA in GSCs, I carried out a focused small molecule qRT-PCR
screen. Among the 23 compounds tested, 14 compounds known to modulate ICAM1
transcription and 9 brain-penetrable compounds that had not yet been implicated
in the regulation of ICAM1 expression were tested (table 3.1). Notably, I identi-
fied two small molecules that synergistically upregulated ICAM1 mRNA expression
together with RA: Vacquinol-1 and KHS101 (figure 3.6). Interestingly, both com-
pounds have been demonstrated to selectively induce hyper-vacuolisation in GSCs
(see section 2.1.1.3 ‘KHS101 induces a lethal vacuolisation phenotype in GSCs’;
[115]). Although eliciting a cell vacuolisation comparable to KHS101, Vacquinol-1
induced cell death has been described as being independent of autophagy and apop-
tosis activation, but being characterised by macropinocytosis. However, similar to
my findings on KHS101-induced ATP (energy) depletion, Kitambi et al. also detect
a reduction in cellular ATP levels upon treatment with Vacquinol-1. The authors
link this depletion of ATP to energy consumption by membrane ruﬄing and vacuole
acidification [115]. Whether metabolic processes such as glycolysis or oxidative phos-
phorylation are also affected by Vacquinol-1 as a cause of low ATP levels, was not
further investigated. Given the similar vacuolisation phenotype and the similar ef-
fect of KHS101 and Vacquinol-1 on RA-induced upregulation of ICAM1 expression,
it would be interesting to investigate if Vacquinol-1 shares an MOA with KHS101
in our GSC models. However, testing the effect of Vacquinol-1 on autophagy, prolif-
eration, ‘stemness’ and metabolism in GSCs side by side with KHS101 would have
been beyond the scope of this thesis. Thus, based on the study by Kitambi et al.,
the MOA described for Vacquinol-1 differs from my data on the MOA of KHS101.
Vacquinol-1 treatment leads to massive macropinocytosis through activating the
MAP kinase MKK4 [115] and the MAP kinase pathway has been shown to be a
critical signaling pathway regulating ICAM1 transcription [174]. This could explain
the effect of RA/Vacquinol-1 on ICAM1 mRNA levels. However, activated MKK4
has been found to phosphorylate the retinoic acid receptor RXR resulting in sup-
pression of RA-induced transcription [299]. I found no evidence that KHS101 acts in
a Vacquinol-1-like manner. Instead, our data suggests that KHS101 downregulates
the critical cell cycle/mitotic spindle regulator protein TACC3 (E.Polson, unpub-
lished data; [116]), and interferes with (yet to be validated) cellular components
that are required for mitochondrial respiration (see section 2.1.4.2 ‘KHS101 induces
metabolic exhaustion in GSCs’). A possible explanation why KHS101 acts as an
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ICAM1 inducer in combination with RA could be provided by an interesting ob-
servation regarding HIF-1α: KHS101-induced metabolic changes are accompanied
by HIF-1α accumulation in the nucleus of GSCs under hypoxic as well as normoxic
conditions leading to HIF-1α target gene expression (E. Polson & C. Abbosh, un-
pulished data). Notably, hypoxia/HIFs have been found to be able to activate the
ICAM1 promoter in vitro [300] [301]. Consistently, stronger ICAM-1 immunopos-
itivity has been detected in hypoxic tumour areas [301]. Hence, KHS101-induced
HIF nuclear translocation and subsequent interaction with the ICAM1 promoter
might lead to improved accessibility of the promoter for RA-induced binding of
RAR/RXR to RA responsive elements within the promoter, thus resulting in ICAM1
upregulation. This hypothesis could be tested by chromatin immunoprecipitation
experiments detecting RAR/RXR or RA (e.g., biotin-labeled) binding to the ICAM1
promoter upon RA, KHS101, RA/KHS101 and RA/hypoxia treatment. To this end,
specific RAR/RXR or biotin antibodies could be used for pulldown of crosslinked
protein/DNA complexes and unlinked/purified DNA fragments could be analysed
by PCR using primers specific for the ICAM1 promoter sequence.
Because I had comprehensively studied the effect of KHS101 as a single agent in
GSCs, I focused on RA/KHS101 for further investigation of chemical compound-
induced ICAM-1 expression. Notably, RA/KHS101 significantly induced ICAM1
mRNA upregulation in all four tested GSC lines (figure 3.8). However, FACS analy-
sis revealed that, in contrast to the additive effect of KHS101 on RA-induced ICAM1
mRNA expression, RA/KHS101 double treatment does not lead to an increase in
ICAM-1 protein over RA single treatment. Furthermore, only GSC1 and GSC4
cells showed a significant increase in the percentage of ICAM-1 positive cells (figure
3.9). Interestingly, the GSC11 model, which is mainly classified as the mesenchymal
subtype, already comprised of >80% ICAM-1 positive cells, respectively. This is
consistent with high levels of ICAM-1 expression reported for mesenchymal stem
cells [255]. In contrast, GSC20 cells, which are derived from a recurrent GBM
and harbour proneural and mesenchymal subtype signatures, are mostly ICAM-1
negative and no significant increase in the number of ICAM-1 positive cells was in-
duced by RA/KHS101 treatment. This was unexpected, as significant upregulation
of ICAM1 mRNA levels was observed for GSC20 cells. This discrepancy between
RA/KHS101-induced ICAM1 mRNA expression and ICAM-1 protein on the cell
surface could be due to failed translation of mRNA into protein, deficient direction
to the endoplasmatic reticulum, immediate degradation of newly synthesised ICAM-
1, impaired transport of ICAM-1 protein through the Golgi apparatus and vesicles
to the plasma membrane, defective or incomplete internalisation of ICAM-1 into the
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plasma membrane or release of ICAM-1 protein into the medium/extracellular space.
The latter seems to be the most likely explanation, as a soluble form of ICAM-1
(sICAM-1) exists, which has been found to be modulated by the same stimuli as
membrane-bound ICAM-1 and which is produced through proteolytic cleavage [302].
Future work should therefore include assays for detection of the amount of ICAM-
1 protein released by GSCs (e.g., enzyme-linked immunosorbent assay). Notably,
similar to membrane-bound ICAM-1, its soluble form also has immunomodulatory
activity [302] and in vivo accumulation of sICAM-1 in the extracellular space in-
duced by RA/KHS101 could have an effect on immune cells.
To address the question whether RA/KHS101-induced ICAM-1 expression is able
to enhance infection of GSCs with CVA21, single cell qRT-PCR for CVA21 mRNA
was performed, a method allowing identification of heterogeneous responses to com-
pound/virus treatment that potentially could not be detected by bulk qRT-PCR
analysis. Indeed, a bimodal expression pattern indicating two subpopulations with
distinct responses to CVA21 infection was identified in RA/KHS101-treated GSCs.
However, both populations showed increased levels of CVA21 mRNA compared to
vehicle-treated cells indicating improved accessibility and replication of CVA21 in
RA/KHS101-treated GSCs. Accordingly, increased CVA21-mediated cell death was
observed in RA/KHS101-treated GSCs compared to vehicle-treated GSCs (figure
3.10). Consistent with the FACS data on RA-induced ICAM-1 protein expression,
RA single treatment also led to significantly enhanced susceptibility of GSCs to
CVA21.
In a pilot experiment, I further tested whether systemically administered RA/KHS101
could increase ICAM-1 protein levels in GSC1-derived xenograft tumours upon
a 2-week dosing using an immunofluorescence readout. However, validation of
RA/KHS101-induced ICAM-1 expression has proven difficult in this setting as no
significant increase in ICAM-1 immunopositivity was detected (data not shown).
Notably, a high variability in ICAM-1 immunopositivity in both, control and treat-
ment group, was observed. This heterogeneity could be explained by the existence
of hypoxic areas in GBM tumours [303] and the correlation of hypoxia and ICAM-1
expression [301] [300]. There are several other factors that might have influenced this
result and complicated its interpretation. For example, reliability of antibody bind-
ing and accessibility of the antigen for the antibody could have been an issue. Also,
the brain bioavailability of RA and KHS101 could have been insufficient to induce
ICAM-1 expression. Furthermore, in vitro RA/KHS101-induced ICAM1 mRNA up-
regulation has been found to be transient (figure 3.8). Thus, timing is critical in
detection of ICAM-1 induction and the in vivo dosing regimen has to be adjusted
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accordingly. Therefore, pharmacokinetic studies of combined RA/KHS101 linked to
ICAM1 expression as a biomarker could provide valuable clues for pharmacological
upregulation of ICAM1 in brain tumours. Suitable dosing regimens could then be
tested to identify the correct timing for RA/KHS101-induced ICAM-1 expression in
vivo. Moreover FACS analysis could provide a more reliable readout to assess the in
vivo applicability of compound-induced ICAM-1 protein expression. Investigating
ICAM-1 expression by FACS would allow for detection of ICAM-1 protein on the
cell surface and could be combined with detection of proposed ‘stemness’ markers
(such as CD133 and CD44), thus defining whether ICAM-1 expression is associated
with ‘stemness’ profiles (in contrast to bulk tumour cells).
Interestingly, my in vitro data showed that RA single treatment leads to an increase
in GSC vulnerability to CVA21-induced oncolysis to the same extent as RA/KHS101
treatment (figure 3.10). Hence, the synergistic/additive effects of RA/KHS101 on
ICAM1 expression observed at mRNA level, are negligible at protein level and re-
garding susceptibility to CVA21, indicating that RA could be sufficient to render
GSCs susceptible to CVA21 virotherapy. How this finding may be translated into
a clinical setting would be worth investigating in the future, as RA is a brain-
penetrable agent and already approved for clinical use [140] [134].
Future pre-clinical in vivo work regarding CVA21 virotherapy would focus on deter-
mining tolerable doses for CVA21 injected intratumourally according to protocols
published for intracranial injection of OVs (e.g., [304]). Most importantly, future
work would also include proof-of-principle experiments determining whether ICAM-
1 expression could enhance efficacy of CVA21 virotherapy. For these studies RA or
RA/KHS101 pre-treated or ICAM-1 overexpressing GSCs could be used and CVA21
injected intratumourally. Monitoring tumour growth and animal survival as well as
determining tumour burden at the experimental endpoint would give valuable in-
sight into the feasibility of this combination treatment approach.
A major obstacle for clinical use of CVA21 therapy is a possible anti-viral immune
response of the patient. As a naturally occurring virus, neutralising antibodies
against CVA21 might be present in patient serum which would counteract efficient
virotherapy. However, strategies to overcome an anti-viral immune response such
as combined virotherapy and immunosuppressive treatment, e.g., using cyclophos-
phamide, have proven effective for other OVs [305]. Another option could be the
use of carrier cells such as mesenchymal stem cells or NSCs which have been suc-
cessfully applied for delivery of adenovirus to the tumour site in orthotopic mouse
glioma models [306] [307]. Both strategies, concomitant immunosuppressive therapy
and the use of carrier cells, might therefore constitute a feasible option for CVA21
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therapy to overcome the possible inhibitory effect of the immune system by sup-
pressing an innate immune response or hiding the virus from detection by immune
cells.
100
4 Conclusion
Despite multi-modal treatment efforts and intensive investigation into novel thera-
peutic approaches such as the use of monoclonal antibodies, immune therapy, on-
colytic virotherapy and new promising chemical compounds, GBM remains an un-
met clinical need as tumour recurrence remains inevitable [13] [15] [16] [144] [12].
The ability to re-grow the tumour after therapeutic intervention has been attributed
to GBM cells with stem-cell characteristics, herein called GSCs. In this study, I
focused on investigating anti-GSC potential using small molecules combined with
cell phenotype-based discovery to 1) identify GSC molecular vulnerabilities, and 2)
chemically induce an ICAM-1 positive cell surface phenotype in GSCs required for
CVA21 oncolytic virotherapy.
In order to identify ‘targetable’ acquired properties intrinsic to cancer cells, a num-
ber of studies have focused on the potential of small molecules (e.g., [114] [108] [115]
[112]). In this context, I investigated the potential anti-tumourigenic activity of
the small molecule KHS101, which has been identified as a differentiation-inducing
agent in rat NPCs. My data indicate that KHS101 exhibits anti-GSC properties by
inducing a GSC fate characterised by lethal vacuolisation. Catastrophic vacuolisa-
tion has recently been identified as a selective vulnerability of GBM cells that can
be efficiently targeted by small molecules (i.e. Vacquinol-1; [115]). In contrast to
the study by Kitambi et al., the vacuolisation induced by KHS101 was accompanied
by a pronounced autophagy phenotype, and significantly reduced GSC ‘stemness’
features upon treatment with sublethal KHS101 doses. Furthermore, gene expres-
sion analysis and extracellular flux assessment revealed that KHS101 exploits piv-
otal GSC dependencies by disruption of cell proliferation (through TACC3), GSC
‘stemness’ (e.g., through significant downregulation of GSC-promoting factors NOS2
and OLIG2), and the critical metabolic process of mitochondrial respiration. By
disrupting oxidative phosphorylation, KHS101 initially triggers compensatory gly-
colytic energy production in the highly metabolically-active GSCs, but ultimately
causes glycolytic exhaustion. Together this data confirms that KHS101-induced
hyper-vacuolisation and autophagy is critically linked to decreased tumourigenic-
ity of GSC. Future work will focus on the identification of the additional direct
target of KHS101. We expect that these MOA studies (such as affinity chromatog-
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raphy approaches) will reveal novel metabolic targets responsible for the energy
metabolism-obstruction caused by KHS101. Thereby, it will be possible to further
clarify the specificity of KHS101 cytotoxicity for malignant cells as determined in
this study for GSCs in contrast to NP cells. Since an altered energy metabolism
is a common hallmark of cancer, specific targeting of the cells’ metabolic state by
KHS101 could potentially be an efficient treatment strategy for other types of can-
cer. Therefore, it would be interesting to test KHS101 treatment on malignant
cells isolated from various different cancer types. Of course, further in vitro and
in vivo examination into the potential therapeutic window of KHS101 treatment
would be equally important to be able to establish tolerable doses of the compound
and to predict possible side effects. However, despite its favourable properties, such
as blood brain barrier penetration, the pharmakokinetics of KHS101, especially its
half-life, would need to be improved via medicinal chemistry. Here, it is important
to achieve a longer half-life and more potent cancer cell cytotoxicity, while keeping
side effects and normal tissue toxicity to a minimum. This approach would increase
the prospect of a translation of KHS101 or KHS101-like drugs into the clinical trial
phase.
Acquired resistance to cytotoxic drugs is a major issue in cancer treatment [308].
These limitations of single drug treatment could be overcome by combination ther-
apy, for example combining pharmacological and biotherapy approaches. Here, I
carried out a focused small molecule screen and identified RA/KHS101 as a potent
ICAM1 mRNA-inducing combination treatment. I further investigated RA/KHS101
treatment followed by oncolytic virotherapy as an anti-GSC treatment strategy. My
findings on this novel combination treatment demonstrate that RA/KHS101-induced
ICAM-1 expression in GSCs results in increased efficiency of infection with CVA21
and CVA21-mediated cell death. For the advancement of this study, it would be
essential to further elaborate and optimise compound-induced ICAM-1 expression
in vivo using different xenograft mouse models. Here, it is worth including the al-
ready clinically approved agent RA as a single treatment, since my in vitro data
suggests that RA single treatment is sufficient in increasing susceptibility to CVA21
through ICAM-1 induction. If RA proves to be efficient enough to enhance CVA21-
mediated cell death in preclinical models, this combination treatment could more
readily become applicable for clinical development, because RA and CVA21 are al-
ready approved for use in human trials.
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In conclusion, my thesis describes a cellular phenotyping profiling approach to iden-
tify targetable vulnerabilities in GSCs and high-grade brain tumours using chemical
and viral treatment approaches. My pre-clinical data on single compound (KHS101)
and compound (KHS101/RA)/oncolytic virus combination treatment may provide
the basis for development of a novel anti-GBM therapy. Importantly, if these two
treatment approaches prove safe and efficient for use in patients, they could be
applied to complement currently available therapies to treat GBM. For instance, af-
ter surgical removal of the main tumour mass and radio-/chemotherapy, combined
KHS101-based therapy could be applied to target the remaining GBM cell popu-
lation and impeding re-growth of the tumour. This treatment strategy could then
even be followed by another line of treatment consisting of RA/KHS101 or RA ad-
ministration and virotherapy with CVA21 to even further increase the chance of
extinguish all tumour cells.
Elimination of a highly invasive and heterogeneous cancer like GBM requires a mul-
timodal treatment strategy targeting a variety of GBM cell features. Ultimately,
KHS101-like drugs and compound/virotherapy could be part of a anti-GBM ther-
apy and benefit patients with incurable brain tumours.
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5.1 Cell culture
GSC lines were derived from surgically resected tumour tissues of consented patients
under the governance of the ethically-approved Leeds multi-disciplinary research tis-
sue bank. The obtained cells were cultured as monolayers in Neurobasal medium
(Gibco; 21103-049) supplemented with basic fibroblast growth factor (bFGF; 40
ng/mL; Gibco; PHG0024), recombinant human epidermal growth factor (rhEGF;
40 ng/mL; R&D; 236-EG) and 0.5x B-27 (Gibco; 17504-044) and 0.5x N-2 (Gibco;
17502-048) at 37°C with 5% CO2 on poly-L-ornithin (5 µg/mL; Sigma; P3655)/lami-
nin-coated (5 µg/mL; Invitrogen; 23017-015) cell culture flasks/dishes.
Human NP cells were derived from non-tumour brain surgical specimens obtained
during epilepsy surgery at Stanford University Medical Center and cultured in
DMEM/F-12 medium (Gibco; 2133-020) supplemented with bFGF (40 ng/mL),
rhEGF (40 ng/mL), 0.5x B-27, 0.5x N-2, 1x GlutaMAX (Gibco; 35050-038) and 5%
(v/v) fetal bovine serum (FBS) at 37°C with 5% CO2 [89] [309].
Mouse glioma cell line CT2A was cultured in Dulbecco’s Modified Eagle (DMEM)
medium (Sigma; D6046) containing 10% (v/v) FBS at 37°C with 5% CO2.
5.2 Single cell gene expression analysis - GBM
subtyping
Individual GBM cells were captured from cell suspensions using the microfluidic
Fluidigm C1 single-cell auto prep system (Fluidigm). Reverse transcription and
pre-amplification were carried out within a 96-well microfluidic C1 chip according
to the manufacturer’s instructions using DELTAgene assays (Fluidigm).
Pre-amplified complementary DNA (cDNA) samples from single cells were analysed
by qRT-PCR using 96.96 Dynamic Array™ IFCs and the BioMark™ HD System
(Fluidigm). Each analysis comprised up to 96 cDNA samples from individual cells
and DELTAgene assays (listed below). Amplified cDNA (3.3 µL) was mixed with 2x
Ssofast EvaGreen Supermix (2.5 µL), Low ROX buffer (2.5 µL; Bio-Rad, PN 172-
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5211), and ‘sample loading agent’ (0.25 µL; Fluidigm, PN 100-3738). DELTAgene
forward and reverse primers were mixed with Fluidigm Assay Loading Reagent (2.5
µL). Samples and assays were loaded onto Fluidigm M96 chips using the HX IFC
Controller (Fluidigm) and then transferred to the BioMark™ HD real-time PCR
reader following the manufacturer’s instructions. PCR was performed using the
(GE Fast 96 x 96 PCR + Melt v2.pcl) thermal protocol:
Step Temperature Time
Thermal Mix
70°C 40 minutes
60°C 30 seconds
Hot Start 95°C 1 minute
Cycle x30
96°C 5 seconds
60°C 20 seconds
Melting
60°C
at 1°C/3 seconds
Data were analysed using the Fluidigm Real-Time PCR Analysis software and Ct
and melting-curve data were exported to Excel and R for further analysis. Re-
sults were assessed using the Fluidigm Real-Time PCR Analysis software (heat map
view). Melting curve analyses was carried out to identify non-specific amplicons,
which were removed from the final data set. For calculation of relative expression
values (∆Ct = LoD Ct - Ct), the limit of detection (LoD) was set to a Ct value of
30 (Ct values of ‘999’ were allocated artificial values ≥30 to allow for the visualisa-
tion of ‘non-expressors’ in bean plots). Box plots were created using BoxPlotR [310].
Gene Assay ID Assay Name Forward Primer Reverse Primer
ID3 GEA0001
6231
ID3 16231 i1 AAAAGGAGC
TTTTGCCAC
TGAC
TTCCGGCAG
GAGAGGTTC
C
CRYAB GEA0001
6958
CRYAB 16958 i0 CACCCAGCT
GGTTTGACA
C
TGCTTCACA
TCCAGGTTG
ACA
PDGFRA GEP0005
6732
PDGFRA 56732 i6 GAGATCACC
ACTGATGTG
GAA
CTTCTTCCT
TAGCACGGA
TCA
RRM2 GEA0002
6114
RRM2 26114 i3 GCAGCAAGC
GATGGCATA
GAAACAGCG
GGCTTCTGT
AA
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Gene Assay ID Assay Name Forward Primer Reverse Primer
SLC2A1 GEP0005
6173
SLC2A1 56173 i8 ATTGTGGGC
ATGTGCTTC
C
AGAACCAGG
AGCACAGTG
AA
ARID5B GEP0006
2252
ARID5B 62252 i5 GAAAGGAAA
ACGCCGATA
GAA
GAGCAGCTT
GAAACATAG
TCC
NDRG1 GEP0005
6378
NDRG1 56378 i5 ATGTACCCC
TCCATGGAT
CA
CTCCTGTTC
CCATGCCAA
TA
ATF4 GEP0005
9442
ATF4 59442 i0 TTGGTCAGT
CCCTCCAAC
AA
ATACCCAAC
AGGGCATCC
AA
MET GEP0005
5841
MET 55841 i11 TCCCCAATG
ACCTGCTGA
AA
CTTTTCCAA
GGACGGTTG
AAGAA
THY1 GEA0001
3840
THY1 13840 i1 TCAGCATCG
CTCTCCTGC
TA
TCCACTAGG
CAGGCCGTT
A
CSPG4 GEA0002
6608
CSPG4 26608 i0 CCTTGGCTT
TGACCCTGA
CTA
CACCTCCAG
GTGGTTCTC
AC
TIMP2 GEA0002
0949
TIMP2 20949 i3 GAAGAGCCT
GAACCACAG
GTA
GGAGATGTA
GCACGGGAT
CA
FLCN GEA0002
8538
FLCN 28538 i5 ATCAACTCC
TGGCCCTTC
C
ATCCAAACT
GCTCTGCCT
CA
SERPINE1 GEP0005
6400
SERPINE1 56400 i3 TGGCTCAGA
CCAACAAGT
TCA
GCAGTTCCA
GGATGTCGT
AGTA
CCNE2 GEP0006
0570
CCNE2 60570 i6 ACCTCATTA
TTCATTGCT
TCCAAAC
CAAGCACCA
TCAGTGACG
TA
KLF4 GEA0001
3688
KLF4 13688 i3 CTGCGGCAA
AACCTACAC
AA
CGTCCCAGT
CACAGTGGT
AA
SERPINI1 GEP0006
2253
SERPINI1 62253 i2 AATGTAGCC
GTGGCCAAC
TA
GCATCAAAA
TCCCTTGGG
GATAC
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Gene Assay ID Assay Name Forward Primer Reverse Primer
G0S2 GEA0001
5255
G0S2 15255 i0 CAACGGACG
CGCTGAC
AGCTCCTGG
ACCGTTTCC
HRK GEA0001
5757
HRK 15757 i0 GCAGGCGGA
ACTTGTAGG
AA
TCCAAGGAC
ACAGGGTTT
TCAC
MYOF GEA0003
1577
MYOF 31577 i19 CCTGTAAGC
CTTTGGCAT
CAA
TGGGCCCAA
GGCAAGTAA
TA
SLC7A1 GEP0005
6173
SLC2A1 56173 i8 ATTGTGGGC
ATGTGCTTC
C
AGAACCAGG
AGCACAGTG
AA
TGFBR2 GEA0001
2318
TGFBR2 12318 i6 GAGGGCGAC
CAGAAATTC
CC
GGTCCCAGC
ACTCAGTCA
AC
PROM1 GEA0001
3765
PROM1 13765 i17 AATTCACCA
GCAACGAGT
CC
CATTCCCTG
TGCGTTGAA
GTA
MKI67 GEA0001
2539
MKI67 12539 i4 GGAAGGAAG
TCAACTGAA
TTTCCAA
CAGAAGAGA
AGCTAGATC
TTGAGACA
TWIST1 GEA0001
5474
TWIST1 15474 i0 CATGTCCGC
GTCCCACTA
AGTCTCTAG
ACTGTCCAT
TTTCTCC
NF1 GEA0001
2355
NF1 12355 i4 GGATTGTGC
AAAATTAAA
ACGACTCC
AACTGCTAA
CTGCGCAAC
C
PTEN GEA0001
1899
PTEN 11899 i0 CCAGACATG
ACAGCCATC
A
TGCAGGAAA
TCCCATAGC
AA
ACTB GEA0000
3909
ACTB 3909 i2 CCAACCGCG
AGAAGATGA
C
TAGCACAGC
CTGGATAGC
AA
FOS GEA0001
2925
FOS 12925 e3 ACTTCCTGT
TCCCAGCAT
CAT
AGGACCCAG
ATAGGTCCA
TGT
SQSTM1 GEA0002
5348
SQSTM1 25348 i7 AGGAAGCTG
CCTTGTACC
C
TCTGGGAGA
GGGACTCAA
TCA
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Gene Assay ID Assay Name Forward Primer Reverse Primer
GFAP GEA0001
1930
GFAP 11930 i4 GCCAGTTGC
AGTCCTTGA
C
GCGCATCTG
CCTCTCCA
RB1 GEA0000
5822
RB1 5822 i22 AATTTCAGA
AGGTCTGCC
AACAC
CCCGAATGA
TTCACCAAT
TGATACTAA
HIF1A GEA0001
2495
HIF1A 12495 i5 CAGTCGACA
CAGCCTGGA
TA
TTCTTCTGG
CTCATATCC
CATCAA
MYC GEA0005
1751
MYC 51751 i1 CCTGGTGCT
CCATGAGGA
CCTGCCTCT
TTTCCACAG
AAA
CCNE1 GEA0000
4353
CCNE1 4353 i3 TGGCCAAAA
TCGACAGGA
C
GGTCTGCAC
AGACTGCAT
TA
CD44 GEA0000
7844
CD44 7844 i0 CCGGACACC
ATGGACAAG
TT
CCTGCAAAG
CGGCAGGT
CDKN2A GEA0001
2387
CDKN2A 12387 e2 CCGGAAGCT
GTCGACTTC
A
GCCATTTGC
TAGCAGTGT
GAC
VEGFA GEA0001
2311
VEGFA 12311 i1 GAGGAGGGC
AGAATCATC
AC
GTCTCGATT
GGATGGCAG
TA
BMI1 GEA0002
6432
BMI1 26432 i1 ACTTCATTG
ATGCCACAA
CCA
TGGTCTCCA
GGTAACGAA
CA
CEBPB GEA0001
2385
CEBPB 12385 e0 TTCCTCTCC
GACCTCTTC
TCC
CAGGCTCAC
GTAGCCGTA
C
C1orf61 GEA0001
2387
C1orf61 24068 i3 CCGGAAGCT
GTCGACTTC
A
GCCATTTGC
TAGCAGTGT
GAC
ATF3 GEA0001
2311
ATF3 51995 e3 GAGGAGGGC
AGAATCATC
AC
GTCTCGATT
GGATGGCAG
TA
NES GEA0001
1931
NES 11931 i0 GCTGCGGGC
TACTGAAAA
CTGAGCGAT
CTGGCTCTG
TA
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Gene Assay ID Assay Name Forward Primer Reverse Primer
TRRAP GEA0003
1155
TRRAP 31155 i27 CCTTCCGTC
ACTCGTACC
TTTA
TCCCTGGAC
TGAGGAAGG
TAA
CDKN1A GEA0000
6173
CDKN1A 6173 i1 TGGAGACTC
TCAGGGTCG
AAAA
CGGCGTTTG
GAGTGGTAG
AA
TACC3 GEA0002
9705
TACC3 29705 i12 AAAGAGGTG
ATCGAGGGC
TA
GTGATCCTT
GCCAGGTAA
TCC
PDGFA GEA0002
3786
PDGFA 23786 i2 GCCCATTCG
GAGGAAGAG
AA
CTGACTCCG
AGGAATCTC
GTAAA
TOX3 GEA0002
3365
TOX3 23365 i3 CTTCACCTC
CAGCAAGCA
AA
GAGCAGCTC
TTTTCTCTC
CAA
WEE1 GEA0002
7199
WEE1 27199 i1 AGGACAGTG
TCGTCGTAG
AA
AAGCTCATA
ATCACTGGC
TTCC
OLIG2 GEA0001
1949
OLIG2 11949 i0 CGGAGCGAG
CTCCTCAAA
ATGGCCCCA
GGGGAAGAT
A
NOS2 GEA0001
2347
NOS2 12347 i17 CTCACAGCC
TTTGGACCT
CA
GAGATTTGA
GCCTCATGG
TGAAC
BECN1 GEA0002
8024
BECN1 28024 i10 GGTTGAGAA
AGGCGAGAC
AC
ACTGCCTCC
TGTGTCTTC
AA
STAT3 GEA0001
2324
STAT3 12324 i22 GGAAATAAT
GGTGAAGGT
GCTGAAC
CCGAGGTCA
ACTCCATGT
CAAA
AURKA GEA0001
3527
AURKA 13527 i6 GGTGGTCAG
TACATGCTC
CA
GCATCCGAC
CTTCAATCA
TTTCA
TP53 GEA0001
2790
TP53 12790 i9 TGAATGAGG
CCTTGGAAC
TCA
TCAGGCCCT
TCTGTCTTG
AA
S0X2 GEA0001
3148
SOX2 13148 e0 CATGAAGGA
GCACCCGGA
TTA
CGGGCAGCG
TGTACTTAT
CC
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Gene Assay ID Assay Name Forward Primer Reverse Primer
GAPDH GEA0000
7833
GAPDH 7833 i1 ACACCATGG
GGAAGGTGA
AG
GTGACCAGG
CGCCCAATA
VCAM1 GEP0005
6408
VCAM1 56408 i5 CAGGCTGGA
AGAAGCAGA
AA
CACTCTCAG
AAGGAAAAG
CTGTA
TUBB3 GEA0000
5739
TUBB3 5739 i1 GAGCGGATC
AGCGTCTAC
TA
GGTTCCAGG
TCCACCAGA
A
BAX GEA0001
2405
BAX 12405 i3 GGGTTGTCG
CCCTTTTCT
AC
TCTTGGATC
CAGCCCAAC
A
PIK3R4 GEA0003
0626
PIK3R4 30626 i17 AGTCCTGCA
GATGGAAAT
CC
TTTCTGGGT
AAGCCAAGT
CC
S100B GEP0005
6445
S100B 56445 i1 GGAGACAAG
CACAAGCTG
AA
CCATGACTT
TGTCCACAA
CC
ATF2 GEP0005
6453
ATF2 56453 i0 CGGGTGACC
GAAAGGATC
A
AGCAGTCCT
TTCTCAAGT
TTCCA
BCL2 GEP0005
3782
BCL2 53782 e1 ATGTGTGTG
GAGAGCGTC
AA
GTGCCGGTT
CAGGTACTC
A
CDKN2B GEP0005
6456
CDKN2B 56456 i0 GGATCCCAA
CGGAGTCAA
C
GCGCTGCCC
ATCATCA
EPHA2 GEA0002
9979
EPHA2 29979 i5 AGTGTGGAA
GTACGAGGT
CAC
TCCAGGGTC
ACGGAGAAA
C
NEUROD1 GEP0005
5465
NEUROD1 55465 i0 GGCCCCAGG
GTTATGAGA
CTA
ATCAGCCCA
CTCTCGCTG
TA
ATG10 GEP0005
6449
ATG10 56450 i2 CCCAGACCA
AGAAGTTGG
AAC
ACGCCTGAG
ACTTGCAGT
AA
CCND2 GEA0000
4282
CCND2 4282 i0 GCAGAAGGA
CATCCAACC
CTA
TCTTCGCAC
TTCTGTTCC
TCA
110
5 Materials and methods
Gene Assay ID Assay Name Forward Primer Reverse Primer
EPHA3 GEA0002
3953
EPHA3 23953 i1 GAGCTGGGC
TGGATCTCT
TA
GGTAAGTCC
TGATGGGTG
TGTA
ID1 GEP0005
6360
ID1 56360 i0 CCCTCAACG
GCGAGATCA
GCGCTTCAG
CGACACAA
ATG12 GEA0000
4282
ATG12 56449 i2 GCAGAAGGA
CATCCAACC
CTA
TCTTCGCAC
TTCTGTTCC
TCA
CCND3 GEP0005
6455
CCND3 56455 i1 CGACAGGCC
TTGGTCAAA
A
ATCATGGAT
GGCGGGTAC
A
ID2 GEP0005
6444
ID2 56444 i0 CTCAACACG
GATATCAGC
ATCC
CACACAGTG
CTTTGCTGT
CA
IRF1 GEA0001
3682
IRF1 13682 i2 AACAAGGAT
GCCTGTTTG
TTCC
TGGGATCTG
GCTCCTTTT
CC
ATG4A GEA0002
7806
ATG4A 27806 i2 AAGTGCTCG
TCTATGGTT
TACA
CCCAACCAG
CATCTGATG
AA
IGFBP3 GEA0001
3118
IGFBP3 13118 i1 CGAGTCCAA
GCGGGAGAC
GGGACTCAG
CACATTGAG
GAA
JUN GEA0001
2227
JUN 12227 e0 AAGAACTCG
GACCTCCTC
AC
TGGATTATC
AGGCGCTCC
A
ATG5 GEP0005
6447
ATG5 56447 i2 TGGTTTGAA
TATGAAGGC
ACAC
GAGCTGAAC
TTGATGCAA
GAA
HK2 GEP0005
6433
HK2 56433 i12 CTGCTGAAG
GAAGCGATC
CA
TAGTTCCGA
CTGTGTCGT
TCAC
ATG7 GEA0003
0493
ATG7 30493 i9 GCACCTTGG
GTTGCAATG
TA
GAGATCTTG
GCATTGTCC
ACAAA
AXIN1 GEA0000
4125
AXIN1 4125 i8 CAAGGAGCT
GCTGACCAA
AA
CACCACCCC
ACAGTCAAA
C
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Gene Assay ID Assay Name Forward Primer Reverse Primer
CDKN1B GEP0005
6333
CDKN1B 56333 i0 GCAATGCGC
AGGAATAAG
GAA
TTGGGGAAC
CGTCTGAAA
CA
PIK3C3 GEA0001
3756
PIK3C3 13756 i7 ACCTTCTGA
CCACGATCT
GAAA
GCTTGGTTG
GTGGATAAC
TCAC
PPIA GEA0000
7842
PPIA 7842 e4 TCTGGTTCC
TTCTGCGTG
AA
CACCCAGGG
AATACGTAA
CCA
CD24 GEA0001
4498
CD24 14498 e0 CCAACTAAT
GCCACCACC
AA
CGAAGAGAC
TGGCTGTTG
AC
CD34 GEP0005
5189
CD34 55189 i3 GCATCTGCC
TGGAGCAAA
A
CCTCTCCCC
TGTCCTTCT
TAAA
VIM GEP0005
5720
VIM 55720 i2 TGCAGGAGG
AGATGCTTC
A
CCAGAGACG
CATTGTCAA
CA
CVA21 GEP0006
2260
CVA21 62260 CCCTGAATG
CGGCTAATC
CT
ACGGACACC
CAAAGTAGT
CG
Table 5.1: List of DELTAgene assays.
5.3 Computational single cell gene expression analysis
After transformation of Ct to expression values, missing values (e.g., resulting from
unspecific amplicons removed after melting curve analysis) were imputed using k-
nearest neighbor imputation [311]. Single-cell expression levels were adjusted for
cell cycle-dependent heterogeneity as described in Buettner et al. using 20 known
cell cycle markers [312]. Gene expression levels of tumour samples with subtype
annotation were obtained from Verhaak et al. and integrated with our single cell
qPCR data set. To this end, both data sets were separately discretised to three
levels on a per gene basis using mixture models. Subsequently, a Random Forest
classifier was trained on the data set reported by Verhaak and colleagues [25], and
used to predict the subtypes of the single cells. Variability of gene expression was
analysed by (i) calculating the fraction of cells expressing a certain gene among all
cells with a non-missing measurement, and (ii) calculating the coefficient of variation
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among all cells with a non-zero expression value.
5.4 Cell viability assay
Cells were seeded at densities of 20,000 cells/well (2 day treatment), or 10,000
cells/well (5 day treatment) in white 96-well plates (Greiner bio-one; 655083) and al-
lowed to adhere overnight. The following day, cells were treated with DMSO (0.1%
v/v; Sigma; 34869) or increasing concentrations of KHS101 in 100 µL volume of
media. Cell viability was determined using the CellTiter-Glo® assay (Promega;
G7572) after 2 or 5 days. Briefly, after both reagent and cells had equilibrated to
room temperature (RT), 100 µL CellTiter-Glo® reagent were added to each well,
mixed by agitation, and then incubated for 10 minutes in the dark. The lumines-
cence signal was measured using the Mithras LB 940 plate reader.
5.5 Caspase3/7 activity assay
Cells were seeded at a density of 2,500 cells/well in a white 96-well plate and allowed
to adhere overnight. The following day, cells were treated with DMSO (0.1% v/v),
7.5 µM KHS101 with or without the caspase inhibitor Z-VAD-FMK (2 µM; Enzo
Life Sciences; ALX-260-020), or staurosporine (1 µM; Sigma; S5921) in 100 µl media.
Caspase3/7 activity was assessed using the Caspase-Glo® 3/7 Assay kit (Promega;
G8090). Reagent and cells were allowed to equilibrate to RT before 100 µL of the
Caspase-Glo® 3/7 reagent was added, mixed by agitation and incubated for 1 hour
at RT. The luminescence signal was measured using the Mithras LB 940 plate reader.
5.6 Live cell imaging
For live cell imaging, cells were plated at a density of 30,000 cells per well in 48-
well plates and allowed to adhere. Cells were treated with DMSO (0.1% v/v) or
KHS101 (7.5 µM) and monitored using the IncuCyte ZOOM® live cell imaging
system (Essen Bioscience).
5.7 Lucifer Yellow assay
For measurement of endocytotic activity, GBM cells were treated with DMSO or
KHS101 together with 2 mM Lucifer Yellow (Thermo Fisher Scientific; L1177) for
16 hours. Then, the cells were washed with phosphate buffered saline (PBS) and
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fixed with 4% (w/v) paraformaldehyde (PFA) for 10 minutes at RT. Images were
obtained using an EVOS digital inverted fluorescence microscope.
5.8 CytoID/LysoID staining
Autophagic and lysosomal compartments were stained using the CytoID® (Enzo
Life Sciences; ENZ-51031) and the LyosID® (Enzo Life Sciences; ENZ-51005)
detection kit respectively according to the manufacturer’s instructions. Briefly,
adherently-grown cells were treated with DMSO (0.1% v/v) or KHS101 (1-7.5 µM)
for the indicated times. Cells were then washed twice with PBS and subsequently
incubated with CytoID® Green (1:500), LysoID® Red (1:500) and Hoechst 33342
nuclear stain (1:1,000) in PBS for 20 minutes in the cell culture incubator (37°C,
21% O2, 5% CO2). After two PBS washes, live cells were imaged immediately using
an EVOS digital inverted fluorescence microscope.
5.9 Immunocytochemistry
Adherently-grown cells were fixed with 4% (w/v) PFA (Sigma; P6148) at RT for 10
minutes. For LC3B staining, cells were then permeabilised with ice-cold methanol
at -20°C for 10 minutes. For Ki67, SOX2 and NESTIN staining, cells were per-
meabilised with PBS containing 0.2% (v/v) Triton X-100 (Sigma; X100) at RT for
10 minutes. Non-specific antibody binding was reduced in PBS ‘blocking buffer’
containing 10% (v/v) FBS and 0.03% (v/v) Triton X-100 at RT for 1 hour. Subse-
quently, cells were incubated with primary antibodies in PBS containing 10% (v/v)
FBS and 0.03% (v/v) Triton X-100 at 4°C overnight. The following primary anti-
bodies were used: anti-KI67 (abcam; ab16667; 1:200), anti-LC3B (Cell Signaling;
2775S; 1:200), anti-NESTIN (Millpore; MAB5326; 1:200), anti-SOX2 (Cell Signal-
ing; 3579S; 1:200), anti-GFAP (DAKO; Z0334; 1:200) and anti-ICAM-1 (Millipore;
MAB2146; 1:200). After three PBS washing steps of 5 minutes each, the cells were
incubated with secondary antibody in PBS containing 10% (v/v) FBS and 0.03%
(v/v) Triton X-100 at RT for 1 hour. Secondary antibodies used were AlexaFluor488
(Molecular Probes; A11029; 1:200) or Cy3 (Jackson ImmunoResearch; 711-165-152;
1:400) conjugated. Following incubation with 4’,6-diamidino-2-phenylindole (DAPI;
1 µg/ml; Sigma) in PBS for 5 minutes at RT and two PBS washes (5 minutes each),
images were acquired using an EVOS digital inverted fluorescence microscope (life
technologies) or a Nikon A1R confocal microscope.
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5.10 Electron microscopy
TEM was performed within the imaging and cytometry department in the bioscience
technology facility at the University of York.
Cell pellets were fixed in 4% formaldehyde/glutaraldehyde solution in 100 mM phos-
phate buffer at RT for 30 minutes, and subsequently washed (2 x 10 minutes) and
stored at 4°C in 100 mM phosphate buffer. Cells were then post-fixed with 1%
buffered osmium tetroxide on ice for 45 minutes, washed in 100 mM phosphate
buffer (2 x 10 minutes), then treated with buffered 1% tannic acid solution (10 min-
utes) and washed again (100 mM phosphate buffer; 2 x 10 minutes). Cell samples
were stained with 2% uranyl acetate and dehydrated in increasing concentrations of
ethanol/acetone before embedding. These samples were then polymerised overnight
at 70°C. Processed cell pellets were sectioned to 1 µm on a Leica EM UC7 microtome
and stained with toluidine blue. Further thin sections were then taken (70 nm) and
placed on 300 mesh uncoated copper grids; these were stained with saturated uranyl
acetate in 50% ethanol followed by Reynolds lead citrate for 10 minutes each. The
sections were imaged using a FEI Tecnai 12 transmission electron microscope at an
accelerating voltage of 120 kV.
5.11 Clonal growth assays
Cells were seeded at a density of 125 cells/well in 24-well plates and allowed to
adhere. The following day, the single cells per well were counted and triplicate wells
were treated with DMSO (0.1% v/v) or KHS101. Clonal colonies consisting of >6
cells were counted 7-10 days later and the percentage of cells that were able to form
a colony was determined.
To assess the colony formation capability of GBM cells after treatment with KHS101,
cells that had been treated with DMSO (0.1% v/v) or KHS101 for 48 hours, were
harvested and re-seeded in triplicates at a density of 125 cells/well in 24-well plates.
Cells were allowed to adhere overnight and single cells per well were counted. Clonal
colonies consisting of >6 cells were counted 7-10 days later and the percentage of
cells that were able to form a colony was determined.
5.12 Illumina gene expression analysis
Cells were grown under adherent conditions and RNA was isolated after 24 hours of
treatment with DMSO (0.1% v/v) or KHS101 (7.5 µM) using the RNeasy Mini Kit
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(Qiagen; 74106) following the manufacturer’s instructions for purification of total
RNA from animal cells. Homogenisation of the samples was achieved by passing
the samples through QIAshredder spin columns (Qiagen; 79656). Gene expression
profiling was performed by Cambridge genomic services, University of Cambridge,
using the Illumina HumanHT-12 v4 beadchip. Analysis of raw data was performed
by Alastair Droop (University of Leeds). Raw data were pre-processed with a quan-
tile normalisation method using Bioconductor. Differential analysis log fold changes
were calculated for all probes and those with a false discovery rate (FDR) ≤ 0.075
were selected.
5.13 Quantitative RT-PCR of bulk cells
Cells were grown under adherent conditions and RNA was isolated after 24 hours
of treatment using the RNeasy Mini Kit following the manufacturer’s protocol for
purification of total RNA from animal cells. Homogenisation of the samples was
achieved by passing the samples through QIAshredder spin columns. Synthesis
of cDNA was performed using SuperScript II Reverse Transcriptase (Invitrogen;
18064-014) according to the manufacturer’s instructions for cDNA synthesis using
Oligo(dT) primer (Invitrogen; 18418012).
For the qPCR using TaqMan Gene Expression Assays (Applied Biosystems) the
following 15 µL reaction mixtures were prepared in triplicates:
Component Volume for 1 reaction
20x TaqMan Gene Expression Assay 0.75 µL
2x TaqMan Universal PCR Master Mix II, no UNG 7.5 µL
cDNA 0.375 µL
Nuclease-free H2O 6.375 µL
Total reaction volume 15 µL
The qPCR reaction was performed using the following PCR conditions:
Step Temperature Time
Hold 95°C 10 minutes
Cycle x40
95°C 15 seconds
60°C 1 minute
The qPCR data was analysed using the 2-∆∆Ct method with the obtained ∆Ct values
being normalised against the ∆Ct values of the DMSO-treated control. GAPDH or
β-actin were used as housekeeping genes.
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Gene Assay ID
ACTB Hs01060665 g1
AKT1 Hs00178289 m1
BHLHE40 Hs01041212 m1
BNIP3 Hs00969291 m1
CCNE2 Hs00180319 m1
DDIT3 Hs00358796 g1
FBXO32 Hs01041408 m1
GABARAPL1 Hs00740588 mH
GAPDH Hs02758991 g1
HK2 Hs00606086 m1
HMOX1 Hs01110250 m1
HRK Hs02621354 s1
ICAM1 Hs00164932 m1
ID1 Hs03676575 s1
ID3 Hs00954037 g1
NDRG1 Hs00608387 m1
NOS2 Hs01075529 m1
OLIG2 Hs00300164 s1
PGK1 Hs00943178 g1
RRM2 Hs00357247 g1
SKP2 Hs01021864 m1
SLC16A3 Hs00358829 m1
SLC2A1 Hs00892681 m1
SLC2A3 Hs00359840 m1
SOD2 Hs00167309 m1
TRIB3 Hs01082394 m1
TXNRD1 Hs00917067 m1
UCP2 Hs01075227 m1
Table 5.2: List of TaqMan probes used for (bulk cell) qRT-PCR.
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5.14 Extracellular flux analysis - metabolic
phenotyping
Assessment of the metabolic phenotypes of GBM and NP cells was performed using
the Seahorse XF extracellular flux analyser. For acute compound injections, cells
were seeded into the provided microplates at a density of 30,000 cells per well and
allowed to adhere overnight. Prior to analysis, the culture medium was replaced with
XF base media (Seahorse Bioscience; 102353-100) and transferred to a 37°C non-CO2
humidified incubator. For the ‘Mito Stress Test’ in GBM cells, XF base media was
supplemented with glucose (25 mM; Sigma; G8769) and sodium pyruvate (0.5 mM;
Sigma; S8636). L-glutamine (2 mM; Gibco; 35050-061) was added for both ‘Mito and
Glycolysis Stress Tests’ with NP cells. Supplemented culture media were adjusted to
pH 7.4 and filtered through a 0.2 µm filter, and maintained at 37°C throughout the
experiments. After the baseline readings of metabolic flux were established (∼18
minutes), DMSO (0.1% v/v) or KHS101 (7.5 µM) were injected. Oligomycin (1
µM), FCCP (0.5 µM), antimycin and rotenone (0.5 µM) were injected according
to the ‘Mito Stress Test’ (Seahorse Bioscience; 101848-400) protocol. Glucose (10
mM), oligomycin (1 µM) and 2-deoxy-glucose (100 mM) were injected according to
‘Glycolysis Stress Test’ (Seahorse Bioscience; 103020-400) protocols. To assess the
bioenergetic phenotype after 24 hours of compound treatment, treated cells were
seeded into poly-ornithine/laminin coated microplates by centrifugation (300 x g for
2 minutes, no brake) at a density of 30,000 live cells per well in the required XF base
medium. ‘Mito Stress Tests’ and ‘Glycolysis Stress Tests’ were performed according
to the manufacturer’s protocols.
5.15 Animal experiments
Animal experiments were approved by the University of Leeds Animal Welfare &
Ethical Review Committee (AWERC) and carried out under UK Home Office project
license approval in line with the Animal (Scientific Procedures) Act 1986 and in
accordance with the UK National Cancer Research Institute Guidelines for the wel-
fare of animals. Animals were maintained under standard conditions on a 12 hour
day/night cycle with food and water ad libitum.
For intracranial xenograft tumour assays 6 to 10-week-old mice were stereotactically
injected with 2 µL of GSC/GBM cells (see table below for cell numbers; containing
30% Matrigel™ BD Biosciences) into the right striatum (2.5 mm from the midline,
2.5 mm anterior from bregma, 3 mm deep). Surgery was performed under general
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anaesthesia using aseptic techniques. Mice were monitored daily for signs of sick-
ness, pain or weight loss. Six weeks after intracranial injection, 6 mg/kg KHS101
or vehicle control (5% (v/v) ethanol, 15% (w/v) (2-Hydroxypropyl)-β-cyclo-dextrin
[Sigma; H107]) was administered subcutaneously (s.c.) twice daily. KHS101 dosing
was maintained for 10 weeks with bi-weekly alteration of 5 and 3 treatment days per
week. Endpoints were 16 weeks after intracranial injections for the GSC1 model.
The mice were sacrificed and tissue was fixed by intracardiac perfusion with PBS
followed by 4% (w/v) PFA. The brains and livers were removed and transferred
into 4% (w/v) PFA. Tissue was subjected to immunohistological analysis (see 5.16
‘Histology and immunohistochemistry’).
Early removal criteria (significant weight loss, hunched position, rough hair coat,
neurological signs or any condition interfering with daily activities e.g. eating and
drinking) were applied for determining survival of mice carrying GBMX-derived
xenograft tumours.
For analysis of immune cell infiltration in a syngeneic mouse model of glioma,
C57BL/6J mice with GFP-expressing hematopoietic cells were used. To generate
this mouse model, bone marrow was isolated from the femur and tibia of UBC-GFP
mice (bred at St. James’s Biological Services unit) and GFP+ hematopoietic stem
cells (Sca-1+) were isolated by MACS using Sca-1 MicroBead Kit (Miltenyi; 130-092-
529). The obtained GFP+ hematopoietic stem cells were transplanted into lethally
irradiated (8.45 Gy) female C56BL/6J mice (Charles River Laboratories, UK) by
intravenous (i.v.) injection (1 x 106 cells/mouse). Flow cytometric analysis was per-
formed six weeks post-transplantation to confirm successful bone marrow reconsti-
tution. The ICAM-1 and Firefly luciferase expressing CT2A cells were intracranially
injected into these mice as described above for GBM1 and GBMX xenograft mod-
els. Tumour growth was monitored by bioluminescence imaging using an IVIS 200
system (PerkinElmer) after subcutaneous injection of luciferin (Regis Technologies;
1-360223-200). Four weeks post-surgery, mice were sacrificed and brain tissue was
harvested after terminal perfusion with a saline/heparin solution. Tissue was fur-
ther processed for flow cytometry (see 5.19 ‘Immune cell infiltration and macrophage
polarisation’)
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Cell line
Number of
cells injected
Mouse model Dosing Analysis
GSC1
2 x 105 (in 30%
MatrigelTM)
NSG KHS101 for 10 weeks Phenotypic analysis
GBMX
8 x 104 (in 30%
MatrigelTM)
BALB/c Nude KHS101 for 10 weeks Survival
CT2A-
mICAM1-
Fluc
5 x 104 C57BL/6J N/A
Immune cell
infiltration &
Macrophage
polarisation
Table 5.3: In vivo studies.
5.16 Histology and immunohistochemistry (IHC)
The harvested brains were fixed in (4% (w/v) PFA at 4°C for two days and sub-
sequently placed in a tube containing sucrose solution (25% sucrose [Sigma; S7903]
in 0.5 M NaH2PO4, 0.5 M Na2HPO4). After the brains had sunken to the bottom
of the tube, they were snap frozen using dry ice and cut on a cryostat to obtain 30
µm thick frozen sections. The sections were stored at -20°C in Walter’s antifreeze
solution (13 mM NaH2PO4, 55 mM Na2HPO4, 30% (v/v) ethyleneglycol, 30% (v/v)
glycerol) until they were needed for analysis. Prior to staining, the brain sections
were equilibrated in PBS at RT for 10 minutes. Staining with Hematoxylin and
Eosin was then performed following standard protocols.
For IHC, the sections were equilibrated in PBS and subsequently permeabilised with
PBS containing 0.2% (v/v) Triton X-100 for 10 minutes, followed by blocking with
PBS containing 10% (v/v) FBS and 0.03% (v/v) Triton X-100 at RT for 1 hour.
Primary antibodies were diluted in PBS containing 10% (v/v) FBS and 0.03% (v/v)
Triton X-100 and the sections incubated in the antibody solution at 4°C overnight.
Following antibodies were used: anti-KI67 (abcam; ab16667; 1:200), anti-HK2 (bior-
byt; orb69302; 1:150), and anti-Vimentin (DAKO; M0725; 1:200). After three PBS
washing steps of 5 minutes each, the sections were incubated with secondary anti-
body in PBS containing 10% (v/v) FBS and 0.03% (v/v) Triton X-100 at RT for 1
hour. Secondary antibodies used were AlexaFluor488 (Molecular Probes; A11029;
1:200) or Cy3 (Jackson ImmunoResearch; 711-165-152; 1:400) conjugated. Following
incubation with DAPI (1 µg/ml; Sigma) in PBS for 5 minutes at RT and two PBS
washes, whole sections were analysed using the EVOS digital inverted fluorescence
microscope or Nikon A1R confocal microscope and selected slides were scanned using
the Leica Ariol system at a magnification of x20 with a resolution of ∼0.35 microns
per pixel.
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5.17 Flow cytometry
For staining of cultured cells, the adherently-grown cells were harvested by trypsini-
sation after 48 hours of treatment with DMSO (0.1% v/v) or RA (2 µM) ± KHS101
(1-7.5 µM). Pelleted cells were resuspended in PBS and 10 µL FcR blocking reagent
(Miltenyi; 130-059-901) was added to block Fc receptors on the cell surface and pre-
vent unspecific binding of the antibody. After 10 minutes incubation at 4°C, cells
were pelleted and washed with PBS. Then, cells were pelleted and resuspended in
100 µL antibody solution (CD54-PE [BD Biosciences; 347977], diluted 1:10 in PBS).
To determine the background signal of non-specific binding, the cells were stained
with appropriate isotype controls (PE mouse IgG1,κ [BioLegend; 400112]) along-
side the CD54 antibody. After incubation with the antibody/isotype control (20-30
minutes at 4°C) the cells were washed with PBS, fixed with 500 µL 1% (w/v) PFA
and analysed using the Attune Acoustic Focusing cytometer (Applied Biosystems).
For the live/dead cell staining all cells (detached cells in the supernatant, trypsinised
cells) were harvested and pelleted cells were resuspended in 1 mL PBS containing 1
µL red fluorescent reactive dye (LIVE/DEAD® Fixable Red Dead Cell Stain Kit;
Invitrogen; L23102) and incubated for 20 minutes at RT. The cells were analysed
using the Attune Acoustic Focusing cytometer (Applied Biosystems).
5.18 Lentiviral transduction
Production of lentivirus stocks for firefly luciferase labeling of cells, HEK293 cells
were used. First, cells were seeded in poly-L-lysine coated 10-cm plates at a density
of 2x106 cells per plate. The following day, a transfection mixture of 0.1x TE (10
mM Tris, pH 8.0, 1 mM ethylenediaminetetraacetic acid [EDTA]) containing Gag-
pol plasmid (6.5 µg), VSV-G plasmid (3.5 µg), Prsv-rev plasmid (2.5 µg) and the
Fluc plasmid (10 µg) in a total volume of 450 µL per plate was prepared. While
this mixture was being vortexed, 500 µL 2x HBS (100 mM HEPES, 281 mM NaCl,
1.5 mM Na2HPO4) was added. This final transfection mixture was then added to
the HEK293 cells drop-wise. The following day, the medium was replaced by fresh
medium. The virus was collected after 24 hours, fresh medium added and a second
batch of virus was harvested another 24 hours later. Prior to storage at -80°C, the
harvested virus was filtered using 0.45 µm filters.
For luciferase labeling, CT2A cells were seeded in 12-well plates and lentiviral par-
ticles containing firefly luciferase expression vector were added immediately after-
wards. The medium was replaced by fresh medium the following day. The labeled
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cells were used for intracranial injection into mice within two weeks of lentiviral
transduction.
For generation of ICAM-1 overexpressing cells, the cells were seeded in 12-well plates
at a density of approximately 50,000 cells/well. Human ICAM-1 (hICAM-1), mouse
ICAM-1 (mICAM-1) overexpression or their respective empty vector containing
lentiviral particles were added before cells had attached. The following day, the
medium was replaced with fresh medium containing 5 µg/mL puromycin (Milli-
pore; 540411) selection marker. Three days later, the puromycin concentration was
reduced and maintained at 1 µg/mL throughout the course of the experiments.
Construct Accession Number Vector backbone Markers Supplier
hICAM-1 NM 000201.2 pLenti-TetCMV-Insert-
GFP/Puromycin GenTarget
Null N/A Rsv(GFP-Puro)
mICAM-1 NM 010493
pLenti-GIII-CMV Puromycin abm
Blank N/A
Table 5.4: Lentiviral vector information.
5.19 Immune cell infiltration and macrophage
polarisation
The anterior right half of the brain was mechanically disrupted, followed by dis-
sociation with collagenase A (3 mg/mL; Roche; 10103578001)/hyaluronidase (250
U/mL; Sigma; H3506-500MG) solution containing DNaseI (100 µg/mL; Roche) at
37°C for 20 minutes. Myelin was removed using Myelin removal beads (Miltenyi;
130-096-733) according to the manufacturer’s instructions. The obtained cells were
blocked with 10% rat serum (AbD Serotec; 135B2) and subsequently stained for
different heamatopoietic markers (table 5.7). For intracellular staining, cells were
fixed and permeabilised using the Intracellular Fixation & Permeabilisation buffer
kit (eBiosciences; 88-8824-00) according to the manufacturer’s instructions. The
cells were then analysed on the LSRII flow cytometer (BD Bioscience).
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Panel 1 - Immune cell infiltration:
Antibody Supplier Catalog Number Volume [µL]∗
F4/80-AlexaFluor700 BioRad MCA497A700T 1.2
CD45-PeCy7 BioLegend 103114 1.2
NKp46-PE Miltenyi 130-102-395 2.4
CD11b-V450 BD Biosciences 560455 2.4
CD3e-APC-Vio770 Miltenyi 130-098-142 1.2
Gr1-PerCP BioLegend 108426 1.2
Ly6G-APC BioLegend 127613 1.2
Ly6C-Viogreen Miltenyi 130-102-207 2.4
Panel 2- Macrophage polarisation:
Antibody Supplier Catalog Number Volume [µL]∗
F4/80-AlexaFluor700 BioRad MCA497A700T 1.2
CD45-APC Vio770 Miltenyi 130-105-463 2.4
CD11b-APC BioLegend 101212 1.2
Gr1-PerCP clone RB6-8C5 BioLegend 108426 1.2
MHCII-Vioblue Miltenyi 130-102-145 2.4
Arg1-PE † R&D IC5868P 1.2
iNOS-PE Cy7 † eBioscience 25-5920-82 1.2
CD206-BrillViol605 † BioLegend 141721 1.2
Isotype controls:
Antibody Supplier Catalog Number Volume [µL]∗
PeCy7 rat IgG2b,κ BioLegend 400617 1.2
Rat IgG2a-PE Miltenyi 130-102-654 2.4
Rat (IgG2b)-AF700 AbD Serotec MCA1125A700 1.2
V450 rat IgG2b,κ eBioscience 48-4031-80 1.2
Rat
(IgG2b,κ)-APC-Vio770
Miltenyi 130-102-657 2.4
PerCP rat IgG2b,κ BioLegend 400629 1.2
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Antibody Supplier Catalog Number Volume [µL]∗
APC rat IgG2a,κ eBioscience 17-4321-81 1.2
Viogreen rat IgG2a Miltenyi 130-102-650 2.4
Rat (IgG2b,κ)-APC clone
RTK4530
BioLegend 400612 1.2
Rat (IgG2b,κ)-PerCP
clone RTK4530
BioLegend 400629 1.2
Rat IgG2b Vioblue Miltenyi 130-102-661 2.4
Rat (IgGa,κ)-PECy7 clone
eBR2a
eBioscience 25-4321-82 1.2
Iso-BV605 BioLegend 400539 1.2
Table 5.7: List of FACS antibodies for analysis of immune cell infiltration and macrophage
polarisation. ∗for max. 1 x 106 cells; †intracellular stains.
5.20 ICAM1 qRT-PCR screen
GBM1 cells were seeded in 12-well plates at a density of 75,000 cells/well and treated
with RA (2 µM), the compounds or a combination of RA and the compounds (see
table 3.1 for a full list of compounds tested). Cells were harvested after 24 hours and
RNA isolation, sample homogenization, cDNA synthesis and qRT-PCR performed
as described in 5.13 ‘Quantitative RT-PCR of bulk cells’.
5.21 Infection with CVA21
ICAM-1 overexpressing cells or GBM cells pre-treated with DMSO (0.1% v/v),
RA (2 µM) or KHS101 (1-7.5 µM) for 48 hours were seeded at a density of 50,000
cells/well in 12-well plates. The same day, coxsackievirus A21 (CVA21; CAVATAK™;
provided by Viralytics Ltd, AU) was added to the cells at multiplicities of infection
(MOI) of 0, 0.01, 0.1 or 1 and cell death was assessed 7 days post-infection by flow
cytometry using the LIVE/DEAD® Fixable Red Dead Cell Stain Kit (see 5.17
‘Flow cytometry’).
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5.22 Image analysis
Immunocytochemistry: Regions of interest (ROIs such as vacuolated area or LC3B
positive area) were manually defined or by colour thresholding using ImageJ (de-
fault settings, color space: HSB), and their percentage of the total cellular area
was calculated. The number of KI67 or CytoID® positive cells was determined in
randomly selected images totaling ≥500 cells per single experiment.
Immunohistochemistry: ROIs (KI67, HK2, VIMENTIN, ICAM1 stained areas or
eosin-dense regions) were isolated from immunofluorescence/phase contrast or im-
munohistological images using ImageJ software and color thresholding with default
settings (color space: HSB). Selected ROIs were measured and percentage of the
total area of interest was determined. Five different tumour sections per specimen
(KI67-positive ROI) or 15 randomly selected images per specimen (HK2-positve
ROI) were analysed for quantification of immunofluorescence staining. For determi-
nation of GBM cell invasion in xenograft tumours, three or four VIMENTIN-stained
sections per specimen were analysed. For determination of ICAM-1 expression in
GBM, ROIs were defined in IHC images from the Human Protein Atlas database
[124] by colour thresholding using ImageJ software. A total of 69 or 61 images
from 12 or 11 patients were analysed for antibodies HPA002126 or HPA004877,
respectively (images available from v13.proteinatlas.org).
5.23 Statistical analysis
In vitro data is shown as mean ± SD or mean of fold changes ± SD and was ana-
lysed using the student’s t-test (two-tailed). For analysis of xenograft tumour data,
the Mann-Whitney U-test was used (http://www.socscistatistics.com/tests/mann
whitney/; one-tailed). For Kaplan-Meier analysis, the significance was calculated
using the log-rank test. P values of ≤ 0.05 were considered significant (*) and P
values of ≤ 0.01 were considered highly significant (**).
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List of abbreviations
µL microlitre
µM micromolar
µm micrometer
2-DG 2-Deoxy-D-Glucose
A Antimycin A
ABC ATP-binding cassette
AKT1 V-akt Murine Thymoma Viral Oncogene Homolog 1
ALA 5-aminolevulinic acid
ALDH1A1 Aldehyde Dehydrogenase 1 Family, Member A1
AMP Adenosine monophosphate
AP-1 Activator protein 1
APC Antigen presenting cell
APL Acute promyelocytic leukemia
Arg1 Arginase-1
ARNT2 Aryl hadrocarbon receptor nuclear translocator 2
ATG5 Autophagy related 5
ATP Adenosine triphosphate
bFGF Basic fibroblast growth factor
BHLHE40 Basic Helix-Loop-Helix Familiy Member E40
BMI1 BMI1 Proto-Oncogene, Polycomb Ring Finger
BMP Bone Morphogenic Protein
BNIP3 BCL2/adenovirus E1B 19 kDa Interacting Protein
C Compound
C/EBP CCAAT/Enhancer Binding Protein
CC Corpus callosum
CCL-1 Chemokine (C-C Motif) Ligand 1
CCNE2 Cyclin E2
CD Cluster of differentiation
CDK Cyclin-dependent Kinase
cDNA complementary DNA
CHI3L1 Chitinase 3-Like 1 (Cartilage Glycoprotein-39)
ch-TOG colonic and hepatic tumor overexpressed gene
cm Centimeter
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CNS Central Nervous System
CRBP1 Cellular retinol binding protein 1
CSC Cancer stem cell
CVA21 Coxsackievirus A21
CYP26B1 Cytochrome P450, Family 26, Subfamily B, Polypeptide 1
DAF Decay-accelerating factor
DAPI 4’,6-diamidino-2-phenylindole
DDIT3 DNA-Damage-Inducible Transcript 3
DLL4 Delta-like 4
DMEM Dulbecco’s Modified Eagle Medium
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
e.g. exempli gratia
ECAR Extracellular acidification rate
EDTA Ethylenediaminetetraacetic acid
EGF Epidermal Growth Factor
EGFR Epidermal Growth Factor Receptor
EM Electron microscopy
EMT Epithelial-mesenchymal transition
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2
EZH2 Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit
F FCCP
FABP5 Fatty Acid Binding Protein 5
FACS Fluorescence-activated Cell Sorting
FBS Fetal Bovine Serum
FBXO32 F-box Protein 32
FC Fold Change
FCCP Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone
FcR Fc receptor
FDA U.S. Food and Drug Administration
FDR False Discovery Rate
FGF Fibroblast growth factor
FGFR Fibroblast growth factor receptor
F-luc Firefly luciferase
G Glucose
GABARAPL1 Gamma-aminobutyric Acid A Receptor-associated Protein-like 1
GABRA1 Gamma-Aminobutyric Acid (GABA) A Receptor, Alpha 1
GBM Glioblastoma Multiforme
GFAP Glial fibrillary acidic protein
GFP Green fluorescent protein
GLI2 GLI family zink finger 2
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GM-CSF granulocyte-macrophage colony-stimulating factor
GSC Glioma Stem Cell
GSEA Gene set enrichment analysis
GSK Glycogen Synthase Kinase
H&E Hematoxilin & Eosin
HAT Histone Acetyltransferase
HER Human Epidermal Growth Factor Receptor
HIF Hypoxia inducible factor
HK2 Hexokinase 2
HMOX Heme oxygenase
HMT Histone Methyltransferase
HRK Harakiri
HSF Heat shock factor
HSV Herpes simplex virus
HT Hydroxytryptamine
i.e. id est
i.p. intraperitoneal
i.v. intravenous
IC50 Inhibitory concentration 50
ICAM-1 Intercellular Adhesion Molecule-1
ID Inhibitor of DNA Binding
IDH1 Isocitrate dehydrogenase 1
IHC Immunohistochemistry
IL Interleukin
kg Kilogram
LC3 Microtubule-associated Protein 1 Light Chain 3
LFA Lymphocyte function-associated antigen
LY Lucifer Yellow
Ly6 Lymphocyte antigen 6 complex
MAP Mitogen-activated protein
MDSC Myeloid-derived suppressor cells
MEK Mitogen-activated protein kinase kinase
MFI Mean Fluorescence Intensity
mg Milligram
MGMT O6-methylguanine-DNA methyltransferase
MHCII Major histocompatibility complex class II
miRNA microRNA
MKK4 Mitogen-activated protein kinase kinase 4
mm Millimeter
MOA Mechanism-of-action
MOI Multiplicity of Infection
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Mrc1 Mannose receptor C type 1 (synonym: CD206)
mRNA messenger RNA
mTORC1 mammalian target of rapamycin complex 1
N/A not applicable
NDRG1 N-myc Downstream Regulated 1
NDV Newcastle disease virus
NEFL Neurofilament, Light Polypeptide
NESTIN Neuroectodermal Stem Cell Marker
NF1 Neurofibromatosis type 1
NF-κB Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells
NK cell Natural killer cell
NKp46 Natural Killer Cell P46-Related Protein
nm nanometer
nM nanomolar
NOS2 Nitric oxide synthase 2 (synonym: iNOS)
NPC Neural progenitor cell
NSC Neural stem cell
NSG NOD scid gamma
O Oligomycin
OCR Oxygen consumption rate
OLIG2 Oligodendrocyte Transcription Factor 2
OV Oncolytic virus
PBS Phosphate buffered saline
PDGFRA Platelet-derived growth factor receptor α
PE Phycoerythrin
PFA Paraformaldehyde
PGK1 Phosphoglycerate Kinase 1
PIK3R1 Phosphoinositide-3-Kinase, Regulatory Subunit 1
PKC Protein kinase C
plγRE Interferon-γ-responsive element
PMA Phorbol 12-myristate 13-acetate
POU3F2 POU Class 3 Homeobox 2
PPAR Peroxisome Proliferator-Activated Receptor
PTEN Phosphatase and Tensin homolog
qRT-PCR Quantitative Reverse Transcription-Polymerase Chain Reaction
R Rotenone
RA Retinoid Acid
RAR Retinoic acid nuclear receptor
RARE RA responsive elements
RB1 Retinoblastoma 1
RFP Red fluorescent protein
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rhEGF Recombinant human epidermal growth factor
RNA Ribonucleic acid
ROCK Rho-associated protein kinase
ROI Region of Interest
RRM2 Ribonucleoside-diphosphate Reductase Regulatory Subunit M2
RT Room temperature
RTK Receptor Tyrosine Kinase
RXR Retinoid X Receptor
s.c. subcutaneously
SALL2 Spalt-Like Transcription Factor 2
SD Standard deviation
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SHH Sonic hedgehog
SKP2 S-phase Kinase-Associated Protein 2
SLC Solute Carrier Familiy
SMO Smoothened, Frizzled Class Receptor
SOD2 Superoxide Dismutase 2
SOX2 SRY-box 2
SP1 Specificity Protein 1
STAT Signal transducers and activators of transcription
SYT1 Synaptotagmin 1
TAA Tumour-associated antigen
TACC3 Transforming Acidic coiled-coil containing protein 3
TCA Tricaboxylic acid
TGF-β Transforming growth factor β
TMZ Temozolomide
TNF-α Tumour necrosis factor α
TP53 Tumour protein p53
TRAIL TNF-related apoptosis-inducing ligand
TRIB3 Tribbles Pseudokinase 3
TRRAP Transformation/transcription domain-associated protein
TSC2 Tuberous sclerosis complex 2
TXNRD1 Thioredoxin Reductase 1
UCP1 Uncoupling Protein 1
ULK1 Unc-51 like autophagy activating kinase 1
UTR Untranslated region
VEGF Vascular Endothelial Growth Factor
VIM VIMENTIN
WHO World Health Organisation
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